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Abstract 
 
Hepatitis C virus (HCV) is a major cause of chronic hepatitis worldwide. Present estimates 
predict that approximately 130 million people are infected with HCV with the majority of 
all infections progressing to chronicity, ultimately leading to fibrosis, cirrhosis and 
hepatocellular carcinoma. The virus, which belongs to the family Flaviviridae, has a 
single-stranded RNA genome of positive polarity that codes for a unique polyprotein of 
approximately 3000 amino acids. 
 
Core protein forms the viral nucleocapsid and is the most highly conserved of all the viral 
proteins. As well as playing a central role in virion assembly, core has been shown to 
modulate several cellular processes mainly due to its interaction with several host factors. 
One such cellular interacting partner of core protein is the DEAD-box RNA helicase 
DDX3. Although, the binding of these two proteins has been shown by yeast-two hybrid 
screening and co-immunoprecipitation (co-IP) assays, an authentic interaction is yet to be 
demonstrated in cells replicating the HCV JFH1 infectious clone. Nevertheless, IF analysis 
of JFH1-infected cells has shown a proportion of DDX3 is redistributed to distinct 
cytoplasmic sites where it colocalises with core, implying that these two proteins interact 
during virus replication. Six JFH1 core alanine mutants (F24A, G27A, I30A, G33A, V34A 
and Y35A) are known to disrupt this core-DDX3 colocalistion without altering viral 
genome replication following direct electroporation of viral RNA into cells. All mutants 
release infectious virus particles, except JFH1G33A. However, substantial reductions in 
RNA replication levels were observed at early time points following infection of naïve 
cells with the infectious mutant virus particles. Furthermore, the G33A mutation appears to 
allow the viral genome some degree of elasticity as during the serial passaging of G33A-
electroporated cells, a progressive increase in infectious virus particles was observed. 
Based on the diverse phenotypes of these mutants it is difficult to conclude as to which 
effects (if any) are directly related to the core-DDX3 interaction. In addition, DDX3 has 
become a topical host factor in HCV research following recent studies demonstrating that 
its knockdown from target cells causes an overwhelming reduction to HCV replication. 
However, these studies failed to demonstrate if the core-DDX3 interaction had any 
functional relevance to this effect.  
 
The aim of this study was to clearly define the role of the core-DDX3 interaction in HCV 
replication. Using highly specific antibodies, a co-IP assay was developed that was 
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sensitive enough to detect an interaction between these two proteins from JFH1 RNA-
electroporated cell lysates. Co-IP analysis of the 6 JFH1 core mutants revealed that only 
one of these (JFH1Y35A) appeared to completely abolish DDX3 binding. Detailed analysis 
of this mutant revealed its replication properties resembled those of the WT virus 
following both electroporation of the viral RNA into cells and infection of naïve cells with 
the virus particles, demonstrating that the core-DDX3 interaction is dispensable for virus 
replication in cell culture. In addition, DDX3 knockdown experiments revealed that as for 
JFH1WT, the replication of JFH1Y35A was equally sensitive to the depletion of endogenous 
DDX3 levels from target cells, indicating that the requirement of DDX3 for HCV 
replication is unrelated to its interaction with the viral core protein. Interestingly, sucrose 
gradient studies showed that DDX3 protein sedimented with the extracellular core protein 
from JFH1WT virus particles. Analysis of the JFH1Y35A virus particles found them to be less 
dense with a lower content of DDX3, alluding to the exciting possibility of DDX3 being a 
novel component of the virion.  The results of this study indicate that the core-DDX3 
interaction is not the mechanism through which HCV utilises this host factor for its 
replication. However, DDX3 may be incorporated into virus particles through its 
association with the nucleocapsid. Investigating the latter possibility is the subject of our 
future work.  
 
In a separate study, the replication properties of JFH1G33A and JFH1F24A were fully 
characterised. These two mutants were chosen for further analysis as they possessed 
unique properties relating to the virus proliferation in cell culture. Of the original 6 JFH1 
core mutants, only JFH1G33A had a defect in secreting infectious virus particles. Upon 
passaging of cells electroporated with this mutant infectious particle production increased 
and eventually achieved peak titers similar to WT. The increase in infectivity consistently 
coincided with the appearance of a second mutation in close proximity to the originally 
mutated residue 33. Although, similar results were reported previously for this mutant by 
Dalrymple, (2007), the present study extended this work by confirming that these second-
site changes were compensatory mutations, which rescued the infectivity of JFH1G33A. In 
contrast to the assembly defect of JFH1G33A, JFH1F24A was efficient at secreting infectious 
virus following electroporation, however the infection kinetics of these particles was 
considerably lower than those derived from JFH1WT. Further analysis, suggested the 
delayed infection of JFH1F24A virus was likely due to an early event in the HCV lifecycle 
following entry into the cell and prior to the release of the infectious genome. Identifying 
the importance of glycine 33 in infectious virus assembly and phenylalanine 24 in virus 
spread provides the basis for further studies into the role that core plays in virus 
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proliferation in cell culture. In its totality, this study has uncovered important details 
regarding the role of core, DDX3 and the core-DDX3 interaction in the HCV lifecycle.  
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One and Three Letter Amino Acid Abbreviations 
 
Amino acid    Three letter code    One letter code 
Alanine     Ala      A 
Arginine     Arg      R 
Asparagine     Asn      N 
Aspartic acid     Asp      D 
Cysteine     Cys      C 
Glutamine     Gln      Q 
Glutamic acid     Glu      E 
Glycine     Gly      G 
Histidine     His      H 
Isoleucine     Ile      I 
Leucine     Leu      L 
Lysine     Lys      K 
Methionine     Met      M 
Phenylalanine     Phe      F 
Proline     Pro      P 
Serine      Ser      S 
Threonine     Thr      T 
Tryptophan     Trp      W 
Tyrosine     Tyr      Y 
Valine      Val      V 
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1. Introduction 
 
 
1.1. Discovery of Hepatitis C Virus 
 
Following the development of serologic tests for hepatitis A virus (HAV) and hepatitis B 
virus (HBV) during the 1970s, it became apparent that most cases of transfusion-associated 
hepatitis were caused by another unknown agent, designated “non-A, non-B hepatitis” or 
NANBH (Feinstone et al., 1975; Prince et al., 1974). Studies in chimpanzees confirmed 
that the blood-borne NANBH agent was transmissible and caused by a small, lipid-
enveloped virus (Alter et al., 1978; Tabor et al., 1978). Then in 1989, Michael Houghton 
and collegues used chimpanzee plasma with high concentrations of NANBH to identify a 
virally encoded antigen belonging to an agent with an RNA genome, subsequently termed 
“hepatitis C virus” (HCV) (Choo et al., 1989). Further characterisation found that HCV 
contained a positive sense, single-stranded RNA genome approximately 9.6 kb in length 
(Choo et al., 1991).  
 
 
1.2. Virion Properties and Classification 
 
HCV has a genetic organisation similar to that of flaviviruses and pestiviruses and has been 
classified within the Flaviviridae family as a unique member in the Hepacivirus genus 
(Choo et al., 1991; Robertson et al., 1998; Takamizawa et al., 1991). Members of the 
Flaviviridae family include the flaviviruses such as yellow fever virus (YFV) and tick-
borne encephalitis virus (TBE), the pestiviruses such as bovine viral diarrhoea virus 
(BVDV), classical swine fever virus (CSFV) and GBV-A, -B and hepatitis G (HGV) 
viruses (Linnen et al., 1996). Flaviviridae comprise a positive single-stranded RNA 
genome encoding a polyprotein composed of structural and non-structural proteins (Reed 
& Rice, 2000). The genomes of Flaviviridae are encapsidated by an icosahedral capsid, 
which is surrounded by an outer envelope (Clarke, 1997), and is assumed to be the case for 
HCV. Transmission studies in chimpanzees first showed that HCV virions were relatively 
small in size (between 30 and 60 nm) and contained a lipid envelope by using filtration and 
chloroform inactivation methods, respectively (Feinstone et al., 1983; He et al., 1987). In 
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line with this, HCV particles observed from human plasma by electron microscopy were 
approximately 50 nm in diameter and could be gold-labelled with antibodies to the HCV 
envelope proteins (Kaito et al., 1994).  
 
In density gradients, HCV RNA containing particles from clinical isolates exhibit a broad 
distribution and unusually low buoyant densities (Andre et al., 2002; Miyamoto et al., 
1992; Nielsen et al., 2006; Thomssen et al., 1992). These properties are likely due to HCV 
particles associating with very low- and/or low-density lipoproteins (VLDLs and LDLs) 
(Andre et al., 2002; Nielsen et al., 2006). These complexes, called lipoviroparticles (LVPs) 
have very low buoyant densities of approximately 1.08 g/ml. In addition, HCV has been 
reported to associate with immunoglobulins, and these complexes exhibit a buoyant 
density of 1.17 – 1.21 g/ml (Choo et al., 1995; Hijikata et al., 1993b; Thomssen et al., 
1993). However, the density of infectious HCV determined by inoculating chimpanzees 
was found between 1.09 – 1.11 g/ml (Bradley et al., 1991). In line with this, the HCV 
RNA derived from highly infectious patient plasma was also found in very low density 
fractions (~1.09 g/ml) (Hijikata et al., 1993b). The recent development of a robust HCV 
cell culture infection system (HCVcc) has allowed the biophysical and biochemical nature 
of the HCV virion to be further characterised. Gradient analysis showed HCVcc RNA 
containing particles sedimented to a density of approximately 1.15 g/ml (Wakita et al., 
2005). The HCV structural proteins core, E1 and E2 were also detected at this density 
confirming for the first time that these proteins are components of the virion. Electron 
microscopy (EM) analysis of these HCVcc particles showed the virus HCV has an inner 
ring of 30-35 nm (thought to be the capsid) and an overall diameter of 50-65 nm (Wakita et 
al., 2005). Another study measuring the specific infectivity (the ratio of viral RNA divided 
by the infectious titer) of HCVcc particles by gradient analyses found the most infectious 
material sedimented at densities between 1.09-1.11 g/ml (Lindenbach et al., 2005), 
consistent with the peak of infectivity for HCV in vivo (see above). In addition, a more 
recent study has shown HCVcc virions are also associated with VLDLs (Chang et al., 
2007). Thus, HCVcc virus particles appear to be biophysically similar to those found in 
vivo.   
 
 
1.3. Transmission and Epidemiology 
 
HCV is regarded as a major human pathogen and recent estimates predict that 2.2 % (~130 
million) of the world’s population are infected with the virus (Alter, 2007). HCV infection 
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is most commonly transmitted by percutaneous exposure to blood or blood products. In 
economically developing countries, HCV is largely transmitted through unhygienic 
medical practices and other percutaneous routes such as intravenous drug use. In 
economically developed countries, the vast majority of new cases are associated with 
injection drug use. Most descriptions of global HCV epidemiology depend on HCV 
seroprevalence studies. These studies are typically cross-sectional in design and only 
performed in select populations, such as blood donors or patients with chronic liver 
disease, which are not representative of the community or region in which they reside. 
Despite population-based studies representative of an entire community being far more 
useful, this kind of study is not possible in most regions of the world. Therefore, in many 
countries the exact magnitude of the problem has not been defined (Lavanchy, 1999). 
Nevertheless, for several years the World Health Organisation has reported data on the 
worldwide prevalence of HCV infection, founded on both submitted data and published 
studies (Shepard et al., 2005). Although HCV is endemic worldwide, there is a large 
degree of geographic variability in its distribution. HCV is estimated to infect 
approximately 0.6 % and 2 % of the UK and US population, respectively (Thomson, 
2009). Fewer data are available for developing countries, where it is believed that HCV 
prevalence is generally higher. For example, Egypt has the highest reported seroprevalence 
rate with 22 % of the total population being infected (Shepard et al., 2005). This high 
percentage is the result of the country’s anti-schistosomal therapy programme, which until 
the 1970s involved intravenous administration of drugs using reusable syringes (Frank et 
al., 2000). 
 
The distribution of the different HCV genotypes also varies between countries. HCV is 
classified into at least six major genetic groups that on average over the complete genome 
differ in 30–35 % of nucleotide sites. Each of these six major genetic groups contain a 
series of more closely related subtypes that typically differ from each other by 20–25 % in 
nucleotide sequences (Simmonds, 2004). This variation is likely the result of the error 
prone replication of HCV and the high production rate of 1012 particles/day (Neumann et 
al., 1998). Although the population-based samples are not consistently available, the 
geographic distribution of HCV genotypes can be mapped using online databases (Fig. 
1.1). Genotypes 1-3 have a worldwide distribution and account for almost all infections in 
the western world with 1a and 1b being the most common.    
 
 
 
Figure 1.1. HCV subtype distribution worldwide.  
 
The geographic and subtype distribution is shown for the 52, 928 sequences available online at 
http://hcv.lanl.gov (accessed November 12, 2009).   
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1.4. Natural History of Infection 
 
HCV is a significant cause of both acute and chronic hepatitis. The clinical course of 
hepatitis C is variable with no single typical course or natural history of disease, but 
instead a broad clinical spectrum of disease presentations and outcomes (Hoofnagle, 1997). 
 
 
 1.4.1. Acute Hepatitis C 
 
Acute HCV infection is marked by the detection of HCV RNA in the serum within 1 to 2 
weeks post-exposure (Farci et al., 1991; Thimme et al., 2001).  However, acute infection is 
infrequently diagnosed because the majority of acutely infected individuals are 
asymptomatic. Indeed, in the transfusion setting, where acute onset of HCV infection has 
been best documented, 70-80 % of cases were found to be asymptomatic (McCaughan et 
al., 1992). In the few individuals (20-30 %) developing clinical symptoms, these are 
evident by 3-12 weeks post-exposure and may include malaise, weakness, anorexia, and 
jaundice (Alter & Seeff, 2000; Thimme et al., 2001). Serum alanine aminotransferase 
(ALT) levels, signifying hepatocyte necrosis, begin rising 2-8 weeks post-exposure, and 
frequently reach levels of greater than 10 times the normal upper limits (Farci et al., 1991; 
Thimme et al., 2001). Resolution of acute infection occurs in 15-40 % of patients, 
signalled by clearance of HCV RNA from blood, the return of serum ALT to normal 
levels, and the disappearance of symptoms, usually within 2-12 weeks (Hoofnagle, 1997). 
Acute infection can be severe but fulminant liver failure is rare (Farci et al., 1996a).   
 
 
1.4.2. Chronic Hepatitis C 
 
Chronic hepatitis C infection is diagnosed by the detection of HCV RNA in the blood for 
at least 6 months after infection.  In general, prospective studies have shown that 60-85 % 
of acutely infected patients will develop chronic infection (NIH Consensus, 2002). Once 
chronic, HCV infection usually persists for decades, causing insidious and progressive 
liver damage in most patients. Most patients (80 %) remain asymptomatic for 10-30 years 
despite having moderate to severe chronic liver disease (Hoofnagle, 1997; Sharara, 1997). 
There are many risk factors involved in the development of chronic HCV infection, 
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including the age at time of infection, gender, ethnicity, and the development of jaundice 
during the acute infection (Table 1). 
 
 
1.4.3. Cirrhosis and Hepatocellular Carcinoma 
 
Structural liver damage, known as fibrosis implies possible progression to extensive tissue 
scarring called cirrhosis. The time from HCV infection to cirrhosis is dependent on 
multiple internal host factors, and cannot be predicted in an individual patient (Table 2). In 
a large cohort study by Poynard et al. (1997) the median duration of infection for 
progression to cirrhosis was estimated to be 30 years, with host factors including ageing, 
alcohol consumption and male sex having a strong association with fibrosis progression. 
Also, 10-20 year follow-up studies show that cirrhosis develops in 20-30 % of patients (Di 
Bisceglie et al., 1991; Haber et al., 1995; Seeff et al., 1992; Takahashi et al., 1993; Vaquer 
et al., 1994). The progression to cirrhosis is often clinically silent, and some patients are 
not known to have hepatitis C until they present with the complications of end-stage liver 
disease or hepatocellular carcinoma (HCC). Virtually all HCV-related HCC occurs among 
patients with cirrhosis.  Once cirrhosis is established, HCC develops at an annual rate of 1-
4 % (NIH Consensus, 2002). 
 
 
1.5. Immunological Response to HCV Infection 
 
1.5.1. Innate Immunity 
 
After HCV infection, the innate immune system is the first response prior to the 
appearance of the adaptive or specific response and is designed to combat the infection 
before the virus has a chance to replicate and produce progeny (Pavio & Lai, 2003). This is 
achieved by a series of intracellular signaling events that lead to the production of an 
antiviral state directly within the infected hepatocyte and indirectly within the surrounding 
tissue (Fig. 1.2). 
 
 
 
 
Risk Factors Reference 
Age at time of infection > 25 years Alter et al. (1999), 
Bellentani & Tiribelli 
(2001) 
Male gender Kenny-Walsh (1999), Wiese 
et al. (2000) 
African American race Seeff et al. (2001), Villano 
et al. (1999) 
No Jaundice or symptoms during acute infection Villano et al. (1999), Wiese 
et al. (2000) 
HIV infection Thomas et al. (2000) 
 
Risk Factors Reference 
Alcohol consumption (>30 g/ day in males, >20 g/ 
day in females) 
(2002)  
Age at time of infection > 40 years Poynard et al. (1997) 
Male gender Poynard et al. (1997) 
Coinfection with HIV Benhamou et al. (1999), Di Martino 
et al. (2001), Ragni & Belle (2001) 
Coinfection with HBV Zarski et al. (1998) 
Immunosuppression Benhamou et al. (1999), Berenguer 
et al. (2000), Bjoro et al. (1994), 
Bjoro et al, (1999) 
 
Table 1. Risk factors for developing chronic HCV infection. 
Table 2. Risk factors for advanced progression of liver fibrosis. 
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Figure 1.2. Signalling pathways in the innate immune response to HCV infection.  
 
(a) The HCV RNA from the infecting virus is presented to recognition receptors expressed in the 
host cell. In hepatocytes, retinoic-acid-inducible gene I (RIG-I) and Toll-like receptor 3 (TLR3) 
signalling comprise the two major host defense pathways triggered by double-stranded RNA. The 
viral RNA of HCV contains extensive regions of secondary double-stranded RNA structure and is 
sufficient for this recognition, which leads to the phosphorylation and activation of interferon 
regulatory factor (IRF)-3 by the Tank-binding kinase 1 (TBK1) or I-kappa-B kinase-ε (IKK-ε) 
protein kinases. The dimer of phospho-IRF-3 translocates to the cell nucleus and binds the 
promoter regions of IRF-3 target genes, including IFN-β. (b) IRF-3 activation results in IFN-β 
production and secretion from the infected cell. (c) IFN-β binding to the IFN-α/β receptor signals 
the activation of the Tyk2 and Jak1 protein kinases that directs the phosphorylation and assembly 
of a STAT1–STAT2 heterodimer and trimeric IFN-stimulated gene factor 3 (ISGF3) complex 
containing IRF-9. The ISGF3 complex localizes to the nucleus, where it binds and directs the 
expression of IFN-stimulated genes (ISGs). (d) The IRF-7 transcription factor is an ISG expressed 
in many tissue types in response to IFN. IRF-7 phosphorylation, dimerization and 
heterodimerization with IRF-3 allow it to bind the promoter region of IFN-α genes resulting in the 
expression of IFN-α subtypes that further signal ISG expression. This increases the abundance of 
RIG-I and viral recognition signalling components whose persistent signalling acts to amplify IFN 
production and anti-viral action within host cells. Adapted from Gale & Foy (2005). 
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Since acute HCV infection is silent in most cases, very few data on the innate immune 
response are available from the acute phase in humans. Interestingly, studies using 
experimentally infected chimpanzees found that during acute infection, HCV-infected 
hepatocytes induce the transcription of numerous interferon (IFN)-stimulated genes (ISGs). 
However, this response appears to have no effect on the viral titer or outcome of infection, 
suggesting HCV can evade these antiviral effects by blocking the subsequent functions of 
ISGs (Su et al., 2002). Indeed, HCV has been shown to successfully avoid several aspects 
of the innate immune response, including expression of IFN-β, IFN signalling, and 
antiviral activities of IFN-induced proteins (Fig. 1.3) hence, the low percentage of patients 
that are able to resolve infection during the acute stage. Such activities are also likely to 
result in defects to the adaptive immune response, thereby contributing to HCV persistence 
in chronic infection. 
 
 
1.5.2. Adaptive Immune Response 
 
The adaptive immune response is divided into two major types of effector: cellular 
effectors comprised of cytotoxic T lymphocytes (CTL), and humoral effectors comprised 
of antibodies secreted by activated B lymphocytes (Pavio & Lai, 2003) (Fig. 1.4). 
 
 
1.5.2.1. Cellular Immune Response 
 
Initial studies of acutely HCV-infected patients revealed that a strong CD4+ T cell 
response to several HCV antigens in the initial phase of acute HCV infection is associated 
with viral clearance (Diepolder et al., 1995; Missale et al., 1996).  CD4+ T cell responses 
are directed mainly against non-structural proteins of HCV and often target the same 
immunodominant epitopes within the non-structural protein NS3 (Neumann-Haefelin et 
al., 2005).  Studies of the role of virus-specific CD8+ T cells in acute HCV infection 
showed that patients with a self-limited course of HCV infection mount vigorous and 
multispecific CD8+ T cell responses, targeting up to eight to twelve epitopes (Gruner et 
al., 2000; Lechner et al., 2000; Neumann-Haefelin et al., 2005). HCV-infected patients 
who develop chronic infection typically have only weak, oligo-/mono-specific or no virus-
specific CD4+ and CD8+ T cell responses in the acute (Diepolder et al., 1995; Gruner et 
al., 2000; Lechner et al., 2000; Missale et al., 1996) and chronic phase of infection 
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(Battegay et al., 1995; Chang et al., 2001; Koziel et al., 1993; Koziel et al., 1995; Lauer et 
al., 2002; Neumann-Haefelin et al., 2005; Rehermann et al., 1996; Wong et al., 2001). 
Viral escape mutations have been proposed to contribute to such failure, thereby promoting 
viral persistence. Indeed, viral amino acid (aa) substitutions that inhibit CD4+ and CD8+ T 
cell recognition have been reported in chronically infected patients and chimpanzees 
(Chang et al., 1997; Frasca et al., 1999; Kaneko et al., 1997; Tsai et al., 1998; Weiner et 
al., 1995).  
 
 
1.5.2.2. Humoral Immune Response 
 
Studies of the humoral response have revealed the presence of antibodies to virtually all 
viral antigens during the course of HCV infection in humans and chimpanzees 
(Bhattacherjee et al., 1995; Mink et al., 1994; Mondelli et al., 1994; Nasoff et al., 1991). 
However, the most attention has been focused on the envelope glycoproteins (E1E2) as 
anti-envelope antibodies have been shown to partially protect chimpanzees against 
infection (Choo et al., 1994). The impact of neutralising antibodies in the resolution of 
acute infection is poorly understood. The analysis of neutralizing responses has been 
hampered by the heterogenous nature of patient cohorts as well as HCV strains. These 
reasons likely explain why many studies assessing antibody-mediated neutralization in 
acute hepatitis C failed to reveal a clear association between neutralizing antibodies and 
viral clearance (Ishii et al., 1998; Lavillette et al., 2005; Logvinoff et al., 2004; Steinmann 
et al., 2004). The above problems were absent in one study using serum samples from a 
group of homogenous patients in a long-term follow-up of a single-source outbreak of 
HCV (Pestka et al., 2007). This unique cohort comprised young healthy females, infected 
with the same HCV genotype 1b strain by intravenous transmission. In these patients, viral 
clearance was associated with the rapid induction of neutralizing antibodies in the acute 
phase of infection and loss of neutralizing antibodies after recovery from infection. In 
contrast, chronic HCV infection was characterized by a complete absence of or reduced 
capacity to neutralize the transmitted virus in the early phase of infection and a delayed 
induction of neutralizing antibodies in the late phase of infection. This study highlights two 
important findings. First, the rapid induction of neutralizing antibodies during the early 
phase of infection may help control HCV infection. Secondly, HCV can persist despite the 
induction of antibodies neutralizing the transmitted virus. The later point is likely 
explained by viral escape from antibody-mediated neutralization by the existence of 
quasispecies with distinct viral variants in infected individuals changing constantly over 
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Figure 1.3. HCV evasion from the innate immune response. 
 
(A) NS3/4A blocks RIG-I and TLR3 signalling. RIG-I activation by HCV induces a 
conformational change that facilitates its interaction with the innate immune adaptor proteins IPS-
1. This leads to assembly of a complex on the mitochondria that signals downstream to activate the 
kinases IKK-ε and TBK1, which phosphorylate the transcription factors IRF-3 and IRF-7. The 
HCV NS3/4A protease cleaves IPS-1 to release it from the mitochondrial membrane thereby 
abolishing RIG-I-mediated signal transduction. NS3/4A also cleaves TRIF (Toll/interleukin-1 
receptor/resistance domain-containing adaptor inducing IFN), the signaling adaptor molecule for 
TLR3, to prevent TLR3-mediated antiviral signaling. (B) HCV core protein blocks the Jak/STAT 
pathway. HCV core protein directly binds to STAT1 to prevent its phosphorylation and subsequent 
activation of downstream anti-HCV ISGs. HCV core protein also induces expression of the 
suppressor of cytokine signaling-3 (SOCS3), a negative regulator of the Jak/STAT signaling 
pathway, causing a decreased STAT1 activation in response to type I IFN. (C) HCV proteins 
directly interfere with the two ISGs Protein Kinase R (PKR) and 2’5’ oligoadenylate synthetase (2-
5 OAS). Both the HCV NS5A and E2 protein bind PKR and inhibit its activation. NS5A also 
blocks the antiviral function of 2–5 OAS through a direct interaction. Adapted from Horner & Gale 
(2009). 
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Figure 1.4. The interaction of different arms of the HCV-adaptive immune response.   
 
Specific CD4+ T helper cells recognise viral peptides bound to HLA class II molecules present on 
the surface of professional antigen presenting cells (APCs) (e.g monocytes, macrophages, B cells, 
dendritic cells).  CD4+ T cell activation results in the development of either Th1 or Th2 helper 
cells.  Th1 cells secrete interleukin (IL)-2, tumour necrosis factor alpha (TNF-α), and IFN-γ, which 
then stimulate the development of CD8+ Cytotoxic T Lymphocytes (CTLs).  Th2 cells, promote 
the development of virus-specific antibody producing B cells through secretion of IL-4, IL-5, IL-
10. Specific CTLs recognise viral peptides bound to HLA class I molecules on the surface of 
infected hepatocytes leading to the elimination of infected cells.  CD8+ T cells perform important 
non-cytolytic effector functions as well, including the secretion of cytokines such as IFN-γ and 
TNF-α that can inhibit viral replication without killing the infected cell (Neumann-Haefelin et al., 
2005; Pavio & Lai, 2003). Adapted from Diepolder et al. (1998). 
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time. Such rapid evolution is likely to be a result of the high mutation (10-3 per nucleotide 
per generation) and replication rate (~1012 virions per day) of HCV in humans (Neumann 
et al., 1998). Indeed, another study using serum samples collected from a chronically 
infected patient, demonstrated that the neutralizing antibody response lags behind the 
rapidly evolving glycoprotein sequences present within the quasispecies population (von 
Hahn et al., 2007). The highest rate of aa substitutions occurred in the most genetically 
variable segment of the envelope protein known as hypervariable region 1 (HVR1). This 
region comprises a ~30 aa stretch at the N-terminus of E2 that is highly tolerant to aa 
substitutions and is subject to strong selection pressure. HVR1 is a target for anti-HCV 
neutralising antibodies and assumed to exist as a polypeptide loop on the surface of the 
virion (Kato et al., 1992a; Kato et al., 1992b; Weiner et al., 1991). In infected patients the 
appearance of anti-HVR1 antibodies can alter the quasispecies, selecting variants that are 
less reactive to such antibodies. This indicates that HVR1 harbours a neutralisation epitope 
that is the site of escape mutations from the humoral immune response (Farci et al., 1996b; 
Kato et al., 1993; Weiner et al., 1992). In line with this, HCV-infected patients with 
humoral immunodeficiency display slower evolution of aa sequence changes within HVR1 
compared to immunocompetent patients (Booth et al., 1998). This suggests that in the 
absence of a virus specific antibody response no selection of mutant viruses occurs. It has 
been suggested that HVR1 may function as an immunologic decoy during infection by 
masking a deeper, more highly conserved structure within the envelope, such as a cellular 
receptor recognition site (Ray et al., 1999). Importantly, deletion of HVR1 does not 
eliminate the ability of HCV to infect chimpanzees, suggesting that it is not critical for 
viral entry or release (Forns et al., 2000). 
 
 
1.6. Pathobiological Changes Induced by HCV Infection 
 
1.6.1. Immune-Mediated Damage in Chronic HCV-Infection  
 
Immunophenotyping of intrahepatic infiltrating inflammatory cells in patients with chronic 
HCV infection revealed a predominance of CD4+ and CD8+ T cells, implying that the host 
immune system is involved in liver disease pathogenesis (Onji et al., 1992). Also, patients 
with mild HCV-related liver disease have been shown to have a strong HCV-specific 
CD4+ T cell proliferative response in peripheral blood in comparison to patients with 
active liver disease (Botarelli et al., 1993; Hoffmann et al., 1995). In terms of 
 9
immmunopathogenesis one explanation for this finding is that HCV-specific CD4+ T cells 
are compartmentalized in the liver of patients with active liver disease and, hence, there is 
a low frequency of HCV-specific CD4+ T cells in peripheral blood. Also, in chronically 
infected patients the frequency of HCV-specific CD8+ T cell precursors was found to be 
higher in liver than in peripheral blood, suggesting active recruitment of HCV-specific 
CD8+ T cells in liver. The detection of HCV-specific CD8+ T cell activity in liver was 
associated with lower levels of viraemia and higher levels of disease activity, providing 
support for their involvement in the control of viral infection and their contribution to 
disease (Nelson et al., 1997). Therefore, the majority of the liver damage experienced in 
patients who fail to clear the virus is most likely due to compartmentalisation of HCV-
specific CD4+ and CD8+ T cells.  
 
 
1.6.2. HCV Cytopathogenicity 
 
The majority of evidence indicates that HCV is not significantly cytopathic in the non-
immunosuppressed state. Arguments against a direct viral cytopathic effect (CPE) include, 
little correlation between intrahepatic HCV load and disease activity (McGuinness et al., 
1996), minimal or no hepatocyte damage occurring despite viraemia (Brillanti et al., 1993), 
and low levels of HCV RNA detected in patient sera with HCV-associated fulminant 
hepatitis (Farci et al., 1996a). These observations taken together with the evidence of 
immunopathogenesis imply that hepatocellular damage is immune-mediated rather viral 
derived.  
 
However, histological examination of HCV-infected livers in early studies showed 
morphological alterations of cellular architecture such as cell shrinkage, cell rounding and 
nuclear pycnosis, which are characteristics of CPE (Bamber et al., 1981; Dienes et al., 
1982). More recent histological observations supporting a CPE specifically induced by 
HCV include hepatocellular steatosis, and fibrosing cholestatic hepatitis (FCH). 
Hepatocellular steatosis is characterized by lipid accumulation in the hepatocyte cytoplasm 
and is found in 41-73 % of patients with chronic hepatitis C. This virus-induced steatosis is 
primarily associated with genotype 3 infection, correlates with serum HCV RNA levels, 
and disappears after successful antiviral therapy (Castera et al., 2005). FCH, initially 
described in HBV infection, is a severe and progressive form of liver dysfunction seen in a 
small subset of organ transplant recipients (Doughty et al., 1998; Schluger et al., 1996; 
Toth et al., 1998). Manifested by rapidly progressive liver failure, FCH is characterized 
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histologically by hepatocyte ballooning, cholestasis, minimal inflammation, and periportal 
fibrosis. The pathogenesis of HCV-induced FCH has been attributed to unrestrained viral 
replication within hepatocytes in the absence of an effective cellular immune response, 
culminating in a direct CPE (Rosenberg et al., 2002). 
 
In addition, patients with impaired cellular responses suffer a more severe course of liver 
disease than immunocompetent patients (Einav & Koziel, 2002). This is particularly 
evident in HCV-infected liver transplant (LT) patients, those co-infected with human 
immunodeficiency virus (HCV/HIV) or those suffering from hypogammaglobulinaemia 
(HGG). As shown in Table 3 these groups of patients have extremely rapid cirrhosis 
progression rates compared to immunocompetent patients. Based on this rationale the lack 
of an efficient immune response in such patients would allow widespread viral replication 
and thus, a direct HCV-induced CPE could well be the pathogenic mechanism responsible 
for the liver damage observed. Unfortunately, the scarcity and divergence of data available 
on the viral load within these studies make it difficult to comment on the association 
between viral load and disease severity. Together, these data suggest that the 
pathobiological changes induced by HCV infection are a result of both the immune 
response and direct viral CPE. 
 
 
1.7. Treatment of HCV Infection 
 
The current reference treatment of naïve patients with chronic hepatitis C is the 
combination therapy with pegylated IFN-α plus ribavirin (Gotto & Dusheiko, 2004). The 
mechanisms through which IFN and ribavirin exert their anti-HCV effects are currently 
unknown. The main aim of HCV treatment is to interfere with progression of chronic 
hepatitis to cirrhosis by the eliminating the virus at an early stage of the disease.  Clearance 
of virus is possible and the aim of therapy is to achieve undetectable HCV RNA 6 months 
following therapy (sustained viral response, SVR). This is maintained long-term and is 
significantly associated with reduction in inflammation and fibrosis (Poynard et al., 2002). 
However, only 40-50 % of individuals infected with HCV genotypes 1 or 4 obtain a SVR, 
compared with 80 % of patients infected with genotypes 2 or 3 (Soriano et al., 2009). To 
date, there is no published data on the treatment outcome in patients with genotypes 5 and 
6. Unfortunately, as well as the limited response rate in treated patents, therapy is costly, 
and can cause severe side effects including myalgia, fever, headaches, haemolytic anaemia 
and severe depression (Fried et al., 2002). Consequently, more effective and better-
Table 3. Time to development of cirrhosis in representative cohorts of 
immunocompetent and different groups of immunosuppressed HCV patients. 
Patient group Time to cirrhosis (years) References 
Immunocompetent 30/ 13-42 Poynard et al. (1997) 
HIV-HCV 6. 9-28   Soto et al. (1997) 
Benhamou et al. (1999) 
Martinez-Sierra et al. (2003) 
Mohsen et al. (2003) 
LT 1-5 Gane et al. (1996) 
Prieto et al. (1999) 
Feray et al. (1999) 
Berenguer et al. (2000) 
HGG 1. 5-15 Bjoro et al. (1999) 
Christie et al. (1997) 
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tolerated therapies to treat HCV infection are urgently required. Indeed, the recent 
advances in understanding the HCV lifecycle through the development of HCV replicons 
(autonomously replicating genomes) and cell culture infectious systems have enabled the 
production of STAT-C (specifically targeted antiviral therapy for hepatitis C) compounds 
designed to specifically inhibit HCV replication. The goal of future HCV therapy is to 
generate antiviral drugs that are less toxic, more potent, and allow shorter duration of 
therapy than the current standard treatment. Ideally, such compounds should have the 
capacity to cure the majority of patients between 12-24 weeks of therapy. The NS3/4A 
protease (required for cleavage of the viral polyprotein) and the NS5B RNA dependent 
RNA polymerase are currently the two most promising targets for the design of specific 
HCV inhibitors (Soriano et al., 2009). Teleprevir (TVR) is the most promising drug 
candidate from the protease inhibitors designed to target NS3/4A. TVR was designed using 
structure based drug-design techniques and its proof of concept was demonstrated by the 
elimination of HCV RNA from cell lines harbouring replicons (Lin et al., 2006a; Lin et al., 
2006b). Phase 2 clinical trials of TVR used in combination with pegylated IFN-α and 
ribavirin produced promising results. This novel triple therapy attained a SVR in 62 % of 
patients with only 12 weeks of therapy, compared to 48 % after 48 weeks using standard 
therapy. The trial found the main side effects of TVR were skin rashes, nausea and 
anaemia. The compound is currently being tested in phase 3 clinical trials (Soriano et al., 
2009). In terms of HCV polymerase inhibitors, R-1626 was one of the promising 
candidates that underwent clinical trails. R-1626 is a nucleoside analogue that acts as a 
chain terminator preventing elongation of the nascent RNA strand, thereby blocking HCV 
replication. Although, this drug demonstrated potent antiviral activity against all HCV 
genotypes in early in vitro experiments, during phase II clinical trials, the majority of 
patients treated with R-1626 in combination with pegylated IFN or pegylated IFN and 
ribavirin suffered severe neutropenia. Moreover, a high rate of HCV infection relapse 
occurred after completion of therapy (Pockros et al., 2008). As a result, the development of 
R-1626 was halted at the end of 2008. 
 
 
1.8. Genome Organisation 
 
The genome of HCV is a positive-sense, single-stranded RNA molecule approximately 9.6 
kb in length. The genome comprises a long (~3000 aa) open reading frame (ORF), 
encoding structural and non-structural (NS) proteins, flanked by two untranslated regions 
(UTRs) at the 5’ and 3’ ends. The structural proteins, located in the N-terminal region, 
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include the core protein, the envelope proteins E1 and E2 and probably p7. The non-
structural region of the ORF comprises six proteins, NS2, NS3, NS4A, NS4B, NS5A and 
NS5B (Fig. 1.5). 
 
 
1.8.1. Untranslated RNA Segments 
 
Depending on the isolate, the HCV 5’ UTR is approximately 341 nucleotides long and has 
a highly conserved sequence with up to 85 % similarity shared between HCV isolates 
(Bukh et al., 1992). The predicted secondary structure of the 5’UTR shows 4 highly 
structured domains (domains I to IV) (Fig. 1.6) (Honda et al., 1999). HCV contains an 
internal ribosomal entry site (IRES) spanning domains II, III and IV of the 5’ UTR, and 
includes the first 24-40 nucleotides of the core-coding sequence (Honda et al., 1996b; 
Reynolds et al., 1996). The HCV IRES allows cap-independent translation initiation of the 
viral ORF (Tsukiyama-Kohara et al., 1992; Wang et al., 1993) and is capable of binding 
directly to the 40S ribosome subunit in the absence of any protein translation initiation 
factor (Pestova et al., 1998). Domains II and III directly contact and position 40S 
ribosomal subunit at the AUG codon for core protein and thus these domains are essential 
for genome translation (Honda et al., 1996a; Honda et al., 1996b). Domain IV is not 
required for ribosome binding, although the structural stability of this region is inversely 
proportional to translation efficiency (Honda et al., 1996a). In addition to its importance in 
translation, the 5’ UTR is also essential for genome replication. Domains I and II are 
sufficient for viral RNA synthesis, although the efficiency of this process is enhanced by 
the presence of the complete 5’ UTR (Friebe et al., 2001; Kim et al., 2002).  
 
A number of host factors are known to associate with the HCV 5’ UTR and regulate both 
replication and translation of the viral genome. These include, polypyrimidine tract binding 
protein (PTB) (Ali & Siddiqui, 1995), La autoantigen (Ali & Siddiqui, 1997) and poly 
(rC)-binding protein (Fukushi et al., 2001). Each of these factors influences viral RNA 
replication, while PTB and La autoantigen are also required for translation (Domitrovich et 
al., 2005; Fukushi et al., 2001). Another cellular protein known to bind the 5’ UTR is 
heterogenous nuclear protein L (Hahm et al., 1998), although the function of this 
interaction remains to be determined. A recent study discovered that the liver-specific 
microRNA-122 (miR-122) base pairs at two locations within the unstructured region 
between domains I and II of the 5’ UTR sequence. This binding is essential for both viral 
5
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Figure 1.5. General features of the HCV genome and polyprotein processing.  
 
5’ and 3’ UTRs flank the HCV ORF, which generates a single polyprotein with structural proteins 
(nucleocapsid protein or core, envelope glycoproteins E1 and E2, and probably p7) grouped at the 
N-terminus followed by the nonstructural proteins (NS2-5B). The polyprotein is cleaved into the 10 
individual HCV proteins by both host and viral proteases through complex co- and 
posttranslational events. Adapted from Tellinghuisen et al. (2007) .  
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Figure 1.6. Proposed secondary and tertiary structure of the HCV 5’ UTR, together with a 
small portion of the core-coding sequence, from genotype 1b infectious clone (HCV-N). 
 
Major structural domains (I through IV) and subdomains (IIIa through IIIf) are indicated with 
Roman numerals and the initiator AUG codon within stem-loop IV is underlined. Adapted from 
Honda et al. (1999). 
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Figure 1.7. Predicted secondary structure of the HCV 3’ UTR from the genotype 1b Con1 
isolate.   
 
The positions of the two stem-loops (VSL1 and VSL2) in the variable region, the 83 nucleotide 
poly (U/UC) tract, and the three stem-loops (SL, SL2 and SL3) in the 3’X-tail are indicated. The 
stop codon of the polyprotein ORF is boxed. Adapted from Friebe & Bartenschlager (2002). 
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RNA replication (Jopling et al., 2008; Jopling et al., 2005) and translation (Henke et al., 
2008).  
 
The HCV 3’ UTR has a tripartite structure comprising a variable region which is poorly 
conserved between genotypes, a poly (U/UC) tract and a highly conserved, 98 nucleotide 
sequence known as the 3’ X tail (Kolykhalov et al., 1996). Biochemical and structural 
studies have confirmed two stem loops in the variable region (VSL1 and VSL2) and three 
stem loops in the 3’ X-tail (SL1, SL2 and SL3) (Fig. 1.7) (Blight & Rice, 1997; Tanaka et 
al., 1996). VSL1 and VSL2 are dispensable for RNA replication in cell culture (Friebe & 
Bartenschlager, 2002) and for HCV infectivity in chimpanzees (Yanagi et al., 1999). The 
poly (U/UC) region is variable in length and composition, consisting of uridine residues 
that are interspersed with occasional cytidine residues. This segment must be at least 26 
nucleotides in length to permit viral RNA replication (Friebe & Bartenschlager, 2002). 
Deletion of any one of the 3’ X-tail stem-loops prevents replication in cell culture (Friebe 
& Bartenschlager, 2002; Yi & Lemon, 2003) as well as infectivity in chimpanzees (Yanagi 
et al., 1999) Aside from roles in replication, the 3’ UTR also stimulates IRES-mediated 
translation of viral RNA. This stimulation was stronger in hepatoma cell lines (Huh-7 and 
HepG2) compared to non-hepatoma lines (BHK and HeLa) (Song et al., 2006). It has been 
proposed that the 3’ UTR enhances IRES-dependent translation by increasing the 
efficiency of termination (Bradrick et al., 2006). Several of the cellular proteins shown to 
interact with the 5’ UTR also bind to the 3’ UTR including PTB and La autoantigen (Ito et 
al., 1998; Spangberg et al., 1999; Wood et al., 2001), although the functional significance 
of these interactions have yet to be determined.  
 
1.8.2. HCV-Encoded Proteins 
 
 
1.8.2.1. Core Protein 
 
The properties of core protein are discussed in detail in section 1.11. 
 
 
1.8.2.2. E1 AND E2 
 
The viral envelope glycoproteins E1 and E2 are located on the surface of the virion and 
mediate particle interaction with cellular receptors. Both proteins are critical for virus entry 
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into host cells (Bartosch et al., 2003a) as well as the assembly of infectious virus particles 
(Wakita et al., 2005). Following genome translation, E1 and E2 are liberated from the viral 
polyprotein following proteolytic cleavage by host cell signal peptidases (Fig. 1.5) 
(Miyamura & Matsuura, 1993). Both proteins are classed as type I transmembrane proteins 
having an N-terminal ectodomain translocated into the endoplasmic reticulum (ER) lumen, 
and a C-terminal hydrophobic anchor inserted into the ER membrane (Op De Beeck et al., 
2001). E1 and E2 associate with each other as a noncovalent heterodimeric complex and it 
is believed that the correct conformational folding of either protein is dependent on the 
expression of the other (Deleersnyder et al., 1997; Michalak et al., 1997). E1 and E2 
undergo asparagine (N) – linked glycosylation with each protein possessing 6 and 11 
potential sites, respectively (Lavie et al., 2007). It is believed that these glycans function in 
protein folding, receptor interactions and sensitivity to neutralising antibodies (Goffard et 
al., 2005; Helle et al., 2007; Lavie et al., 2007; Lozach et al., 2003).  
 
 
1.8.2.3. p7 
 
The tenth HCV-encoded cleavage product to be identified was the p7 polypeptide, which is 
located at the junction between the structural and nonstructural proteins of the HCV 
polyprotein (Lin et al., 1994a). Whether p7 corresponds to a structural or non-structural 
protein remains to be determined. Cleavage of p7 from the polyprotein is mediated by a 
host signal peptidase, which, due to the presence of an E2-p7-NS2 precursor and stable E2-
p7 form, is likely to occur post-translationally (Lin et al., 1994a). p7 is a polytopic 
membrane protein harbouring two transmembrane domains (TMDs) connected by a 
cytoplasmic loop with both its N- and C termini orientated towards the ER lumen (Carrere-
Kremer et al., 2002). In studies using recombinant expression plasmids, p7 has been found 
localised to ER (Carrere-Kremer et al., 2002; Isherwood & Patel, 2005) and mitochondrial 
membranes (Griffin et al., 2005), with a small fraction also being detected at the plasma 
membrane (Carrere-Kremer et al., 2002). However, a more recent report suggests that HA-
tagged p7, expressed from the full-length HCVcc infectious RNA, localises solely to the 
ER (Haqshenas et al., 2007).  Interestingly, the p7 polypeptide has been shown to exhibit 
ion channel activity in artificial membranes (Griffin et al., 2003; Pavlovic et al., 2003). In 
accordance with these data, p7 has been shown to oligomerize in vitro and form hexameric 
structures indicative of ion channels (Griffin et al., 2003; Luik et al., 2009). Also, this p7 
function can be inhibited by amantadine, a compound that inhibits the influenza A-encoded 
M2 ion channel activity (Griffin et al., 2003). p7 is not required for RNA replication 
 15
(Lohmann et al., 1999), but injection of viral RNAs harbouring p7 deletions into 
chimpanzees has shown that the protein is essential for HCV infectivity in vivo (Sakai et 
al., 2003). Using the HCVcc system, it has been demonstrated that deletion of p7 
eliminates infectious virus production and furthermore, that this block occurs prior to the 
assembly of HCV virions (Jones et al., 2007; Steinmann et al., 2007a). In line with this, 
compensatory and adaptive mutations in p7 have been shown to enhance virus production 
(Kaul et al., 2007; Murray et al., 2007; Russell et al., 2008; Yi et al., 2007).  Interestingly, 
two recent studies have shown that several inhibitory compounds known to interfere with 
the p7 ion channel activity in vitro also repress the release of infectious virus particles in 
the HCVcc system (Griffin et al., 2008; Steinmann et al., 2007b). Strikingly, Griffin et al. 
(2008) found moderate effects of these inhibitors on virus entry, suggesting p7 may be a 
component of the virion. Together, these data suggest that the ion channel activity of p7 is 
critical for its role in HCV propagation, highlighting this protein as an attractive target for 
antiviral therapies. 
 
 
1.8.2.4. NS2 
 
NS2 functions in the proteolytic cleavage of the NS2/NS3 junction (Fig. 1.5). The catalytic 
activity of this protease requires the C-terminal half of NS2 and the N-terminal one-third of 
NS3 (Grakoui et al., 1993b; Hijikata et al., 1993a). This NS2/NS3 enzyme has been 
described as a cysteine proteinase (Pallaoro et al., 2001). The crystal structure of the NS2 
C-terminal region reveals a dimeric cysteine protease with two composite active sites. For 
each active site, the catalytic histidine and glutamate residues are contributed by one 
monomer, and the nucleophilic cysteine by the other (Lorenz et al., 2006). NS2 associates 
with ER membranes and is predicted to be a polytopic membrane protein with possibly 4 
TMDs (Santolini et al., 1995; Yamaga & Ou, 2002). It was recently shown that residues 3-
23 of NS2 form an interrupted α-helix that is likely to serve as the first TMD (Jirasko et 
al., 2008). NS2 is the only NS protein that is not required for RNA replication (Jones et al., 
2007; Lohmann et al., 1999). Although, full-length NS2 has been shown to be important 
for the assembly of infectious particles in HCVcc, this effect is independent of the proteins 
proteolytic function (Jirasko et al., 2008; Jones et al., 2007).  Interestingly, the crossover 
sites for generating infectious inter/intragenotypic chimeric HCVcc genomes containing 
the NS3-NS5B region from strain JFH1 and the structural genes from other genotypes have 
been mapped to the NS2 junction (Gottwein et al., 2009; Lindenbach et al., 2005; 
Pietschmann et al., 2006). Numerous studies have also identified adaptive mutations in 
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NS2 that enhance HCVcc virus production (Gottwein et al., 2009; Russell et al., 2008; Yi 
et al., 2007), further supporting the role of this protein in the virus assembly pathway. 
Interactions between NS3, NS4A and a p7-E1-E2 complex have been reported for NS2 
(Flajolet et al., 2000; Kiiver et al., 2006; Selby et al., 1994; Steinmann et al., 2007a). In 
line with this, a recent HCVcc study identified compensatory mutations in E1, E2, NS3 
and NS4A that could suppress the virus assembly defects caused by several engineered 
mutations within conserved NS2 residues (Phan et al., 2009). Thus, NS2 likely contributes 
to virus assembly in concert with other structural and non structural proteins.  
 
 
1.8.2.5. NS3 and NS4A  
 
NS3 is a multifunctional protein, containing a serine protease within its N-terminal third 
(Bartenschlager et al., 1993; Grakoui et al., 1993a; Hijikata et al., 1993a; Tomei et al., 
1993) and an NTPase/helicase within its C-terminal two-thirds (Kim et al., 1995; Suzich et 
al., 1993). The NS4A polypeptide functions as a co-factor for both these enzymatic 
activities. The NS3 serine protease domain facilitates 4 cleavage events, acting in cis to 
liberate itself from the HCV polyprotein (Section 1.8.2.4) and in trans to produce the N-
termini of NS4B, NS5A and NS5B (Bartenschlager et al., 1993; Grakoui et al., 1993a; Lin 
et al., 1994b; Tomei et al., 1993) (Fig. 1.5). The C-terminal domain of NS4A is required 
for efficient cleavage of the downstream polyprotein, especially at the NS4B/5A cleavage 
site (Bartenschlager et al., 1994; Failla et al., 1994). The C-terminal two-thirds of NS3 
encodes a DExH-box RNA helicase whose RNA unwinding activity requires an NS3 dimer 
(Serebrov & Pyle, 2004; Tai et al., 1996). For efficient RNA helicase activity, NS3 
requires both its protease domain and its NS4A cofactor (Beran et al., 2009; Frick et al., 
2004; Pang et al., 2002). The crystal structure of the NS3 helicase shows a Y-shaped 
molecule composed of 3 subdomains (Kim et al., 1998; Yao et al., 1997).  While this 
structure provides important insights into the mechanisms behind its nucleotide unwinding 
activities, the exact function(s) of this RNA helicase in the virus lifecycle remains 
unknown.  NS3 has no TMD but is targeted to ER through its non-covalent association 
with the central domain of NS4A (Wolk et al., 2000). NS3 is essential for viral RNA 
replication (Lohmann et al., 1999), and depends on both the RNA binding and helicase 
activity of the protein (Beran et al., 2009). In accordance with these findings, cell culture 
adaptive mutations have been identified in the protease and helicase regions of NS3, which 
enhance the RNA replication of subgenomic replicons (SGRs) (Lohmann et al., 2003) 
(Section 1.9.2). More recently, studies using HCVcc have identified compensatory 
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mutations in NS3 that rescue the assembly of infectious virus from defective mutant and 
chimeric genomes (Ma et al., 2008; Phan et al., 2009; Yi et al., 2007). Together, these data 
indicate NS3 is an important viral protein for RNA replication and infectious particle 
assembly. In addition to its requirement in NS3 enzymatic activity and membrane 
targeting, NS4A influences NS5A phosphorylation and HCV RNA replication through its 
acidic C-terminal region (Lindenbach et al., 2007). 
 
 
1.8.2.6. NS4B 
 
NS4B localises to the ER independent of the other HCV proteins and is believed to have at 
least 4 TMDs between aa 75-191 that bind the protein tightly to ER membranes (Hugle et 
al., 2001; Lundin et al., 2003). Upstream of these TMDs, the N-terminal segment is 
predicted to contain an amphipathic α-helix (Elazar et al., 2004) and a fifth TMD (Lundin 
et al., 2003). One likely function of NS4B is to induce ER membrane alterations required 
for the formation of viral RNA replication complexes. These structures induced by NS4B 
expression are referred to as the membranous web (Egger et al., 2002; Gosert et al., 2003) 
or membrane-associated foci (MAF) (Gretton et al., 2005). Other NS proteins have been 
shown to localise to these structures, including NS3, NS4A, NS5A and NS5B (Elazar et 
al., 2004; Hugle et al., 2001). Importantly, disrupting the ability of NS4B to bind to ER 
membranes leads to a loss of proteins at these foci in addition to abolishing replication of 
the viral genome (Elazar et al., 2004). Thus, these NS4B-induced membrane alterations are 
likely to create an environment suitable for viral RNA replication. Cell culture adaptive 
mutations within NS4B that significantly enhance the RNA replication levels of SGRs 
have been reported (Lohmann et al., 2003). Also, recent studies that performed detailed 
mutagenesis of NS4B revealed specific aa changes with the ability to enhance as well as 
abolish RNA replication of SGRs (Jones et al., 2009; Lindstrom et al., 2006). In HCVcc, 
NS4B mutations were identified that could influence the level of infectious virus release 
(Jones et al., 2009). Together, these data indicate NS4B functions in the formation of 
replication complexes, RNA replication and infectious particle release.  
 
 
1.8.2.7. NS5A 
 
NS5A is composed of 3 domains that are separated by low complexity sequences (LCS I 
and LCS II) (Tellinghuisen et al., 2004). Preceding domain I is an N-terminal amphipathic 
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α-helix that anchors the protein to ER membranes and disruption of this structure leads to a 
loss in membrane binding and viral RNA replication in SGRs (Brass et al., 2002; Elazar et 
al., 2003). Domain I is the most conserved NS5A domain and is capable of binding a 
single zinc atom per molecule, which is required for SGR RNA replication (Tellinghuisen 
et al., 2004). The crystal structure of domain I reveals that it may dimerise to form a basic 
groove that could accommodate a single-strand RNA molecule (Tellinghuisen et al., 2005). 
In line with this, NS5A has been shown to bind to the 3’ ends of both positive- and 
negative-strand HCV RNA (Huang et al., 2005). Replication enhancing mutations have 
also been identified in domain I using SGRs, highlighting the important role of this domain 
in RNA replication (Blight et al., 2000; Lohmann et al., 2003). Domains II and III are 
poorly characterised compared to domain I. Recent studies have suggested that domain II 
is flexible and disordered in nature (Liang et al., 2006), while domain III is mostly 
unstructured (Hanoulle et al., 2009). Deletion analyses have shown that large portions of 
domain II and the entire domain III are dispensable for SGR and HCVcc RNA replication 
(Appel et al., 2008; Tellinghuisen et al., 2008b). While, a nearly complete deletion of 
domain II had little effect on HCVcc virus production, large domain III deletions 
significantly impaired virus infectivity (Appel et al., 2008; Hughes et al., 2009; Masaki et 
al., 2008).  It has recently been reported that core and NS5A associate with LDs, an event 
that is crucial for virus assembly in HCVcc (Section 1.10.3). Moreover, mutations within 
domain I of NS5A prevent its association with LDs, severely impairing virus production as 
a result (Miyanari et al., 2007). Interestingly, Appel et al. (2008) found that the deletions in 
domain III that impaired virus production did not prevent NS5A-LD attachment but instead 
abolished its association with core protein on LDs.  
 
NS5A is a phosphoprotein that exists in hypophosphorylated and hyperphosphorylated 
forms (Tanji et al., 1995). It is not known which of the numerous potential phosphorylation 
sites in NS5A are relevant to these forms. However, accumulating evidence suggests that 
hypophosphorylation primarily targets residues in domains II and III, whereas the 
hyperphosphorylation sites cluster in and around domain I (Huang et al., 2007b). A recent 
study showed that mutation of two separate clusters (CLA and CLB) of domain III serine 
residues impaired the hypophosphorylation of NS5A. While the RNA replication of both 
mutants was unaltered, CLB had severely impaired virus production of HCVcc while CLA 
was unaffected (Masaki et al., 2008). The effect of CLB was later found to be caused by 
these mutations disrupting a direct interaction of NS5A with core protein, resulting in a 
loss of NS5A-LD association. One study found that reducing NS5A hyperphosphorylation 
by mutating serine clusters around domain I resulted in enhanced SGR RNA synthesis 
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(Appel et al., 2005). More recently, a single serine residue in domain III was identified that 
impaired NS5A hyperphosphorylation, had no effect on HCVcc RNA replication but 
almost completely abolished virus production (Tellinghuisen et al., 2008a). Overall, these 
data suggest NS5A is a key mediator of viral RNA replication and virus production 
through distinct mechanisms.  
 
 
1.8.2.8. NS5B 
 
NS5B is the HCV RNA-dependent RNA polymerase (RdRp) that synthesises the positive 
and negative-strand viral RNAs during RNA replication. NS5B can initiate RNA synthesis 
de novo, a mechanism that is likely to operate in vivo (Luo et al., 2000; Oh et al., 1999; 
Zhong et al., 2000). NS5B is capable of copying HCV genomes in the absence of other 
viral or cellular factors (Behrens et al., 1996; Lohmann et al., 1997). However, in cell 
culture an interaction between NS5A and NS5B is critical for the RNA replication of SGRs 
(Shimakami et al., 2004). NS5B associates to the ER membrane via a C-terminal TMD, 
which is critical for SGR RNA replication (Ivashkina et al., 2002; Moradpour et al., 2004). 
NS5B contains motifs common to all RdRps, including the GDD sequence that represents 
the hallmark signature of most polymerases (Bartenschlager et al., 2004). The crystal 
structure of NS5B has been determined by several groups (Ago et al., 1999; Biswal et al., 
2005; Bressanelli et al., 1999; Lesburg et al., 1999; Simister et al., 2009). As with other 
nucleic acid synthesising enzymes, it was found to be a typical right-hand polymerase with 
a central palm domain harbouring the catalytic GDD motif and the fingers and thumb 
domains on either side creating a channel for binding the RNA template. Extensive 
interactions between the fingers and thumb domains result in a completely enclosed active 
site, a feature shared with other RdRps. A recent study reported the RdRp from the JFH1 
strain exhibited a far greater capacity to initiate RNA synthesis de novo than the closely 
related J6 strain RdRp. The crystal structure of JFH1 NS5B revealed a more closed 
conformation than a genotype 2a consensus structure and previously reported HCV 
polymerase structures. This closed conformation is more suited for single-stranded RNA 
binding, which may promote more efficient de novo initiation (Simister et al., 2009). These 
observations may in part explain the outstanding replication efficiency of SGRs and full-
length genomes harbouring the JFH1 replicase compared to those tested from other 
isolates.  
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1.9. Systems to Study HCV Replication 
 
1.9.1. Animal Models 
 
Until very recently, the restrictive host range of HCV limited animal studies to 
chimpanzees. Indeed, the chimpanzee model was first used to characterise the 
physicochemical properties of the NANBH agent, prior to the cloning of HCV from 
plasma collected from a persistently infected chimpanzee in 1989 (Section 1.1). However, 
it was not until 1997 that the first functional full-length HCV molecular clones were 
established. Two genomes constructed from a genotype 1a isolate (strain H77) could 
establish productive infection in chimpanzees after intrahepatic inoculation with in vitro 
transcripts (Kolykhalov et al., 1997; Yanagi et al., 1997). Other infectious clones have 
since been reported in chimpanzees (Bartenschlager & Sparacio, 2007). The chimpanzee is 
an ideal model for HCV infection given their genetic similarity to humans (98.5 %) and 
their disease progression following a clinical course similar to that seen in human patients. 
Despite the invaluable contributions this model has made to HCV research, due to limited 
availability, expense and the ethical issues which arise from their use, chimpanzees have 
not been utilised for anti-HCV drug discovery. This knowledge will best be attained 
through a widely available and easily accessible animal model for HCV (Grakoui et al., 
2001). Rodents are regarded the most suitable for all biological studies given their short 
gestation period, small size and low cost. Although, rodents are naturally non-receptive to 
HCV infection, if maintained in an immunosuppressed state, they can undergo successful 
transplantation with human hepatocytes allowing viremia to develop. The most successful 
HCV rodent model has been the Alb-uPA transgenic mouse developed in mice with severe 
combined immunodeficiency (SCID). These mice contain an additional copy of the 
urokinase-type plasminogen activator (uPA) expressed from an albumin (Alb) promoter. 
The Alb-uPA transgene overexpression is hepatotoxic and results in homozygous mice 
with severe liver damage (Heckel et al., 1990). This defect, in combination with severe 
immunodeficiency allows the mice livers to be repopulated with non-transgenic human 
hepatocytes that are susceptible to HCV infection (Mercer et al., 2001). Inoculation of 
mice with virus obtained from HCVcc or the sera from HCV positive patients leads to a 
rapid increase in viremia that is sustained over several weeks (Lindenbach et al., 2006; 
Mercer et al., 2001; Meuleman et al., 2008; Vassilaki et al., 2008). This model has 
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demonstrated in vivo infection can be prevented by inhibitory antibodies targeting the viral 
glycoproteins (Law et al., 2008; Vanwolleghem et al., 2008) and the HCV cellular receptor 
CD81 (Meuleman et al., 2008). Such chimeric mice have also been used for the study of 
pharmacokinetics and drug toxicity (Katoh et al., 2008; Vanwolleghem et al., 2007). Thus, 
these xenotransplanted humanized mice hold great potential as a means of assessing drug 
efficacy. The uPA mouse model, however, has certain limitations that include excessive 
mortality, low breeding efficiency, transgene reversion, and overall colony management 
(Meuleman & Leroux-Roels, 2008). Robust HCV propagation has recently been described 
in a new triple knockout transgenic mouse model (the Fah–/–Rag2–/–Il2rg–/– mouse) that 
solves many of the problems described for the uPA-SCID mouse (Bissig et al., 2010). 
Suitable immunodeficiency is created by crossing Fah–/– mice with both the Rag2–/– mice, 
which are depleted of mature B and T lymphocytes and Il2rg–/– mice, which have impaired 
B, T and NK cell development (Bissig et al., 2007). The absence of the enzyme fumaryl 
acetoacetate hydrolase (FAH) from these mice leads to an accumulation of toxic tyrosine 
catabolites within mouse hepatocytes. The selection pressure for transplanted human 
hepatocytes can be regulated by the drug, 2-(2-nitro-4-trifluoro-methylbenzoyl)-1,3-
cyclohexanedione (NTBC), which prevents the toxicity caused by the lack of FAH, while 
human hepatocytes stay healthy due to the human homolog. This growth disadvantage for 
mouse hepatocytes and positive selection for transplanted human hepatocytes allows the 
human cells to expand and repopulate up to 95 % of the murine liver. The advantage of this 
regulatable system is that animals with low human chimerism can be put back on the drug 
NTBC and hence do not undergo liver failure and eventually death. Highly repopulated 
triple knockout mice could be stably infected with different HCV strains including a 
genotype 1a clinical isolate, HCVcc genotype 2a and HCVcc genotype 1b/2a and 1a/2a 
chimeras. Viral infection could be sustained for more than 6 months and be passaged from 
one chimeric mouse to another. Importantly, the mice were suitable for antiviral drug 
screening (Bissig et al., 2010). Pathogenesis and immunity studies are limited in chimeric 
mice, as the animals lack a functional immune system to avoid the rejection of the 
xenograft. Transgenic mice carrying HCV proteins have been used in a vast number of 
studies to investigate the pathogenic properties of these proteins on the host. Despite some 
contradictory results, transgenic mice have provided a wealth of information on the effects 
of HCV and specific viral proteins on lipid metabolism, HCC and the immune response 
(Kremsdorf & Brezillon, 2007). 
 
 
 
 22
 
1.9.2. In Vitro Systems to Study HCV  
 
In terms of studying HCV in cell culture, three major systems were developed between 
1999 and 2005 that have proved invaluable in the study of the HCV life cycle. These are 
replicons, retrovirus-based HCV pseudoparticles (HCVpp), and HCVcc (Fig. 1.8). 
 
 
1.9.2.1. Replicons 
 
Despite the development of HCV molecular clones that could infect chimpanzees, efficient 
and reproducible replication of these clones could not be achieved in cell culture for 
reasons unknown. The first major breakthrough for analysing HCV RNA replication in cell 
culture came in 1999 with the development of the SGR (Lohmann et al., 1999). The first 
SGR was a bicistronic construct, derived from a genotype 1b strain, Con1. The first cistron 
encoded the neomycin phosphotransferase (neo) gene and was translated under the control 
of the HCV IRES. The second cistron encoded the NS3-5B HCV region and was translated 
under the control of the EMCV IRES. Following electroporation of these in vitro 
transcribed RNAs into Huh-7 cells, and subsequent G418 selection, a small number of 
resistant colonies supporting autonomously replicating HCV RNAs could be generated. 
While this system was a major advancement in the propagation of HCV genomes in cell 
culture, the replication of these RNA species was relatively inefficient as only small 
populations of resistant cell clones could be obtained. Subsequent studies identified two 
main reasons responsible for the amplification of genomes within certain cell populations: 
cell culture adaptive mutations and host cell permissiveness. Cell culture adaptive 
mutations were found in each of the HCV NS proteins although they tended to cluster in 
NS5A. Upon insertion into the parental replicon several of these adaptive mutations were 
shown to increase RNA replication levels to various extents (Blight et al., 2000; Krieger et 
al., 2001; Lohmann et al., 2001). In addition to cell culture adaptive mutations, the 
efficiency of replicon RNA replication is also determined by the selection of particular 
cells that are highly permissive. This comes from the observation that removal of the 
replicon from a cell clone by IFN treatment often results in cell clones that sustain greater 
levels of RNA replication compared to naïve Huh-7 cells. The exact reason for the higher 
permissiveness is largely unknown, but for one particular cell clone, designated Huh-7.5 
(Blight et al., 2002), a defective IFN response caused by a mutation in the RIG-I gene was 
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Figure 1.8. In vitro systems for the study of HCV replication, entry, and infectivity.  
 
(A) HCV SGRs, allow for the study of viral RNA replication in cell culture. Bicistronic replicon 
RNAs, encoding a selectable marker, under control of the HCV IRES in the first cistron and the 
HCV non-structural NS3-NS5B proteins under the control of the encephalomyocarditis virus 
(EMCV) IRES in the second cistron, are electroporated into Huh-7 cells and derived sub-lines. 
RNA replication results in the expression of the selectable marker and allows for selection of cell 
colonies that support viral RNA replication. (B) HCVpp allows for the study of HCV entry. 
Recombinant retrovirus particles that contain HCV envelope glycoproteins on their surface are 
produced in HEK-293T cells by co-transfecting plasmids encoding the HCV glycoproteins, 
retroviral or lentiviral core and polymerase proteins and a proviral genome harbouring a reporter 
gene. Following infection of permissive cell lines, the retrovirus genomes express a reporter gene, 
such as luciferase, allowing for a quantitative measure of cell entry. (C) HCVcc allows for the 
study of the entire HCV lifecycle. This system uses either JFH1 HCV genomic RNA or chimeric 
versions of this genome. Electroporation of these RNAs into permissive cell lines allows for viral 
RNA replication and the production of infectious particles that can infect naïve cells. Productive 
infection can be monitored by several methods allowing the detection of intracellular viral RNA or 
protein levels. Adapted from Tellinghuisen et al. (2007). 
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shown to be involved (Sumpter et al., 2005).  The advancements in the understanding of 
the SGR system led to the development of autonomously replicating full-length genomic 
replicons harbouring the entire HCV ORF (Blight et al., 2003; Ikeda et al., 2002; 
Pietschmann et al., 2002). However, none of these genomes supported the production of 
infectious virus particles. In 2003, a SGR based on a genotype 2a strain (JFH1) isolated 
from a patient with fulminant hepatitis was described. In contrast to the other replicon 
systems, the JFH1 SGR was capable of highly efficient replication (Kato et al., 2003) 
without the need for cell selection or cell culture adaptive mutations. It was the unique 
properties of this unusual strain that led to the establishment of the first cell culture 
infectious system for studying the complete HCV lifecycle. 
 
 
1.9.2.2. HCVpp 
 
In 2003, several groups reported the production of infectious lentiviral particles bearing 
HCV E1 and E2 glycoproteins, known as HCVpp (Bartosch et al., 2003a; Drummer et al., 
2003; Hsu et al., 2003). These particles were generated by co-transfection of 293T cells 
with plasmids encoding the HCV glycoproteins, retroviral or lentviral core and polymerase 
proteins and a packaging competent but replication defective proviral genome harbouring a 
reporter gene, such as GFP or luciferase. HCVpp have a tropism for human liver cells and 
are neutralised by anti-HCV glycoprotein antibodies, confirming HCVpp as a valid system 
for studying HCV entry.  
 
 
1.9.2.3. HCVcc 
 
Electroporation of in vitro transcribed full-length JFH1 RNA into Huh-7 cells resulted in 
HCV replication and secretion of infectious particles that could spread in culture (Wakita 
et al., 2005). A slightly later study demonstrated this genome could generate peak virus 
titers of 104 -105 infectious units/ml. The productive infection of these virus particles in 
Huh-7 cells was relatively slow, however, the infection kinetics of JFH1 was found to be 
improved using the highly permissive Huh-7-derived clonal cell line Huh-7.5.1 cells 
(Zhong et al., 2005). Huh-7.5.1 cells were developed by curing the Huh-7.5 I/5A-GFP-6 
replicon cell line with IFN-γ. The exact reason for these cells improving the virus infection 
kinetics is currently unknown. At the same time as the full-length JFH1 cell culture 
infectious clone was described, Charlie Rice and collegues reported an infectious chimeric 
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clone harbouring the JFH1 NS3-NS5B fused to the core-NS2 region of a different 
genotype 2a isolate, J6 (Lindenbach et al., 2005). Using Huh-7.5 cells, this chimera could 
produce similar virus titers to those reported for JFH1 in Huh-7.5.1 cells (Zhong et al., 
2005). A later study improved the virus release of this chimera by altering the fusion 
junction from NS2/NS3 to a breakpoint within NS2 after the first predicted transmembrane 
segment (Pietschmann et al., 2006). The findings of Lindenbach et al. (2005) and 
Pietschmann et al. (2006) were generalized and have since been used to produce viable 
JFH1 chimeras covering all 6 HCV genotypes (Gottwein et al., 2009). Thus, today there 
are many derivatives of the HCVcc system with different chimeric viruses and Huh-7-
derived cells. The intragenotypic chimera (Jc1) remains the most efficient at virus release, 
with peak titers 1-2 logs greater than JFH1 after transfection in Huh-7 or Huh-7.5 cells 
(Griffin et al., 2008; Pietschmann et al., 2006; Shavinskaya et al., 2007). 
 
 
1.10. The HCV Lifecycle 
 
All evidence to date suggests the HCV lifecycle is entirely cytoplasmic. A hypothetical 
model of the complete replication lifecycle is schematically represented in Fig. 1.9. The 
different stages of the replication cycle including HCV entry, genome replication and virus 
assembly and release are discussed in detail in the following sections. 
 
 
1.10.1. Virus Attachment and Entry 
 
HCV entry is initiated by the initial binding of virus particles to attachment factors which 
are believed to be glycosaminoglycans (GAGs) (Barth et al., 2003; Koutsoudakis et al., 
2006), low density lipoprotein receptor (LDLR) (Agnello et al., 1999; Chang et al., 2007; 
Germi et al., 2002; Molina et al., 2007) and C-type lectins such as DC-SIGN and L-SIGN 
(Cormier et al., 2004a; Lozach et al., 2004; Lozach et al., 2003). Upon attachment at least 
four receptors are important for particle internalization. These include CD81 (Pileri et al., 
1998), scavenger recepotor B-1 (SR-BI) (Scarselli et al., 2002) and the tight junction 
proteins claudin-1 (CLDN-1) (Evans et al., 2007) and occludin (OCLN) (Benedicto et al., 
2009; Liu et al., 2009; Ploss et al., 2009) (Fig. 1.10) 
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Figure 1.9. Model of the HCV lifecycle.  
 
(a) HCV binding to cell-surface receptor molecules leads to (b) receptor-mediated endocytosis (c) 
into a low-pH vesicle. Following HCV glycoprotein mediated membrane fusion, the viral genome 
is liberated into the cytosol. (d) The viral RNA functions as a template for translation of the HCV 
ORF that is processed into the 10 mature HCV proteins. (e) Viral RNA replication occurs within 
membrane-associated replication complexes (membranous web). (f) Replication occurs through a 
positive-strand replicative intermediate to produce progeny RNA, a portion of which is 
encapsidated. (g) Particles are enveloped by budding into the lumen of the ER where they are 
thought follow the cellular secretory pathway and, during this transit, maturation of particles 
occurs. (h) Mature virions are secreted from the cell, completing the life cycle (h). Adapted from 
Tellinghuisen et al. (2007). 
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Figure 1.10. Current model for HCV entry.  
 
Initial host-cell attachment may involve GAGs.  Through the association of HCV with LDLs and 
VLDLs, the LDLR may also function at the early entry steps. After cell-surface binding, the virion 
interacts with four entry factors including SR-B1, CD81 and the two tight junction proteins CLDN-
1 and OCLN. Following these interactions, the HCV particle is internalised by clathrin-mediated 
endocytosis where acidification of the endosome induces HCV glycoprotein-mediated membrane 
fusion. Once liberated into the cell cytosol, the genome containing nucleocapsid interacts with 
microtubules, which facilitate its transport to the ER where genome translation and RNA 
replication take place. Adapted from Burlone & Budkowska (2009). 
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SR-B1 is expressed in various mammalian tissues with the highest levels found in the liver 
and adrenal glands. SR-B1 has two TMDs and is a multi-ligand receptor for various classes 
of lipoproteins including HDL, LDL and VLDL (Acton et al., 1996; Acton et al., 1994). 
SR-B1 was first identified as a putative receptor based on its ability to bind soluble, 
truncated E2 (sE2) via HVR1 (Bartosch et al., 2003b; Scarselli et al., 2002). However, sE2 
is not representative of E2 structures on the HCV virion (Owsianka et al., 2001) and an 
interaction between SR-B1 and the E1E2 heterodimers has yet to be confirmed. The 
lipoproteins associated with the HCV virion have also been proposed to interact with this 
receptor (Maillard et al., 2006). Despite the uncertainty as to how HCV interacts with SR-
B1, the specificity of this receptor to the viral entry process has been confirmed using both 
the HCVpp (Bartosch et al., 2003b; Voisset et al., 2005) and HCVcc systems (Catanese et 
al., 2007; Grove et al., 2007; Kapadia et al., 2007). Evidence from recent HCVcc studies 
has shown SR-B1 to be involved in an early step of the virus/cell recognition prior to the 
other receptors (Catanese et al., 2010; Evans et al., 2007). 
 
The first identified and best characterised HCV receptor is CD81, a member of the 
tetraspanin family of transmembrane proteins. This widely expressed cell surface protein 
has various functions including tissue differentiation, cell-cell adhesion and immune cell 
maturation (Levy et al., 1998). It consists of a small and a large extracellular loop (LEL) 
with four TMDs. CD81 was identified as a putative receptor through the binding of its LEL 
to sE2 (Pileri et al., 1998) as well as E1E2 heterodimers (Cocquerel et al., 2003). CD81 
has been confirmed as an essential HCV entry factor by utilising HCVpp (Bartosch et al., 
2003a; Cormier et al., 2004b; Zhang et al., 2004) and HCVcc (Lindenbach et al., 2005; 
Wakita et al., 2005; Zhong et al., 2005). Inhibition assays with HCVcc using anti-CD81 
antibody suggest CD81 acts subsequent to initial virus binding, possible via SR-BI 
(Catanese et al., 2010).  
 
The most recently identified receptors are the tight junction proteins CLDN-1 (Evans et al., 
2007) and OCLN (Benedicto et al., 2009; Liu et al., 2009; Ploss et al., 2009), which are 
both required for HCVpp and HCVcc entry. Tight junctions are major components of cell-
cell adhesion complexes that maintain cell polarity by forming an intramembrane barrier 
that regulates the diffusion of certain molecules (Shin et al., 2006). Tight junctions possess 
several important liver functions in hepatocytes, such as bile formation and secretion. 
CLDN-1 contains two extracellular loops and four TMDs with the first extracellular loop 
being required for HCVpp entry (Evans et al., 2007). Experiments to date have failed to 
detect an interaction between the viral glycoproteins and CLDN-1 (Evans et al., 2007; 
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Krieger et al., 2009). However, several studies have shown an association between CD81 
and CLDN-1, implying these two entry factors act in a cooperative manner during HCV 
entry (Harris et al., 2008; Krieger et al., 2009). Similar kinetics of inhibition was shown 
for HCVcc and HCVpp by anti-CLDN-1 and anti-CD81 antibodies. Also, anti-CLDN-1 
antibodies that could disrupt this CLDN-1-CD81 association were able to reduce sE2 and 
HCVcc binding to permissive cells (Krieger et al., 2009). Therefore, it is plausible that 
CLDN-1 may potentiate CD81 association with HCV particles by way of E2 interactions. 
Two other members of the CLDN family, CLDN-6 and CLDN-9, have also been shown to 
mediate HCVcc entry (Meertens et al., 2008; Zheng et al., 2007). OCLN contains four 
transmembrane regions and two extracellular loops (Furuse et al., 1993). A direct 
interaction has been shown between OCLN and E2 from HCVcc-infected cells, indicating 
the association of HCV with OCLN during entry is facilitated by this interaction (Liu et 
al., 2009). The expression of SR-BI, CD81, CLDN-1 and OCLN renders murine and 
hamster cells permissive for HCVpp infection, which strongly suggests these four proteins 
represent the complete set of cell surface receptors required for HCV entry (Ploss et al., 
2009).  
 
Following attachment to these specific receptors HCV internalisation likely occurs via 
clathrin-mediated endocytosis, with delivery of the nucleocapsid via early endosomes. pH 
sensitivity is a reasonable indicator for viral entry by endocytosis.  Indeed HCVpp and 
HCVcc entry is sensitive to substances that neutralise the acidic pH of early endosomes 
(Blanchard et al., 2006; Hsu et al., 2003; Koutsoudakis et al., 2006; Meertens et al., 2006). 
Furthermore, treatment of cells with agents that disrupt clathrin-coated pit formation or the 
use of siRNA targeting clathrin, reduces HCVpp and HCVcc entry (Blanchard et al., 2006; 
Meertens et al., 2006). Once internalised, the virus glycoproteins are proposed to fuse with 
the membranes of early endosomes (Meertens et al., 2006). The acidic pH of endosomes is 
likely to trigger the fusion process by inducing conformational changes in the envelope 
proteins (Op De Beeck et al., 2004). A recent study found that HCV entry is also 
dependent on an intact microtubule (MT) network. Their HCVcc data suggest that 
following entry and fusion the nucleocapsid integrates itself into the MT lattice, through an 
interaction between core and tubulin, for transport of the virus capsid in the infected cell 
(Roohvand et al., 2009). Presumably the capsid is transported to the sites of genome 
translation at which point the viral RNA would be released. 
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1.10.2. Genome Translation and RNA Replication 
 
In mammalian cells, the two methods of translation initiation are cap-dependent and cap-
independent. The prior represents the standard mode for most cellular mRNAs where 
translation initiation begins with the recruitment of the 40S ribosomal subunit to the 
mRNA 5’-terminal m7GpppN cap structure. The cap-independent method involves the 
interaction of ribosomes with an IRES, which is utilised by some cellular transcripts as 
well as some positive-strand RNA viruses including HCV (Shih et al., 2008). Following 
infection, the HCV genome is liberated into the cytoplasm where it serves as an mRNA for 
the synthesis of viral proteins. The HCV IRES, located at the 5’ end of the genome, binds 
and directs the ribosome to the initiator codon within the core gene where translation 
begins (Section 1.8.1). No viral factors are required for the translation of the HCV genome 
(Pestova et al., 1998). Translation occurs at ER membranes, which produces a single 
polyprotein that undergoes co- and post-translational cleavage events facilitated by viral 
and cellular proteases to generate the structural and NS proteins (Figure 1.5). As with all 
positive-sense RNA viruses, once sufficient translation of HCV RNA has occurred, a 
molecular switch is believed to direct the initiation of RNA replication within a membrane 
bound replication complex (Novak & Kirkegaard, 1994). 
 
Indeed, a specific membrane alteration, named the membranous web, was identified as the 
site of RNA replication in Huh-7 cells containing SGRs. Importantly, these structures have 
also been recently observed in HCVcc-infected Huh-7 cells (Goueslain et al., 2009). These 
structures, believed to be derived from ER membranes, contain positive- and negative-
strand viral RNA and the HCV NS proteins (Egger et al., 2002; Gosert et al., 2003; 
Mottola et al., 2002; Quinkert et al., 2005; Waris et al., 2004). These viral RNA and NS 
proteins are ribonuclease and protease resistant, indicating that these structures may 
enclose and protect the viral replication components from the intracellular environment 
(El-Hage & Luo, 2003; Quinkert et al., 2005; Waris et al., 2004).  Within these replication 
compartments, the instigation of HCV RNA synthesis occurs by an unknown mechanism 
but likely involves the de novo initiation of RNA replication by NS5B. Using the positive-
strand genome NS5B generates a negative-strand template that is then used to amplify 
multiple positive-strand RNA molecules (Lohmann et al., 1999; Negro et al., 1992; 
Takehara et al., 1992). During this process the complementary negative-strand RNA is 
believed to form a double-stranded RNA molecule with the positive-strand that acts as a 
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recycling template for the synthesis of nascent positive-stranded RNA (Targett-Adams et 
al., 2008a). Quantitative analyses of these replication compartments formed by replicons 
estimate that an active replicase complex consists of one negative-strand RNA, up to ten 
positive-strand RNAs and several hundred NS proteins (Quinkert et al., 2005). Replicon 
studies have shown negative-strand RNAs are detectable at 4 hours post-electroporation, 
implying that these RNA replication compartments form rapidly after virus entry (Binder 
et al., 2007). 
 
 
1.10.3. HCV Assembly 
 
Recent HCVcc studies have shown HCV core protein to be a central instigator in the virion 
assembly process. Core protein is targeted to lipid droplets (LDs) (Section 1.11.2), and 
disruption of this process in HCVcc prevents infectious virus production (Boulant et al., 
2007; Miyanari et al., 2007). Detailed analyses revealed that core protein recruits the HCV 
NS and envelope proteins as well as the viral replication complexes to these sites. NS5A 
also aids in the recruitment of the NS proteins and replication complexes to these sites and 
harbours residues in domain I that target this protein to LDs (Section 1.8.2.7). Indeed, 
mutating these residues reduced the level of NS5A, NS proteins and viral RNAs to these 
sites but did not effect the core-LD association. These effects correlated with an 
impairment in infectious virus release. Thus, the recruitment of the viral replication 
compartments to these viral assembly sites occurs in a core- and NS5A-dependent manner. 
EM analyses of infected cells revealed a proportion of LDs were located in close proximity 
to membrane cisternae (presumably of the ER), an effect not observed in naïve cells. 
Moreover, virus-like particles were observed (50 nm diameter) in close proximity to these 
LD-associated membranes that reacted to core- and E2-specific antibodies, arguing that 
these particles represent true virions and these are indeed the sites of virus assembly 
(Miyanari et al., 2007).  
 
It is core protein alone that induces the initial redistribution of LDs from their native 
disperse cytoplasmic localisation to aggregates around the cell nucleus. The trafficking of 
LDs is dependent on the MT network and in HCV-infected cells LDs aggregate near the 
microtubule organisation centre (MTOC) near the nucleus. Interestingly, the disruption of 
MTs resulted in a reduction in LD redistribution and virus titres, implicating these 
transport networks in virus assembly. Adipocyte Differentiation Related Protein (ADRP), 
an abundant protein located on the LD surface, is crucial for maintaining the dispersed 
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distribution of LDs within the cells. Strikingly, the loading of core protein causes ADRP to 
be displaced from LDs, an effect that results in their redistribution to ER membranes. 
Thus, it is hypothesised that core on LDs induces their movement on MTs towards the 
nucleus through the displacement of ADRP (Boulant et al., 2008). This mechanism may 
coordinate interactions between RNA replication complexes and virus assembly sites 
resulting in the LD-associated membranes described by Miyanari et al. (2007) (Fig. 1.11). 
 
Although, the sites of virus assembly have been well characterised the molecular events of 
genome encapsidation and envelopement have yet to be determined in the HCVcc system. 
Nucleocapsid formation most likely involves an interaction of the core protein with the 
viral genome. Indeed, several studies have reported an interaction between core protein and 
HCV RNA (Masaki et al., 2008; Santolini et al., 1994). The RNA binding residues in core 
were mapped to residues 1-75 (Santolini et al., 1994) and a direct interaction of core 
protein with the 5’ UTR of the genome was shown (Tanaka et al., 2000). Given the main 
function of the viral core protein is to provide a protective shell for the genome, its ability 
to multimerise would be an indispensable property for nucleocapsid assembly. Different 
studies have found residues in both domains I (residues 1-118) and II (residues 119-174) 
(Section 1.11.1) of core to be involved in homotypic interaction (Matsumoto et al., 1996; 
Nolandt et al., 1997). In agreement with these finding, residues 1-124 was found to 
assemble into virus-like particles only in the presence of the HCV 5’ UTR RNA, whereas 
the full-length core could undergo de novo assembly in the absence of RNA (Kim et al., 
2006). These data suggest domain I of core may be involved in multimerisation upon 
interaction with RNA while domain II initiates spontaneous multimerization of core during 
the early stages of capsid formation. Subsequent to nucleocapsid formation, the 
envelopement stage is thought to occur at ER membranes given that the HCV 
glycoproteins localise predominantly to the ER (Dubuisson et al., 1994). Interestingly, core 
has been shown to interact with E1, which may function in the envelopment of the 
nucleocapsid (Lo et al., 1996). 
 
As described in section 1.2, low density HCV particles isolated both in vivo and in vitro are 
associated with host VLDLs and are more infectious than high density particles. 
Hepatocytes play an essential role in maintaining the lipid homeostasis in the body through 
the assembly and secretion of VLDLs. Interestingly, LDs provide the bulk of the lipid 
incorporated into VLDLs. Apolipoprotein B (apo B) and E (apo E) are structural 
components of VLDL and microsomal triglyceride transfer protein (MTP) is required for 
the transport of triglyceride to the ER for VLDL assembly (Blasiole et al., 2007; 
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Figure 1.11.  The role of the core-LD association in virion assembly.  
 
(A1) ADRP (blue) coated LDs (red) are freely mobile on MT resulting in uniform distribution 
throughout the cell. (A2) Following infection core protein (green) loads LDs and displaces ADRP 
(A3) inducing the movement of LDs towards the MTOC and ER membranes. (A4) This 
redistribution brings LDs in close contact with the HCV RNA replication complexes. (B) LD-
associated ER membranes are formed and core recruits the NS proteins, envelope proteins and 
replication complexes to these sites allowing virus assembly to proceed. Adapted from Boulant et 
al. (2008) and Miyanari et al. (2007). 
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McLauchlan, 2009). Studies using infected patient liver and serum samples suggest that 
LVPs are comprised of HCV RNA and structural proteins, Apo B, Apo E, Apo C, 
triglyceride, cholesterol and phospholipids (Andre et al., 2002; Diaz et al., 2006; Meunier 
et al., 2005; Nielsen et al., 2004; Nielsen et al., 2006; Thimme et al., 2001). As LVPs 
appear to have characteristics of both lipoproteins and virus particles they are believed to 
circulate as functional carriers of dietary lipids (Diaz et al., 2006). Recent HCVcc studies 
have shown the treatment of infected cells with brefeldin, a broad range inhibitor of the 
secretory pathway, decreased infectious particle secretion and led to an accumulation of 
intracellular infectious virus. Also, inhibiting the VLDL assembly process using MTP 
inhibitors or knockdown of apo B and apo E protein expression, prevented both the release 
of particles and brefeldin induced intracellular accumulation. These treatments caused no 
alteration to HCV intracellular RNA replication, indicating they inflict a specific block to 
virion assembly (Chang et al., 2007; Gastaminza et al., 2008; Huang et al., 2007a; 
Nahmias et al., 2008). Hence, the current model predicts that VLDL and HCV assembly 
may act in parallel to one another allowing the formation of infectious HCV LVPs that are 
released from the cell following their trafficking through the secretory pathway (Fig. 1.12). 
 
 
1.11. HCV Core Protein 
 
1.11.1. Structural Determinants  
 
Sequence analysis of 52 HCV isolates found the core gene to be 573 nucleotides and 191 
aas long. With an extremely high level of nucleotide (79.4-99.0 %) and protein (85.3-100 
%) sequence similarity, core is the most highly conserved HCV gene  (Bukh et al., 1994). 
Core protein has been divided into 3 domains based on the hydropathicity pattern of its aa 
sequence (Hope & McLauchlan, 2000). Domain I, spanning residues 1-118, contains a 
high proportion of basic residues (24 %) along with 2 short hydrophobic domains. Domain 
II (aa 119-174) is more hydrophobic than domain I with a lower proportion of basic 
residues.  Domain I and domain II are mainly α-helical and the folding of domain I seems 
to depend on the presence of domain II (Boulant et al., 2005). Domain II contains two 
amphipathic α-helices at aa 119-136 and 148-164, connected by an unstructured region 
called the hydrophobic loop (HL). Domain III (residues 175-191) is extremely 
hydrophobic and acts as the signal sequence that directs the nascent polypeptide chain to 
the ER membrane and induces translocation of E1 into the ER lumen (Santolini et al., 
1994). During the processing of core in the cell, this signal peptide is cleaved by signal 
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peptidase (SP) releasing the N-terminal end of E1 and leaving core anchored in the ER 
membrane (Hussy et al., 1996; Liu et al., 1997; Moradpour et al., 1996; Santolini et al., 
1994; Yasui et al., 1998). This 191 aa polypeptide is an immature or unprocessed form of 
core protein, which is named p23 according to its migration size of 23 kDa on a 
polyacrylamide gel (Ait-Goughoulte et al., 2006; Ogino et al., 2004). Mature or processed 
core is then generated by a second cleavage event within the core-E1 signal peptide by the 
signal peptide peptidase (SPP), which releases core from the ER membrane allowing its 
attachment to LDs (McLauchlan et al., 2002) (Fig. 1.13). The mature core protein has a 
molecular weight of 21 kDa (p21) (Ait-Goughoulte et al., 2006; Ogino et al., 2004) and is 
177 aa long (Ogino et al., 2004; Okamoto et al., 2008). Recent studies using the HCVcc 
system have shown that the processing of p21 core by SPP is crucial for the production of 
infectious virus (Okamoto et al., 2008; Targett-Adams et al., 2008b).  
 
 
1.11.2. The Core-LD Association and Virus Production 
 
The intracellular location of core was first described in studies expressing core in human 
osteosarcoma (U-2 OS) cells, where the protein localised to the surface of LDs as well as 
ER membranes surrounding mitochondria (Moradpour et al., 1996). However, the 
relevance of the core-LD association in the virus lifecycle was realized after observing this 
localisation in liver biopsies from HCV-infected chimpanzees (Barba et al., 1997). The 
targeting of core to LDs has been described in a range of cell types including Chinese 
Hamster Ovary (CHO) (Barba et al., 1997), Baby Hamster Kindney (BHK) (Hope & 
McLauchlan, 2000), HepG2 (Barba et al., 1997), and Huh-7 cells (McLauchlan et al., 
2002; Shi et al., 2002), indicating this association is not cell-type specific. Numerous 
studies found that this core-LD association was mediated by domain II (Barba et al., 1997; 
Hope & McLauchlan, 2000; Moradpour et al., 1996) with the two prolines at positions 138 
and 143 being critical for this attachment (Hope et al., 2002). 
 
Rouille et al. (2006) first showed the core-LD association in HCVcc-infected Huh-7 cells 
by colocalisation of core protein with ADRP. However, a time course analysis following 
HCVcc RNA transfection revealed an initial attachment of core to LDs at early time-points 
(24 h), followed by the progressive loading and eventual covering of the entire organelle at 
later time-points (48-72h) (Boulant et al., 2007). Interestingly, JFH1 harbouring alanine 
substitutions at the two proline residues P138 and P143 (PP/AA) produced core protein 
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Figure 1.12. Hypothetical model of assembly and secretion of VLDL and HCV virions in 
hepatocytes.  
 
VLDL assembly begins with the lipidation of newly synthesized apo B in the rough ER by MTP to 
create a VLDL precursor particle. Following translocation into the lumen of the ER, the MTP-
mediated lipidation continues through the fusion of the precursor with LDs, which add the majority 
of triglycerides and cholesterol to pre-VLDL. Additional lipoprotein components, such as apo E are 
added to generate mature VLDL that is secreted into the plasma through exocytosis. In infected 
hepatocytes, virus proteins and replication complexes are concentrated around LD-associated ER 
membranes, which are believed to allow the co-assembly of virions and lipoprotein particles to 
produce LVPs. Adapted from Ye (2007). 
SP
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E1
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Figure 1.13. Model for the release of HCV core protein from the ER membrane.  
 
During HCV polyprotein processing, the signal peptide between core and E1 is cleaved by SP to 
produce an immature form of core and the N-terminal end of E1. Subsequent cleavage of the core-
E1 signal peptide by SPP liberates mature core protein containing domain I and domain II from the 
membrane, which then attaches to LDs via domain II. Adapted from McLauchlan et al. (2009).  
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that could attach to LDs but was blocked in its ability to progressively coat LDs following 
transfection. This defect also correlated with a complete loss in infectious virus production, 
showing for the first time that the core-LD association functions in the assembly process 
(Boulant et al., 2007). A slightly later study showed that LD-attached core protein recruits 
the viral NS proteins, envelope proteins and replication complexes to LD-associated 
membranes, creating an environment for virion assembly to proceed (Section 1.10.3) 
(Miyanari et al., 2007). 
 
 
1.11.3. Core is the Viral Nucleocapsid 
 
The detection of core protein from patient sera (Kashiwakuma et al., 1996; Klein et al., 
2004) suggests core is associated with the virus particle. In line with this, in vitro studies 
have shown that core binds RNA and forms multimers; both expected properties of capsid 
proteins (Section 1.10.3). The availability of HCVcc has allowed the anlaysis of infectious 
HCV particles and led to a better understanding of core protein and its role as capsid 
protein for HCV. Indeed, HCVcc has confirmed the presence of core protein within 
extracellular virus particles (Lindenbach et al., 2005; Wakita et al., 2005). Using HCVcc, a 
recent study performed extensive mutagenesis across a large part (aa 57-191) of the core-
coding region where a total of 34 mutant viruses were constructed each containing alanine 
changes in blocks of four aas (Murray et al., 2007). This work revealed numerous residues 
that were critical for infectious virus production but did not alter viral RNA replication. Of 
the viruses harbouring changes in domain I, all were non-infectious except 4 (69-72, 89-92, 
93-96, and 101-104) that displayed minimal infectivity values (~2-3 logs lower than WT). 
These results demonstrate the importance of these domain I residues in virus assembly, 
which may be due to impaired RNA binding and/or multimerisation. No mutagenesis 
within the first 57 residues of domain I was performed to avoid complications caused by 
the RNA secondary structures (Section 1.11.5) (Tuplin et al., 2004) known to be important 
for RNA replication (McMullan et al., 2007).  
 
 
1.11.4. Alternative Reading Frame Protein  
 
Using a newly developed software tool called “Frame splitter” Walewski et al. (2001) 
performed a genome-wide search on HCV with the aim of identifying novel genetic 
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control elements. By analysing eight highly diverse HCV sequences, this software mapped 
regions in which synonymous substitutions are suppressed. HCV core was found to contain 
an unusually high number of such regions and further analysis of viral sequences present in 
the Genbank database revealed the presence of a +1 alternative reading frame protein 
(ARFP) in core, also known as the “F” protein. The existence of this putative ARFP in 
natural HCV infection was confirmed by the presence of anti-ARFP antibodies in sera 
from HCV-infected patients (Walewski et al., 2001). Cell-free expression studies 
performed by Xu et al. (2001) on a genotype 1a isolate (HCV-1 strain) found F is 
synthesised as a 17 kDa protein in addition to the 21 kDa mature core. Their data indicate 
that the F protein translation is initiated at the start codon (AUG) of the main HCV ORF. 
The ribosome reads in frame until codons 8-11 where it encounters a frame shift-prone 
region of 10 consecutive alanines, known as the AAA-rich sequence. A +1 frame shift 
event then occurs facilitating translation of F until termination at the first in-frame stop 
codon positioned at nucleotides 485-487 (Xu et al., 2001). However, in the absence of the 
AUG start codon and the AAA-rich sequence, it was found that an F protein could be still 
generated through internal translation initiation from the AUG codons at positions 85/87 
(Vassilaki & Mavromara, 2003). In accordance with these findings, another study reported 
that F protein synthesis could be initiated at a codon overlapping codon 26 in the main 
ORF (Baril & Brakier-Gingras, 2005). While the above results were obtained in genotype 
1a core, one group found that genotype 1b core could generate F protein via two frame 
shift events. This double frame shifted protein was produced by a +1 frameshift at codon 
42 followed by a rephrasing through a -1 frameshift at position 144 (Boulant et al., 2003). 
Thus, despite being found in all genotypes (Walewski et al., 2001), the mechanism and 
size of the F protein generated may be genotype dependent. Although, an F-encoded 
product has yet to be detected in infected tissue, numerous studies have shown that specific 
antibodies and cellular immune responses against ARFP antigens are present in HCV-
infected patient sera (Bain et al., 2004; Varaklioti et al., 2002; Walewski et al., 2001; Xu et 
al., 2001). Although, these studies provide strong evidence that the core +1 ORF-derived 
proteins are produced during natural HCV infection in humans, their biological importance 
is still unknown. However, it was recently shown that F is not required for virus 
propagation in vitro (HCVcc) or in vivo (uPA/SCID mice and chimpanzees) by testing 
genotype 1a and 2a infectious clones harbouring termination codons that abolish all forms 
of F protein expression (McMullan et al., 2007; Vassilaki et al., 2008).  
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1.11.5. Conserved RNA Stem Loop Structures 
 
The HCV RNA encoding the core region contains four highly conserved stem-loop 
structures (Fig. 1.14), designated SL47, SL87, SL248 and SL443 that were predicted by 
combining bioinformatic analysis with enzymatic mapping of RNA transcripts (Tuplin et 
al., 2004). By introducing silent mutations predicted to disrupt these stem-loops two 
studies have shown that the integrity of SL47 and SL87 are important for the efficient 
propagation of HCV in vitro (HCVcc) and in vivo (uPA/SCID mice and chimpanzees) 
(McMullan et al., 2007; Vassilaki et al., 2008). From experiments with HCVcc, Vassilaki 
et al. (2008) showed that the defects in virus proliferation caused by disrupting these stem-
loops was due to a delay in the translation of the viral genome. In addition, this same group  
found that the remaining stem-loops SL248 and SL443 were not important for HCVcc 
proliferation. 
 
 
1.11.6. Pathogenic Effects of Core 
 
1.11.6.1. Apoptosis 
 
Expression of HCV core has been shown to modulate apoptosis through a variety of 
mechanisms. ER stress leading to apoptosis was shown in HepG2 and Huh-7 cells 
transiently expressing core, Huh-7 cells harbouring full-length replicons and liver tissue 
from transgenic mice expressing core (Benali-Furet et al., 2005). Apoptosis can be caused 
by various stimuli such as oxidative stress, heat shock, ionizing radiation, cytokines and 
virus infection. The two main apoptotic pathways include the intrinsic or mitochondrial 
pathway and the extrinsic or death receptor pathway (Elmore, 2007). The intrinsic 
apoptotic signaling pathways involve various non-receptor-mediated stimuli that trigger an 
increase in the permeability of the outer mitochondrial membrane.  Mitochondria play an 
important role in the regulation of cell death. They contain many pro-apoptotic proteins 
such as cytochrome c that are released following Mitochondrial Permeability Transition 
(MPT) pore formation in the outer membranes. Cytochrome c and other key molecules 
then activate initiator caspase-9 followed by the effector caspases, primarily caspase-3, -6 
and -7, which execute the cell death program. The MPT pores are likely induced by the 
pro-apoptotic members of the bcl-2 family of proteins, which in turn are activated by 
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Figure 1.14. Schematic representation of the four predicted core RNA secondary structures.  
 
The structures shown, SL47 (nucleotides 388-423), SL87 (nucleotides 427-507), SL248 
(nucleotides 588-665) and SL443 (nucleotides 783-815) are derived from the JFH1 sequence. The 
polyprotein initiator codon (AUG) is underlined. Adapted from Vassilaki et al. (2008).  
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apoptotic signals such as cell stress, free radical damage or growth factor deprivation 
(Elmore, 2007).  The extrinsic apoptotic signaling cascade is initiated by the activation of 
death receptors such as Fas, TNF-R1, TRAIL-R1 and TRAIL-R2. To date, the best-
characterized ligands and corresponding death receptors include FasL/FasR, TNF-
α/TNFR1. The association of Fas ligand to the Fas receptor results in binding to the 
adaptor protein FADD. The association of TNF ligand with the TNF receptor results in 
TRADD (adaptor protein) binding followed by the recruitment of FADD and RIP. FADD 
then associates with initiator caspase-8 via dimerization of the death effector domain. At 
this point the death-inducing signaling complex (DISC) is formed that promotes 
autoactivation of initiator caspase-8 and the subsequent activation of the effector caspases, 
(Elmore, 2007; Igney & Krammer, 2002). Death receptor mediated apoptosis can be 
inhibited by a protein called FLICE (FADD-like interleukin-1-beta-converting enzyme)-
like inhibitory protein (c-FLIP) which binds to FADD and caspase-8, rendering them 
ineffective (Scaffidi et al., 1998). There is also evidence that cross talk exists between the 
intrinsic and extrinsic pathways whereby molecules in one pathway can influence the 
other. In certain cell types the amount of active caspase-8 formed at the DISC is 
insufficient and the mitochondria are used to enhance the apoptotic signal.  In this scenario, 
death receptor recruited caspase-8 cleaves the pro-apoptotic bcl-2 protein, bid, which 
subsequently induces MPT pore formation (Scaffidi et al., 1998). 
 
Reports describing the influence of core protein on Fas- and TNF-α-mediated apoptosis are 
somewhat conflicting. In HepG2 cells, core expression has been shown to inhibit 
(Marusawa et al., 1999) as well as induce (Ruggieri et al., 1997) Fas-mediated apoptosis. 
Core protein was reported to sensitize HepG2, HeLa and murine BC10ME cells to TNF-α-
induced apoptosis, and these effects may be related to the interaction found between core 
and the cytoplasmic tail region of TNFR1 (Zhu et al., 1998).  A follow-up study found that 
core protein also interacted with the TNF signal transduction molecule FADD in core 
expressing HEK-293T cells, suggesting that core enhances TNF-α-mediated apoptosis by 
recruiting FADD to TNFR1 (Zhu et al., 2001). In contrast, two studies found an inhibition 
of TNF-α-induced apoptosis in MCF7 cells and HepG2 cells expressing core protein 
(Marusawa et al., 1999; Ray et al., 1998a). More recently, this core-mediated inhibition of 
TNF-α-induced apoptosis in HepG2 cells was shown to be due to an up regulation of c-
FLIP by core, which in turn inhibits the cleavage and activation of caspase-8, thereby 
inhibiting apoptosis (Saito et al., 2006).  The contradictory nature of these reports is likely 
due to the different cells lines or mode of core expression used. 
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Core also sensitises all-trans-retinoic acid (ATRA)-induced cell death in MCF-7 cells. The 
effect is likely due to an interaction between core and Sp110b, a nucleur transcriptional 
corepressor of the retinoic acid response element that prevents the enhancement of 
downstream proapoptotic gene expression. Core was shown to sequester Sp110b from the 
nucleus, thereby releasing the suppressive function of Sp110b and leading to ATRA-
induced cell death (Watashi et al., 2003). Core protein interacts with the intracellular 
domain of the Lymphotoxin-β Receptor (LT-βR), a member of the tumour necrosis factor 
receptor family involved in cytolytic activation in certain cell types (Chen et al., 1997; 
Matsumoto et al., 1997). Although, expression of core protein in HeLa cells enhanced LT-
βR-mediated apoptosis, this effect was absent in core expressing HepG2 or Huh-7 cells 
(Chen et al., 1997). A recent study demonstrated that core protein has a functional bcl-2 
homology 3 domain near the C-terminal region. This domain was essential for its 
proapoptotic property and ability to interact with human myeloid cell factor 1 (Mcl-1), a 
prosurvival member of the Bcl-2 family. This domain is highly conserved among the major 
HCV genotypes, with the exception of genotypes 2a and 6k, which have V and M residues 
at position 119, respectively. Interestingly, mutation V119L in the genotype 2a HCVcc 
significantly increased apoptosis in infected cells and also established an interaction 
between HCVcc core and Mcl-1 that was absent in the parental form from infected cells. 
Similarly, replacing L119 to V in genotype 1b core reduced the proapoptotic property of 
core overexpressed in Huh-7 cells (Mohd-Ismail et al., 2009). 
 
 
1.11.6.2. Transformation 
 
The suggestion that core functions as an oncogenic protein is a controversial issue. The 
first indication of the potential oncogenic properties of core came from its ability to alter 
the transcriptional regulation of cellular proto-oncogenes. These included the 
transactivation of the human c-myc promoter and the suppression of c-fos promoter activity 
by core expression in HepG2 cells (Ray et al., 1995). Another study found p53 activation 
was enhanced by core protein expressed in Hep3B and HepG2 cells. This resulted in the 
enhanced expression of the cyclin/cyclin-dependent kinase (cdk) inhibitor p21Waf, an effect 
previously linked to cell cycle suppression (Ko & Prives, 1996). In line with this, Hep3B 
cell growth was suppressed by core protein expression (Lu et al., 1999). Also, this group 
found an interaction occurred between core and p53, suggesting core might activate p53 
through a direct physical interaction. Another study found core protein interacted with 
p21Waf (Wang et al., 2000a) and core expression in HeLa or Huh-7 cells lowered p21Waf 
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expression at the post-transcriptional level. Moreover, core negated p21Waf–mediated 
suppression of cyclin/cdk by an undetermined mechanism. This negation may be caused by 
core-mediated p21Waf degradation or the binding of core to the same C-terminal region of 
p21Waf known to be involved in its cdk inhibitory activity (Yoshida et al., 2001). A later 
study by the same group found that core inhibited the synthesis and accumulation of p21Waf 
and p53 in HeLa cells with the inhibition of p21Waf occurring at the translational level (Oka 
et al., 2003). However, core protein repressed transcriptional activity of the p53 tumour 
suppressor when expressed in COS7 and HeLa cells (Ray et al., 1997).  In line with this, a 
later study by the same group found that core expression suppressed p21Waf transcriptional 
activity when tested in NIH3T3, HepG2 and HeLa cells (Ray et al., 1998b). Core 
expression was also shown to transform NIH3T3 cells that resulted in core-expressing 
tumours when inoculated into SCID mice. This transformation and tumourigenicity of core 
expressing cells coincided with a reduction in p53 transactivation (Smirnova et al., 2006).  
Core protein can transform primary rat embryo fibroblasts in co-operation with the H-ras, 
implicating it as a co-factor in the development of HCC (Ray et al., 1996).  In line with 
this, it was demonstrated that the stable expression of core in Rat-1 fibroblasts could 
induce tumourigenic transformation (Chang et al., 1998).  
 
The most compelling evidence regarding the potential oncogenic properties of core protein 
came from studies in transgenic mice. Approximately 30 % of transgenic mice expressing 
core protein developed HCC between 16-19 months from birth, compared to a 0 % 
incidence in the control mice. Immunologic analysis found that the expression of core 
protein was higher in the tumours cells than in surrounding normal hepatocytes (Moriya et 
al., 1997). Several other studies using transgenic mice have failed to observe HCV-induced 
HCC (Kawamura et al., 1997; Matsuda et al., 1998; Pasquinelli et al., 1997). However, it 
should be noted that these studies found core expression was barely detectable, and may 
therefore account for the absence of HCC in these mice.  
 
 
1.11.6.3. Immune Response 
 
Several lines of evidence implicate core protein in suppression of the immune response to 
HCV infection. Positive- and negative-strand RNA was found in peripheral blood 
mononuclear cells (PBMCs) from chronically infected patients, suggesting HCV infection 
(Lerat et al., 1998). In line with this, a study found that the expression of core and E1 
protein using recombinant adenovirus in dendritic cells disrupted their antigen presenting 
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function, leading to impaired T-cell stimulation (Sarobe et al., 2002). The ability of HCV 
to enter and replicate in cells from the immune system and the possible dysregulation of 
normal cell functions associated with core protein expression could be one factor 
responsible for the establishment of HCV persistence in the host.   
 
The expression of HCV core in mice using recombinant vaccinia virus impaired their 
protective immune response, including both the antiviral CTL response and IL-2/IFN-γ 
production (Large et al., 1999). One of the molecular mechanisms of HCV core-mediated 
immunomodulation was later determined by identification of an interaction between core 
and the complement receptor gC1qR (Kittlesen et al., 2000). Clq is the natural ligand for 
gCLqR and is the first molecule to be activated in the classical complement cascade and 
plays a vital role in modulating both innate and adaptive immunity (Ghebrehiwet et al., 
2001). The binding of complement protein C1q to the gCLqR receptor specifically blocks 
the proliferation of CTLs. HCV core protein mimicked this effect by specifically inhibiting 
T-cell proliferation, an effect that could be blocked using antibodies against gC1qR1 or 
HCV core (Kittlesen et al., 2000). Subsequent anlaysis found the core-gClqR interaction 
impaired activation of the ERK/MEK MAP kinase, which inhibits the transcription of the 
early genes such as IL-2, thereby suppressing the T cell response (Yao et al., 2001). A 
significant issue relating to the core/gCLqR-mediated immune suppression in chronic HCV 
infection is the detection of circulating core protein in the blood of HCV-infected patients 
that could possibly interact with peripheral T-lymphocytes. Core protein has also been 
shown to be secreted from transfected cell lines expressing the core gene (Sabile et al., 
1999). This idea of circulating core protein suppressing the host immune responses to HCV 
is supported by high levels of core protein being detected during an early stage of infection 
before the production of anti-core antibodies (Aoyagi et al., 1999; Urushihara et al., 1994). 
These results suggest that core-induced immune suppression may play a critical role in 
establishing and maintaining HCV persistence during early viral infection. Interestingly, 
the core-gClqR binding causes differential regulation of B-cell and T cell activation. HCV 
core treatment led to upregulation of IgM and IgG production, cellular proliferation as well 
as surface receptor expression in B-cells, but to decreased IFN-γ production in T-cells 
(Yao et al., 2008).  Such effects may drive B-cell clonal expansion, a process that is 
thought to contribute to B-cell lymphoproliferative disorders, such as mixed 
cryoglobulinaemia and B-cell non-Hodgkin Lymphoma, associated with chronic infection 
(Racanelli et al., 2001; Sansonno & Dammacco, 2005).  
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1.11.6.4. Transcription 
 
Three putative nuclear localization signals (NLS) are present within domain I of core at 
residues 38-43, 58-64 and 66-71 (Shih et al., 1993). Interestingly, truncated core protein 
lacking the hydrophobic domain II region is localized to the nucleus in mammalian cells 
and deletion studies revealed the first predicted NLS (aa 38-43) plays an important role in 
this nuclear translocation (Suzuki et al., 1995). The HCV-1 strain encodes a unique 16 kDa 
species of core (p16) that lacks the C-terminal residues present in the p21 form.  This 
species is mainly localised to the nucleus (Lo et al., 1995) and has been proposed to have 
regulatory functions on host gene expression (Ray et al., 1995). Also, the p21 species from 
a genotype 1b core protein was shown to localize to the nucleus as well as the cytoplasm. 
Experiments using a panel of monoclonal antibodies indicated that these nuclear forms are 
conformationally distinct to those found in the cytoplasm (Yasui et al., 1998). The 
existence of such forms of core in the nucleus in addition to a putative DNA binding motif 
(aa 99-102) (Bukh et al., 1994) within the core protein sequence, suggests it may have a 
functional role in host gene regulation. Indeed, several studies have shown that core 
protein can modulate both viral and cellular gene expression. It was demonstrated that core 
protein could suppress the gene replication and expression of HBV in Huh-7 cells (Shih et 
al., 1993). Strikingly, these inhibitory effects coincided with the cellular relocalisation of 
core from the cytoplasm to the nucleus. A follow-up study to this work then demonstrated 
that core is phosphorylated by protein kinase A (PKA) and C (PKC) and that 
phosphorylation of Ser-99 and Ser-116 regulated the suppressive acitivity of core on HBV 
gene expression and replication (Chen et al., 2003). Other studies using reporter plasmids 
have shown core protein to elevate expression levels in constructs containing the cellular c-
myc, SV-40 early promoter and Rous sarcoma virus long terminal repeat (Ray et al., 
1995).  In addition, core has suppressive effects on the expression from c-fos (Ray et al., 
1995), p21Waf (Ray et al., 1998a), p53 (Ray et al., 1997) and HIV-LTR promoters (Ray et 
al., 1995). 
 
It is unclear if core protein exerts its effects through a direct interaction with each of these 
promoters. However, the range of promoters affected by core argues for an indirect effect 
of this viral protein through a common transcription factor. This hypothesis is strengthened 
by the protein-protein interaction described between core and the cellular transcriptional 
regulator heterogenous nuclear ribonucleoprotein K (hnRNP K). Furthermore, core protein 
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could partially reverse the suppressive effect of hnRNP K on the human thymidine kinase 
promoter. Core protein binds to the proline-rich regions of hnRNP K, which are known to 
be critical for the interaction of hnRNP K with other cellular factors. Thus, core binding to 
hnRNP K may disrupt the association of this transcriptional regulator with other cellular 
protein partners, which in turn affects its proper function within the cell (Hsieh et al., 
1998). 
 
 
1.11.6.5. Lipid Metabolism 
 
A common condition observed in chronically infected HCV patients is steatosis, which is 
the accumulation of lipids in the liver (Lefkowitch et al., 1993; Scheuer et al., 1992). 
HCV-induced steatosis appears to be a direct cytopathic lesion mostly seen in patients 
infected with genotype 3, in whom it correlates directly with the level of viral replication 
(Section 1.6.2). For reasons unknown, other genotypes are rarely associated with steatosis 
(Castera et al., 2005; Hezode et al., 2004). Transgenic mice expressing either the full-
length HCV genome (Lemon et al., 2000; Lerat et al., 2002; Lerat et al., 2009) or core 
protein (Moriya et al., 1997) alone can develop steatosis, suggesting a direct involvement 
of core protein in the development of this condition. In addition, an increase in the 
proportion of carbon 18 monounsaturated (C18:1) fatty acids, such as oleic and vaccenic 
acids, was found in the livers of both transgenic mice expressing core and patients with 
chronic hepatitis C (Moriya et al., 2001). Core was found to interact with apolipoprotein 
AII, a major component of high density lipoproteins, and may be a mechanism by which 
core alters liver lipid metabolism (Sabile et al., 1999). The numerous studies describing the 
association of core with LDs and the importance of this association in the viral lifecycle 
supports this possibility (Section 1.11.2). One mechanism for the induction of steatosis by 
core protein may be the suppression of lipid secretion as reduced serum levels of 
cholesterol and apo B have been reported in core-expressing transgenic mice (Perlemuter 
et al., 2002). In line with this, HCVcc infection causes the overproduction of LDs 
(Miyanari et al., 2007) and the RNA replication of SGRs is enhanced by increases in 
saturated and monounsaturated fatty acids (Kapadia & Chisari, 2005). Together, these data 
suggest that the regulation of lipid metabolism by the core protein plays crucial roles in the 
HCV lifecycle, which may in turn result in pathogenic affects.  
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1.11.6.6. Host Cell Proteins Interacting with Core 
 
A number of host cell proteins have been identified to interact with HCV core protein 
(Summarised in Table 4). In 1999, three independent studies revealed an interaction 
between HCV core and a putative cellular RNA helicase belonging to the DEAD-box 
family. This cellular protein was referred to as DBX (Mamiya & Worman, 1999), CAP-Rf 
(Core-associated protein-RNA helicase full-length) (You et al., 1999) and DDX3 
(Owsianka & Patel, 1999), the latter of which is the term approved by the HUGO/GDB 
Nomenclature Committee. The interacting domains of the two proteins were mapped to aa 
1-59 (Owsianka & Patel, 1999) or 1-40 (You et al., 1999) of core protein, and aa 553-622 
(Owsianka & Patel, 1999) or 473-611 (You et al., 1999) of the full-length 662 aa DDX3. 
Colocalisation between core and DDX3 was observed following the expression of core in 
Hela or COS-7 cells expressing c-myc-tagged DDX3 (Mamiya & Worman, 1999), Huh-7 
cells expressing FLAG-tagged DDX3 (You et al., 1999) and Hela cells expressing 
endogenous DDX3 (Owsianka & Patel, 1999). The lack of information on the cellular 
role(s) of DDX3 and the absence of a robust system to study the HCV lifecycle made it 
difficult to interpret the possible function(s) of this interaction. Nevertheless, there was 
evidence that this interaction may modulate host gene expression (Mamiya & Worman, 
1999; You et al., 1999). The yeast homologue to DDX3, known as Ded1p, functions in 
translation initiation (Chuang et al., 1997) and a Ded1p-deletion renders yeast non-
functional. Interestingly, DDX3 supplied in trans rescues these Ded1p-deletion mutants, 
and this effect is severely inhibited by the co-expression of full-length core protein. These 
data demonstrate that DDX3 may have an important function in translation initiation, 
which is disrupted by its interaction with HCV core (Mamiya & Worman, 1999). In 
accordance with a function of DDX3 in translation, You et al. (1999) found DDX3 to 
upregulate translation from a reporter plasmid in Huh-7 cells. Co-expression of truncated 
core protein (aa 1-122) significantly enhanced these levels, suggesting this interaction may 
modulate gene expression regulation in the host. However, given that this truncated form 
of core is targeted to the nucleus, the in vivo relevance of this finding is questionable.  
 
 
 
 
 
Interacting 
protein name 
Core residues 
required 
Protein 
residues 
required 
Reference 
DDX3 1-59 473-622 Owsianka & Patel (1999), 
Mamiya & Worman (1999), 
You et al. (1999) 
TNFR1 1-115 345-407 Zhu et al. (1998) 
FADD 1-153 80-205 Zhu et al. (2001) 
Sp110b 21-80 389-453 Watashi et al. (2003) 
LTβR 31-90 338-395 Matsumoto et al. (1997) 
p53 1-151 366-380 Lu et al. (1999) 
p21Waf 24-52 139-164 Wang et al. (2000) 
LZIP -  -  Jin et al. (2000) 
p73 -  321-353 Alisi et al. (2003) 
HCV NS5A -  -  Goh et al. (2001), Masaki et al. 
(2008) 
gC1qR 26-124 199-259 Kittlesen et al. (2000) 
Mcl-1 119 -  Mohd-Ismail et al. (2009) 
14-3-3ε 49-97 165-234 Aoki et al. (2000) 
hnRNP K 25-91 250-392 Hsieh et al. (1998) 
ApoAII 160-173 -  Sabile et al. (1999) 
PA28-γ 44-71 -  Moriishi et al. (2003) 
Fibrinogen-β -  -  Ait-Goughoulte et al. (2009) 
Heat shock 60 
kDa protein 1 
-  -  Kang et al. (2005) 
DDX5  -  -  Kang et al. (2005) 
Cytokeratin 8, 18 
and 19  
-  -  Kang et al. (2005) 
Vimentin -  -  Kang et al. (2005) 
Solute carrier 
family 22 
member 7 
isoform b 
-  -  Kang et al. (2005) 
Hepatocarcinoma 
high expression 
protein 
-  -  Kang et al. (2005) 
FK506-binding 
protein 
-  -  Kang et al. (2005) 
TXNL2 -  -  Kang et al. (2005) 
MHC class I 
antigen 
-  -  Kang et al. (2005) 
Low Mw 
phosphotyrosine 
protein 
phosphatase 
-  -  Kang et al. (2005) 
 
Cofilin -  -  Kang et al. (2005) 
 
Table 4. Cellular and viral proteins shown to interact with HCV core protein. 
Interacting 
protein name 
Core residues 
required 
Protein residues 
required 
Assay(s) used  Reference 
hnRNP K 25-91 250-392 Yeast-two 
hybrid, Co-IP, 
GST-Pulldown, 
Far western 
blotting 
(Hsieh et al., 
1998) 
ApoAII 160-173 -  Yeast-two 
hybrid 
(Sabile et al., 
1999) 
PA28-gamma 44-71 -  Yeast-two 
hybrid, co-IP 
(Moriishi et al., 
2003) 
Fibrinogen-β -  -  Yeast-two 
hybrid, co-IP 
(Ait-
Goughoulte et 
al., 2009) 
Heat shock 
60kDa protein 1 
-  - MALDI-TOF 
MS 
(Kang et al., 
2005) 
DDX5  -  -  MALDI-TOF 
MS 
(Kang et al., 
2005) 
Cytokeratin 8, 18 
and 19  
-  -  MALDI-TOF 
MS 
(Kang et al., 
2005) 
Vimentin -  -  MALDI-TOF 
MS 
(Kang et al., 
2005) 
Solute carrier 
family 22 
member 7 
isoform b 
-  -  MALDI-TOF 
MS 
(Kang et al., 
2005) 
Hepatocarcinoma 
high expression 
protein 
-  -  MALDI-TOF 
MS 
(Kang et al., 
2005) 
FK506-binding 
protein 
-  -  MALDI-TOF 
MS 
(Kang et al., 
2005) 
TXNL2 -  -  MALDI-TOF 
MS 
(Kang et al., 
2005) 
MHC class I 
antigen 
-  -  MALDI-TOF 
MS 
(Kang et al., 
2005) 
Low Mw 
phosphotyrosine 
protein 
phosphatise 
-  -  MALDI-TOF 
MS 
(Kang et al., 
2005) 
Cofilin -  -  MALDI-TOF 
MS 
(Kang et al., 
2005) 
 Table 4. Continued… 
 42
 
1.12. DEAD-Box Proteins 
 
The DEAD box protein family, first described in 1989 (Linder et al., 1989), belongs to 
RNA helicase superfamily 2 (Caruthers & McKay, 2002). DEAD-box proteins act in the 
unwinding of double-stranded RNA structures and the remodelling of RNA-protein 
interactions in an ATP-dependent manner. They are found in most organisms and play 
pivotal roles in nearly all aspects of RNA metabolism including transcription, pre-mRNA 
splicing, ribosome biogenesis, RNA export, translation and RNA decay. DEAD-box RNA 
helicases are defined by a cluster of 9 conserved motifs situated in the protein molecules 
centre and spans a region of approximately 400 aas (Fig. 1.15). In contrast, the N- and C-
termini are highly variable in both sequence and length and are thought to be involved in 
substrate interaction, subcellular localisation and interaction with cellular factors (Cordin 
et al., 2006). The Q motif is involved in control of ATP binding and hydrolysis as well as 
RNA substrate affinity (Cordin et al., 2004; Tanner et al., 2003). Motif I, also known as 
the Walker A motif (Walker et al., 1982), is essential for ATPase and helicase activities. 
Motif II, also known as the Walker B motif (Walker et al., 1982), gives rise to the name 
DEAD-box and is involved in ATP-binding and/or ATP hydrolysis (Pause & Sonenberg, 
1992; Walker et al., 1982). Motif III is proposed to participate in the linking of ATPase 
and helicase activities (Pause & Sonenberg, 1992). Motif IV is the least-well studied 
DEAD-box protein motif, with no definite function assigned as yet (Cordin et al., 2006). 
Motif V is proposed to be an RNA binding motif (Caruthers et al., 2000) and motif VI is 
required for RNA binding and ATP hydrolysis (Pause et al., 1993). 
 
 
1.13. DDX3 
 
DDX3 is a ubiquitous cellular protein belonging to the DEAD-box RNA helicase family. 
The human genome contains two functional genes of the DDX3 family (Kim et al., 2001). 
These include DDX3 located on the X chromosome, also termed DDX3X (Park et al., 
1998) and the highly homologous (91 %) DDX3Y located on the Y chromosome (Lahn & 
Page, 1997). While DDX3Y is expressed only in the male germ line, the DDX3X gene is 
ubiquitously expressed across a wide range of human tissues (Rosner & Rinkevich, 2007). 
Known homologues of DDX3 include mouse PL10 (Leroy et al., 1989), mDEAD3 (Gee & 
Conboy, 1994), Xenopus An3 (Gururajan et al., 1991) and yeast Ded1 (Jamieson & Beggs, 
GAxxPxxxQ    AxxGxGKT    PTRELA    TPGR    DEAD    SAT    LIV    ARGID    HRxGRxGR    
Q I Ia Ib II III IV V VI
ATP binding
ATP hydrolysis
RNA binding
ATPase activity
Helicase activity
N C
?
Figure 1.15. Diagram illustrating the 9 conserved motifs of DEAD-box proteins flanked by 
variable N- and C-termini.  
 
The aa sequence of each motif is detailed in coloured boxes with the motif name listed above. 
Symbol x represents any residue. The proposed function(s) of each motif are indicated. Adapted 
from Rocak & Linder (2004). 
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1991). Since its labelling as a putatitve RNA helicase based on its sequence homology, it 
has been demonstrated experimentally that DDX3 has ATPase and helicase activities 
(Franca et al., 2007; Yedavalli et al., 2004). Although, to date the exact cellular functions 
of DDX3 remain unknown, it has been implicated in numerous cellular processes including 
splicing, translation, tumourigenesis, nucleo-cytoplasmic RNA shuttling, RNA transport, 
IFN induction and apoptosis. As the list of cellular processes increases for DDX3 so to 
does the number of viruses whose replication is dependent on this multifunctional protein. 
The following sections will summarise the literature available on DDX3 to date.   
 
 
1.13.1. Cellular Localisation of DDX3 
 
The majority of studies analysing the intracellular distribution of DDX3 have reported this 
protein to be predominantly cytoplasmic (Franca et al., 2007; Lai et al., 2008; Lee et al., 
2008; Mamiya & Worman, 1999; Schroder et al., 2008; Yedavalli et al., 2004).  However, 
DDX3 has been shown to shuttle consistently between the cytoplasm and nucleus in HeLa 
cells by virtue of the export shuttling protein CRM1 (Chromosome maintainance region 1) 
which DDX3 binds. Treatment of cells with the CRM1 inhibitor Leptomycin B (LMB) 
results in DDX3 accumulation in the nucleus (Yedavalli et al., 2004). These results were 
also reproduced in HEK-293T cells (Schroder et al., 2008).  Thus, the high rate of nuclear 
export may explain why most studies report DDX3 in the cytoplasm. However, two studies 
have also reported a nuclear localisation of DDX3 in HeLa cells (Owsianka & Patel, 1999; 
You et al., 1999).  This discrepancy may be caused by the antibodies used in each study 
recognising DDX3 within nuclear complexes more strongly than its cytoplasmic form. 
 
 
1.13.2. Splicing 
 
Sequence analysis found DDX3 to possess a C-terminal (aa 582-632) arginine/serine rich 
RS-domain consisting of 7 serine-arginine or arginine-serine dipeptides, similar to that of 
other splicing factors (Owsianka & Patel, 1999). In HeLa cell nuclei, DDX3 is reported to 
be present in spliceosomal complexes (Deckert et al., 2006), and also is detected with 
spliced mRNA as part of mRNPs (messenger ribonulceoprotein particles) (Merz et al., 
2007). This suggests DDX3 may not have an active role in splicing, but rather associates 
with RNPs after splicing for roles such as RNA transport. In line with this, DDX3 is 
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reported to form part of the Kinesin RNA-transport granules that transport specific 
populations of mRNAs to the neuronal dendrites for translation. However, knockdown of 
DDX3 by RNA interference (RNAi) had very little effect on RNA transport, indicating 
DDX3 may function in other process besides transport (Kanai et al., 2004). 
 
 
1.13.3. Innate Immune Response 
 
So far, three groups have revealed a function for DDX3 in innate immune signalling 
through enhancing the induction of anti-viral gene expression in HEK-293T cells. Soulat et 
al. (2008) found DDX3 to be an interacting partner of TBK1. The two related kinases 
IKK-ε and TBK1 function under the TLR-induced signalling pathway where they 
phosphorylate and activate IRF-3 and-7 that subsequently activate the IFN-β gene (Figure 
1.2). Knockdown of endogenous DDX3 using small inhibitory RNA (siRNA) technology 
showed DDX3 to be required for TBK1/IRF-3-mediated IFN-β production. Moreover, the 
phosphorylation of DDX3 by TBK1 was required to stimulate IFN-β production following 
stimulation of the innate immune response. Also, DDX3 influenced IFN-β gene expression 
by binding to the IFN-β promoter enhancing region, independent of IRF-3. Given their 
results and the known functions of DDX3 in transcription initiation (Chao et al., 2006), 
nuclear export of HIV RNAs (Yedavalli et al., 2004) and cap-dependent mRNA translation 
(Shih et al., 2008) the authors propose different possible mechanisms for DDX3 in IFN-β 
activation. The activated TBK1 phosphorylates DDX3 in the nucleus, which is recruited to 
the IFN promoter for either stimulating transcription of the IFN-β gene and/or nuclear 
export and translation of the mRNA. Schroder et al. (2008) also found DDX3 to be a 
positive regulator of IFN-β induction. They found DDX3 interacts with IKK-ε after sendai 
virus infection, thereby contributing to IRF-3 activation. Interestingly, they found the 
vaccinia virus protein K7 interacted with DDX3 and inhibited its function in the IFN 
induction pathway. Interestingly, K7 binds to the same N-terminal region of DDX3 (aa 1-
139) that is required for its effects on the IFN-β promoter. Therefore, the inhibitory effect 
of K7 on IFN induction may be caused by the binding of K7 to this region of DDX3 
preventing downstream signalling. Also, the most recent report found that DDX3 bound to 
the RIG-I adaptor protein IPS-I after overexpressing tagged forms of each protein in HEK-
293T cells (Oshiumi et al., 2010). IPS-I is an adaptor protein which binds RIG-I following 
the recognition of viral RNA in the cytoplasm. Using yeast-two hybrid screening residues 
622-662 in the C-terminal region of DDX3 were shown to facilitate its interaction with 
IPS-I. Forced expression of DDX3 and IPS-I in HEK-293T cells also upregulated the IFN-
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β promoter activity. These data suggest that DDX3 is required for IPS-I signalling 
following viral infection, although its exact mechanism in this signaling process remains to 
be determined. These results together with those from Soulat et al. (2008) and Schroder et 
al. (2008) suggest that DDX3 has multiple roles in the innate immune response pathway.  
 
 
1.13.4. Apoptosis 
 
To date, only two studies have reported DDX3 to function in apoptosis, although the 
results are somewhat conflicting. Using the non-transformed swiss mouse embryo 
fibroblast NIH3T3 cell line, Chang et al. (2006) found DDX3 knockdown enhanced 
cellular proliferation and reduced apoptosis. The authors also mentioned preliminary 
findings that caspase-6 and -9 could not be activated in DDX3 knockdown cells, 
suggesting that DDX3 functions in the intrinsic apoptotic pathway. In contrast, Sun et al. 
(2008) reported an anti-apoptotic role for DDX3 within the extrinsic signalling pathway.  
They identified an anti-apoptotic death receptor complex comprising glycogen synthase 
kinase-3 (GSK3), DDX3 and cellular inhibitor of apoptosis protein-1 (cIAP), which caps 
the TRAIL-R2 death receptor and inhibits signalling. GSK3 inhibition or DDX3 
knockdown released this inhibitory cap to allow stronger apoptotic signalling upon death 
receptor stimulation. Stimulation of death receptors including TRAIL-R2 disables these 
proteins causing inactivation of GSK3 and cleavage of DDX3 and cIAP-1 to permit 
apoptotic signalling. These effects were shown in the transformed HeLa cell line and 
MDA-MB-231 human breast cancer cells as well as Jurkat cells. It is not possible that 
DDX3 has a pro-apoptotic effect on the intrinsic pathway (Chang et al., 2006) and an anti-
apoptotic effect on the extrinsic pathway (Sun et al., 2008). The differences in the findings 
from these two studies may be explained by the different cell lines used. 
 
 
1.13.5. Tumourigenesis 
 
DDX3 has also been reported to function in cell cycle regulation and tumourigenesis. 
DDX3 was found to be overexpressed in ten liver cancer cell lines (PLC5, Huh-7, Hep3B, 
SK-Hep1, HepG2, Mahlavu, Huh-6, HCC36, HA22T and Tong) showing anchorage 
independent growth (AIG) (Huang et al., 2004). Overexpression of DDX3 in AIG-negative 
Tong cells led to a 60-80-fold increase in transformed colonies in AIG assays. In addition, 
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this group found that the DDX3 mRNA expression levels were elevated in 64 % of all 
HCC tissue samples (n=45) tested relative to their adjacent normal tissues. Thus, these data 
indicate that DDX3 promotes cellular transformation. In contrast, two reports found DDX3 
may be down-regulated in liver tumour cells and may affect cell cycle progression via 
regulation of p21waf gene expression. Firstly, immunohistochemical staining of 41 paraffin 
embedded HCC specimens revealed that DDX3 expression was decreased in 59 % 
compared to non-tumour tissue (Chang et al., 2006). Western blot analysis from another 60 
HCC specimens found DDX3 expression was lower in 50 % of paired (tumour versus non-
tumour) samples. DDX3 knockdown in non-transformed murine fibroblast NIH3T3 cells 
resulted in the premature entry into S phase and an accelerated proliferation rate. This 
effect correlated with higher expression levels of cyclin D1, a key regulator in early-mid G1 
phase, and lower expression levels of p21waf (Chang et al., 2006). Similarly, 
overexpression of DDX3 protein exerted an inhibitory effect on cell growth in Huh-7 and 
NIH3T3 cells. Overexpression also led to the upregulation of endogenous p21waf protein 
expression, which required the ATPase activity of DDX3 but not the helicase activity 
(Chao et al., 2006). Similar to the report by Chang et al. (2006) DDX3 mRNA and protein 
expression was found to be generally lower in HCC tissue specimens compared to non-
tumour specimens (Chao et al., 2006). Furthermore, the vast majority (77 %) of tissue 
specimens with decreased DDX3 mRNA levels also showed simultaneous p21waf mRNA 
down-regulation. These two reports provide strong evidence for a role of DDX3 in cell 
cycle progression and tumourigenicity via regulation of p21waf gene expression. Using the 
non-tumourogenic human breast epithelial cell line (MCF 10A cells), Botlagunta et al. 
(2008) showed that the carcinogenic compound benzo[a]pyrene diol epoxide increased 
DDX3 expression levels.  Stable overexpression of DDX3 in MCF 10A cells increased 
AIG, motility and invasion, which are all markers of cellular transformation. However, no 
correlation between the expression levels of DDX3 and the regulation of p21waf were 
observed, contrary to previous studies (Chang et al., 2006; Chao et al., 2006). Thus, the 
data regarding the role of DDX3 in tumourigenesis is some what contradictory with studies 
describing both tumour suppressor (Chang et al., 2006; Chao et al., 2006) and tumour 
promoting (Botlagunta et al., 2008; Huang et al., 2004) functions.  The reasons for these 
discrepancies are currently unclear but may be the result of the different cells lines and 
cancer specimens analysed in each study.   
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1.13.6. Protein Translation 
 
As described in section 1.11.6.6, Ded1p is a yeast homologue of DDX3, which is required 
for translation initiation (Chuang et al., 1997) and is therefore essential for cell growth.  
DDX3 supplied in trans was able to rescue a functionally crippled yeast containing a lethal 
Ded1p-deletion mutant (Mamiya & Worman, 1999), suggesting a role for DDX3 in protein 
translation. In mammalian cells cap-dependent translation initiation is the standard mode of 
translation for most cellular mRNAs. This process is facilitated by a cap binding complex 
known as eukaryotic translation initiation factor 4F (eIF4F). This eIF4F complex contains 
the cap-binding protein eIF4E and adaptor protein eIF4G. The eIF4G protein bridges the 
mRNA and ribosome by binding to eIF4E and to ribosome associated factor eIF3. The 
interaction of eIF4G and eIF4E occurs via two conserved motifs and is required for 
translation initiation and therefore its disruption or reinforcement is an important target for 
translational control. The eIF4E inhibitory proteins (EBPs) utilize this conserved region to 
modulate cap-dependent translation by prevention of eIF4F complex formation through the 
sequestrating of available eIF4E. These EBPs play fundamental roles in cell cycle 
progression, metabolism, development, tumor formation and responses to various stimuli 
(Shih et al., 2008). 
 
Shih et al. (2008) showed that DDX3 specifically represses cap-dependent translation, but 
not HCV IRES-mediated translation, in a helicase independent manner. Overexpressing 
DDX3 in HEK-293T cells showed a dose-dependent decrease in cap-dependent and 
increase in cap-independent translation. Also, knocking down DDX3 in HeLa cells 
resulted in an increase in cap-dependent translation but had no effect on cap-independent 
translation. Moreover, they also showed that DDX3 interacts with eIF4E via the conserved 
eIF4E binding motif on DDX3 between residues 38-44. Two separate mutations within this 
binding motif (Y38A and L43A) could disrupt this interaction. Using these mutants they 
showed that DDX3-eIF4E binding inhibited cap-dependent translation by blocking eIF4E-
eIF4G complex formation in HEK-293T cells. Together, the data suggest DDX3 is a novel 
eIF4E inhibitory protein involved in translation initiation regulation. Previously, this group 
reported DDX3 to function as a tumour suppressor and ectopic expression in Huh-7 cells 
inhibited cell proliferation (Chao et al., 2006). Their recent study found a substantial 
increase in colony formation (20-46 % of control) after overexpressing Huh-7 cells with 
the DDX3-eIF4E binding mutants Y38A and L43A compared to the WT control (4-6 % of 
control) (Shih et al., 2008). Together, these data indicate that the DDX3-eIF4E interaction 
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contributes to the tumour suppressor function of DDX3 in addition to its transactivation of 
p21waf. 
 
Lai et al. (2008) reported in HEK-293T cells that DDX3 could interact with Tip-associated 
protein (TAP), which required aas 536-661 of DDX3. TAP is the major mRNA nuclear 
export factor. DDX3 bound TAP primarily in the nucleus, and siRNA knockdown of TAP 
increased the levels of DDX3 in the nucleus and decreased accordingly its levels in the 
cytoplasm in HEK-293T cells. Therefore, it seems DDX3 can be exported from the 
nucleus via the TAP-mediated pathway. In addition, DDX3 and TAP associated with stress 
granules in the cytoplasm of HeLa cells, which are formed after exposure to environmental 
stress and contain several translation initiation factors that represent stalled translation pre-
initiation complexes. DDX3 was shown to interact with the translation initiation factors 
eIF4A, eIF2-α and PABP1 in HEK-293T cells. DDX3 silencing did not prevent arsenite-
induced stress granule formation in HeLa cells, suggesting DDX3 is not required for stress 
granule assembly. However, overexpression of DDX3 induced stress granule formation in 
line with the role of DDX3 in general translation repression (Shih et al., 2008).  DDX3 
knockdown had no effect on the global translation profile of HeLa cells, suggesting DDX3 
is not required for general translation in mammalian cells (Lai et al., 2008). 
 
 
1.13.7. Virus Replication 
 
1.13.7.1. HIV-1  
 
Following HIV-1 entry, the viral RNA genome is reverse transcribed into DNA by the 
virion associated reverse transcriptase.  Following the integration of the provirus into 
cellular chromosomes, the genome is transcribed. More than 30 different species of HIV-1 
mRNAs have been identified to date. Thus, the virus utilizes complex splicing schemes to 
generate diversity and to maximize its coding capacity. The three general categories of 
viral mRNAs include genomic, singly spliced, and multiply spliced RNAs. During the 
early phases in viral infection the multiply spliced mRNAs encoding the Tat, Rev, and Nef 
proteins predominate in the cytoplasm.  Later on in infection, the unspliced and singly 
spliced RNAs become the major species in the cytoplasm. The Rev protein is a key 
regulator in this transition (Wang et al., 2000b).  The exit of HIV RNAs from the nucleus 
is a significant issue because unspliced/partially spliced cellular mRNAs are routinely 
retained in and not permitted for export from the nucleus. The Rev protein binds a highly 
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secondary structured element called the Rev responsive element (RRE) that is present in all 
unspliced and partially spliced HIV transcripts. This binding specifically distinguishes, for 
purposes of nuclear export, viral transcripts from cellular RNAs. In its role of RNA 
transportation from the nucleus Rev directly interacts with the nuclear export receptor 
CRM1. CRM1 is required for Rev-mediated export of HIV RNAs (Jeang & Yedavalli, 
2006). It was recently shown that DDX3 is a member of the Rev-CRM1-RRE complex 
through its binding to CRM1 (Yedavalli et al., 2004). This interaction was demonstrated in 
HeLa cells as well as the Jurkat and MT4 T cell lines. This study also showed for the first 
time that purified DDX3 could unwind double-stranded RNA in a helicase and ATPase 
dependent manner. Knockdown of DDX3 expression in HeLa cells using either an anti-
sense vector or dominant negative mutants inhibited the export of unspliced/partially 
spliced HIV-1 RNAs from the nucleus and consequently impaired HIV-1 replication. It 
was also found that the function of DDX3 within this complex was dependent on its 
helicase activity and that DDX3 interacted with nucleoporins and localised with the 
cytoplasmic side of nuclear pores.  From their findings, the authors speculated that 
following the initial delivery of the HIV RNAs by Rev/CRM1 into the nuclear pore the 
enzymatic unwinding action of DDX3 may facilitate the final release of the HIV-1 RNAs 
from the cytoplasmic side of the nuclear pore. 
 
 
1.13.7.2. HBV 
 
HBV is a member of the hepadnavirus family. Infectious virions contain a partially double-
stranded, circular but not covalently closed DNA genome referred to as relaxed circular or 
RC-DNA. During infection, RC-DNA is converted into covalently closed circular DNA 
(cccDNA) within the host cell nucleus, which serves as a template for the transcription of 
several genomic and subgenomic RNAs by cellular RNA polymerase II.  Of these, the 
pregenomic RNA (pgRNA) is packaged into progeny capsids and reverse transcribed by 
the co-packaged viral polymerase (reverse transcriptase) into new RC-DNA genomes 
(Beck & Nassal, 2007). In the search for host factors that bound the HBV polymerase, 
Wang et al. (2009) identified DDX3 from HEK-293T cells stably expressing FLAG-tagged 
HBV polymerase. Surprisingly, overexpression of DDX3 in HBV replicating HepG2 cells 
decreased HBV DNA synthesis in a dose-dependent manner. Also, knockdown of DDX3 
from these cells resulted in a dose-dependent increase in HBV DNA synthesis. The impact 
of DDX3 overexpression or knockdown on HBV genome replication in HEK-293T cells 
was essentially identical to the results obtained with HepG2 cells, indicating that DDX3 
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inhibits HBV DNA synthesis in both hepatoma cells and non-hepatoma cells. This was not 
caused by inhibition of pgRNA encapsidation but instead by DDX3 being incorporated 
into the viral nucleocapsids to inhibit reverse transcription. Although, these results suggest 
DDX3 is a cellular host factor restricting HBV genome replication, the exact mechanism 
and physiological relevance behind these findings remain to be determined. The authors 
speculate their findings may connect to the previous report by Chang et al. (2006) showing 
a decrease in DDX3 expression levels in HCC tissue samples (Section 1.13.5). HBV might 
downregulate DDX3 expression during infection to relieve the inhibitory effect of DDX3 
on its replication and thereby contribute to the development of HBV-induced HCC.  
 
 
1.13.7.3. HCV 
 
The importance of DDX3 in HCV replication was first demonstrated in a study that 
performed a systematic RNAi screen targeting 62 host genes encoding proteins known to 
interact with HCV RNA, HCV proteins or belonging to cellular pathways thought to 
modulate HCV infection. These genes were silenced in Huh-7.5 cells that were 
subsequently infected with HCVcc (Randall et al., 2007). Strikingly, out of all the host 
genes targeted, DDX3 silencing resulted in the greatest drop in infectious virus release (42-
fold) and RNA replication (1800-fold), without affecting cell viability. A slightly later 
study then carried out a more detailed analysis into the role of DDX3 in HCV replication 
(Ariumi et al., 2007). DDX3 expression levels were reduced in Huh-7-derived cells 
through transduction with a lentivirus vector encoding a short hairpin RNA (shRNA) 
targeting DDX3. Efficient DDX3 knockdown severely impaired intracellular RNA 
replication (>95 %), core protein expression and colony formation in cells harbouring a 
replicative full-length genotype 1b HCV replicon (HCV-O). In addition, infection of 
DDX3 knockdown cells with JFH1 virus caused approximately 90 % reductions in both 
intracellular HCV RNA levels and core protein release into the supernatant. However, 
shRNA knockdown of DDX3 only reduced SGR RNA replication by approximately 50 %, 
suggesting that the requirement of DDX3 for HCV replication applies more to the full-
length genomes. To confirm the core protein from HCV-O and JFH1 interacted with 
DDX3, HEK-293T cells were co-transfected with vectors that expressed core from each 
genotype and HA-tagged DDX3. Immunoprecipitation of these transfected cell lysates 
using anti-HA antibody, followed by immunoblotting for core showed strong binding of 
HCV-O core but very weak binding of JFH1 core to DDX3. In addition, either core protein 
lacking the N-terminal first 40 aas failed to interact with DDX3 indicating this region 
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contains the DDX3 binding motif. They next tested the core-DDX3 interaction in Huh-7 
derived cells lines harbouring HCV-O or infected with JFH1 by mixing each set of lysates 
with those from HEK-293T cells overexpressing HA-DDX3 and immunoprecipitating each 
mixture as before. While the HCV-O core was effectively co-immunoprecipitated, no 
JFH1 core was detectable. Thus, the core protein from the JFH1 strain appears to have a 
weaker interaction with DDX3 than the HCV-O core. The authors speculated that the RNA 
replication of full-length genomes is more impaired by DDX3 knockdown than the SGRs 
as they possess core. It is possible that core sequesters DDX3 to function in the efficient 
synthesis of full-length genomes. However, their results clearly made no link between 
DDX3 knockdown affecting virus replication and the core-DDX3 interaction (Ariumi et 
al., 2007).  
 
 
1.14. Aims 
 
The aim of this project was divided into two lines of investigation. The first aim was to use 
the HCVcc model to characterise the interaction between core and DDX3 during authentic 
viral replication. To ascertain whether this interaction functions in the viral lifecycle, 
detailed characterisation studies were performed on a panel of HCVcc core mutants with 
altered binding affinity to DDX3. Secondly, the importance of two highly conserved core 
residues in HCVcc replication was investigated, specifically with respect to their roles in 
infectious particle assembly and productive viral infection. 
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2. Materials and Methods 
 
 
2.1. Materials 
 
 
2.1.1. Chemicals 
 
Chemical / Reagent Supplier 
Absolute ethanol  Bamford Laboratories, UK 
30 % Acrylamide/bis solution 37.5:1  Bio-Rad laboratories 
Agarose  Melford 
2-Amino-2-(hydroxymethyl)-1,3-
propanediol (TRIS) 
BDH 
Ammonium persulphate (APS)  Bio-Rad Laboratories 
Ampicillin (Amp)  Melford 
Bromophenol blue (BPB) BDH 
Butanol Fisher Scientific 
Chloroform Sigma 
4’,6-diamidino-2-phenylindole (DAPI) Promega 
Electroporation cuvettes (1 and 4 mm) Apollo 
Ethanol Fisher Scientific 
Ethidium bromide Sigma 
Glucose  BDH 
Glycine BDH 
Isopropanol    Fisher Scientific 
β-Mercaptoethanol Sigma 
Methanol   Fisher Scientific 
Mung Bean nuclease NEB 
Pipette tips (RNase free) Starlabs 
Phenol Sigma 
Proteinase K Invitrogen 
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Restriction enzymes NEB 
Sodium chloride (NaCl) BDH 
Sodium dodecyl sulphate (SDS) BDH 
Sucrose BDH 
N,N,N’,N’-Tetramethylethylene-
diamine (TEMED)   
Sigma 
Triton X-100 Sigma 
TRIzol Invitrogen 
Tween-20   Bio-Rad Laboratories 
 
 
2.1.2. Kits 
 
Kit Source 
Advantage® cDNA polymerase Kit Clonetech 
QIAprep Spin Miniprep Kit Qiagen 
QIAquick Gel Extraction Kit  Qiagen 
Qiagen Plasmid Maxi Kit Qiagen 
QuickChange Site-Directed Mutagenesis 
Kit 
Stratagene 
RNeasy Plus Mini Kit Qiagen 
TaqMan Reverse Transcription Kit Applied Biosystems 
MEGAscript High Yield Transcription 
Kit 
Ambion 
MEGAclear Purification Kit Ambion 
 
 
2.1.3. Cells 
 
Cells Description Source 
Huh-7  Human Hepatoma cell line Jean Dubuisson (CNRS, 
Institut de Biologie de Lille, 
Lille, France) 
HEK-293T Human Embryonic Kidney American Type Culture 
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cell line Collection 
 
 
2.1.4. Transfection Reagents 
 
Reagent Source 
Lipofectamine RNAiMAX  Invitrogen 
Calcium phosphate Transfection 
Kit 
Sigma 
 
 
2.1.5. Cell Culture Growth Medium 
 
All cell culture media components were supplied by Invitrogen. Huh-7 and HEK-293T 
cells were grown in complete Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10 % fetal calf serum (FCS), 100 U/ml penicillin, 100 μg/ml 
streptomycin, 0.1 mM non-essential aas and 2 mM glutamine.  
 
 
2.1.6. Primary Antibodies  
 
The monoclonal antibodies and polyclonal antisera used in this study are listed below: 
Antibody Name Type  Raised in Source 
Anti-core C7-50 mAb Mouse Bioreagents 
Anti-core  R308 pAb Rabbit Hope & 
McLauchlan 
(2000) 
Anti-core  R526 pAb Mouse Clayton et al. 
(2002) 
Anti-NS5A  9E10 mAb Mouse  Lindenbach 
et al. (2005) 
Anti-NS5A  Anti-NS5A pAb Sheep Macdonald et 
al. (2003) 
Anti-E2 AP33 mAb Mouse Clayton et al. 
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(2002) 
Anti-E2 ALP98 mAb Mouse Clayton et al. 
(2002) 
Anti-ADRP ADRP 4 pAb Sheep Targett-
Adams et al. 
(2003) 
Anti-DDX3 AO196 mAb Mouse Angus et al. 
(2010) 
Anti-DDX3 R648 pAb Rabbit Angus et al. 
(2010) 
Anti-GFP Anti-GFP mAb Mouse Sigma 
Anti-α-Tubulin Anti-Tubulin mAb Mouse Sigma 
Anti-CD81 Anti-CD81 mAb Mouse BD 
Biosciences 
Anti-core 
biotinylated 
BR526 Biotin labelled 
pAb R526 
Rabbit A. Owsianka, 
unpublished 
Anti-DDX3 
biotinylated 
BR648 Biotin labelled 
pAb R648 
Rabbit Angus et al. 
(2010) 
 
 
2.1.7. Secondary Antibodies 
 
Antibody Source 
FITC-conjugated donkey anti-sheep IgG Invitrogen 
FITC-conjugated donkey anti-mouse IgG Invitrogen 
FITC-conjugated goat anti-rabbit IgG Invitrogen 
TRITC-conjugated goat anti-mouse IgG Invitrogen 
TRITC-conjugated donkey anti-sheep IgG Invitrogen 
Cy5-conjugated donkey anti-rabbit IgG Invitrogen 
Anti-streptavidin-HRP conjugate Sigma 
Anti-mouse-HRP conjugate Sigma 
Anti-rabbit-HRP conjugate Sigma 
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2.1.8. Clones 
 
Name Vector Details Source 
pJFH1 pUC Full-length JFH1 cDNA 
downstream of the T7 RNA 
polymerase promoter. 
Wakita et al. (2005) 
pJFH1∆E1E2 pUC As pJFH1, except carries a  
deletion in the envelope 
glycoprotein sequences situated 
downstream of the T7 RNA 
polymerase promoter. 
Wakita et al. (2005) 
pJFH1GND pUC As pJFH1, except carries a 
mutation in the NS5B GDD 
motif, downstream of the T7 
RNA polymerase promoter. 
Wakita et al. (2005) 
pJFH1DP pUC As pJFH1, except carries two 
mutations in core (P138A and 
P143A), downstream of the T7 
RNA polymerase promoter. 
Boulant et al. (2007) 
pJFH1F130E pUC As pJFH1, except carries a 
mutation in core (F130E), 
downstream of the T7 RNA 
polymerase promoter. 
Boulant et al. (2007) 
pJFH1VLVL pUC As pJFH1, except carries four 
mutations in core (A180V, 
S183L, C184V and T186L), 
downstream of the T7 RNA 
polymerase promoter. 
Targett-Adams et al. 
(2008b) 
pGEM T-JFH11-
2614 
pGEM T 
Easy 
Cloning vector containing JFH1 
strain nucleotides 1-2614  
Dalrymple, (2007) 
pJFH1F24A pUC As pJFH1, except carries a  
mutation in core (F24A), 
downstream of the T7 RNA 
Dalrymple, (2007) 
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polymerase promoter. 
pJFH1G27A pUC As pJFH1, except carries a 
mutation in core (G27A), 
downstream of the T7 RNA 
polymerase promoter. 
Dalrymple, (2007) 
pJFH1I30A pUC As pJFH1, except carries a 
mutation in core (I30A), 
downstream of the T7 RNA 
polymerase promoter. 
Dalrymple, (2007) 
pJFH1G33A pUC As pJFH1, except carries a 
mutation in core (G33A), 
downstream of the T7 RNA 
polymerase promoter. 
Dalrymple, (2007) 
pJFH1V34A pUC As pJFH1, except carries a 
mutation in core (V34A), 
downstream of the T7 RNA 
polymerase promoter. 
Dalrymple, (2007) 
pJFH1Y35A pUC As pJFH1, except carries a 
mutation in core (Y35A), 
downstream of the T7 RNA 
polymerase promoter. 
Dalrymple, (2007) 
pJFH1∆E1E2(Y35A) pUC As pJFH1, except carries a 
mutation in core (Y35A) and a 
large deletion in the envelope 
glycoprotein sequences, 
downstream of the T7 RNA 
polymerase promoter. 
A. Patel, unpublished 
pJFH1G32D/G33A pUC As pJFH1, except carries two 
mutations in core (G32D/G33A), 
downstream of the T7 RNA 
polymerase promoter. 
A. Angus, this work 
pJFH1G33A/V34A pUC As pJFH1, except carries two 
mutations in core (G33A/V34A), 
downstream of the T7 RNA 
A. Angus, this work 
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polymerase promoter. 
pJFH1G33A/L36S pUC As pJFH1, except carries two 
mutations in core (G33A/L36S), 
downstream of the T7 RNA 
polymerase promoter. 
A. Angus, this work 
pJFH1G33A/L37S pUC As pJFH1, except carries two 
mutations in core (G33A/L37S), 
downstream of the T7 RNA 
polymerase promoter. 
A. Angus, this work 
pJFH1F24L pUC As pJFH1, except carries a 
mutation in core (F24L), 
downstream of the T7 RNA 
polymerase promoter. 
A. Angus, this work 
pJFH1F24I pUC As pJFH1, except carries a 
mutation in core (F24I), 
downstream of the T7 RNA 
polymerase promoter. 
A. Angus, this work 
pJFH1F24V pUC As pJFH1, except carries a 
mutation in core (F24V), 
downstream of the T7 RNA 
polymerase promoter. 
A. Angus, this work 
pJFH1F24Y pUC As pJFH1, except carries a 
mutation in core (F24Y), 
downstream of the T7 RNA 
polymerase promoter. 
A. Angus, this work 
EGFP-DDX3 pEGFP-
C1 
Full-length DDX3 gene cloned 
into the BamHI site, in frame to 
sequences encoding EGFP. 
Angus et al, (2010) 
 
 
2.1.9. Bacterial Strains 
 
Plasmids were manipulated and grown in the Escherichia coli strain DH5-α. 
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2.1.10. Solutions 
 
2.1.10.1. Bacterial Expression 
 
Solution Components 
L-Broth (LB)*  170 mM NaCl, 10 g/l Bactopeptone, 5 g/l 
yeast extract 
LB-agar*  LB plus 1.5 % (w/v) agar 
Yeast tryptose broth (YTB)*  85 mM NaCl, 16 g/l Bactopeptone, 10 g/l 
yeast extract 
* Prepared in-house by the media department 
 
 
2.1.10.2. DNA Manipulation  
 
Solution Components 
DNA loading dye 30 % glycerol; 0.25 % BPB 
TBE (10x) 8.9 M Tris-borate, 8.9 M boric acid, 0.02 
M EDTA (pH 8.0) 
 
 
2.1.10.3. SDS-PAGE 
 
Solution Components 
Running gel buffer  40 mM Tris, 185 mM Glycine, 0.1 % SDS 
Resolving gel buffer 0.5 M Tris-HCl pH 8.9, 0.4 % SDS 
Stacking gel buffer 0.5 M Tris-HCl pH 6.9, 0.4 % SDS 
Sample loading buffer (reducing) 100 mM Tris-HCl pH 6.9, 2 % SDS, 10 % 
glycerol, 5 % β-mercaptoethanol, 1 µg/ml 
bromophenol blue 
Sample loading buffer (non-reducing) 100 mM Tris-HCl pH 6.9, 2 % SDS, 10 % 
glycerol, 1 µg/ml BPB 
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2.1.10.4. Western Immunoblotting 
 
Solution Components 
Towbin buffer 25 mM Tris-HCl (pH 8.0), 192 mM 
glycine, 20 % (v/v) methanol 
PBS (A)* 170 mM NaCl, 3.4 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4, 
25 mM Tris-HCl (pH 7.2) 
PBS (A) –Tween (PBST) PBS (A), plus 0.05 % (v/v) Tween-20 
Blocking buffer PBST plus 5 % (w/v) dried milk (Marvel) 
*Prepared in-house by the media department 
 
 
2.1.10.5. Cell Lysis  
 
Solution Components 
Immunoprecipitation buffer (LB2) 20 mM Tris-HCl pH 7.4, 20 mM 
iodoacetamide, 150 mM NaCl, 1 mM 
EDTA, 0.5 % Triton X-100 
Cell Lysis/Co-immunoprecipitation buffer 
(Masaki Buffer) 
20 mM Tris-HCl, pH 7.4, 135 mM NaCl, 
0.1 % Triton X-100, 50 mM NAF, 5 mM 
NA3VO4, 1 mM Phenylmethylsulfonyl 
fluoride (PMSF) 
 
 
2.1.10.6. Tissue Culture 
 
Solution Components 
Trypsin solution 0.25 % (w/v) Difco trypsin dissolved in PBS(A), 
0.002 % (w/v) phenol red 
Versene 0.6 mM EDTA in PBS(A), 0.002 % (w/v) phenol red
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2.1.11. Oligonucleotide Synthesis 
 
Oligonucleotides were ordered from Sigma. 
 
 
2.1.12. siRNAs 
 
Two pre-validated siRNA duplexes targeting different regions of the human DDX3 gene 
(s4004 and s4005) and a negative control siRNA composed of a scrambled sequence were 
supplied by Appied Biosystems in 1 nM quantities. These were resuspended in RNase free 
water to yield a stock concentration of 10 µM.  
 
 
2.2. Methods 
 
2.2.1. Tissue Culture Maintenance 
 
2.2.1.1. Cell Passaging  
 
Huh-7 cells were propagated at 37 °C in complete DMEM in an atmosphere of 5 % CO2. 
Cell lines were typically grown in 80 cm2 or 175 cm2 tissue culture flasks (Nunc). Passage 
of cells was carried out when cells reached 90 % confluency by first gently washing cells 
in ice-cold PBS(A) followed by their removal with trypsin (Sigma) diluted 1:100 in 
versene (TV). Cells were then resuspended in 10 ml of complete DMEM before re-seeding 
or use in experiments. 
 
 
2.2.1.2. Long Term Storage of Cells 
 
Aliquoted cells were stored in DMEM containing 25 % FCS and 10 % DMSO. Aliquots 
were left overnight at -70 °C before being transferred to -180 °C for long-term storage. 
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2.2.2. Production of Electrocompetent Bacterial Cells  
 
LB (1 L) was inoculated with 10 ml of fresh overnight E. coli DH5-α culture and grown at 
37 °C to an OD600 of ~0.8. The flask was chilled on ice for 30 min and centrifuged at 4000 
r.p.m. for 10 min at 4 °C using a Sorval RC-5B Refrigerated Superspeed Centrifuge. 
Supernatant was removed and the pellet resuspended in 1 L ice-cold deionised molecular 
biology grade water (dH2O). Cells were re-centrifuged as before and resuspended in 500 
ml ice-cold dH2O with 10 % glycerol. Again cells were centrifuged as before and 
resuspended in 2-3 ml ice-cold dH2O with 10 % glycerol before being aliquoted into 70 μl 
aliquots and stored for up to 6 months at -70 °C. 
 
 
2.2.3. DNA Manipulation 
 
2.2.3.1. Quantitation of DNA 
 
DNA aliquots were diluted 1:50 in dH2O and the OD measured using a BioPhotometer 
(Eppendorf). 
 
 
2.2.3.2. Restriction Enzyme Digestion of DNA 
 
All restriction enzyme digests of plasmid DNA were carried out at 37 °C for at least 1 h 
unless otherwise specified by the manufacturer. Typically, 10 U of each enzyme per μg 
DNA were used in a total volume of 50 μl. All reactions were performed using the 
appropriate enzyme buffers and BSA if necessary. 
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2.2.3.3. Ligation of DNA Fragments 
 
Gel purified DNA fragments (Section 2.2.3.7) were ligated for 16 h at 16 °C in 10 µl 
reactions containing 1x ligase buffer and 2 U of T4 DNA ligase. Following ligation, 2 µl 
DNA was used for electroporation into competent E. coli bacteria (Section 2.2.3.4). 
 
 
2.2.3.4. Transformation of Electrocompetent E.coli Cells 
 
Plasmid or ligated DNA (2 µl) was added to 70 μl electrocompetent E. coli in a pre-chilled 
1 mm gap cuvette and electroporated (1.8 kV, 25 μF, 200 Ω) using a BioRad GenePulser 
Xcell. The bacteria were then resuspended in 0.5 ml YTB and incubated at 37 °C for 1 h 
before being plated on LB-agar plates with ampicillin, final concentration 100 μg/ml (LB-
agar + Amp). Plates were then incubated overnight at 37 °C.  
 
 
2.2.3.5. Small Scale Plasmid Preparation from Transformed Bacteria  
 
A single colony from a freshly streaked selective agar plate was picked (Section 2.2.3.4) 
and used to inoculate a 5 ml culture of LB with ampicillin (LB-Amp). Following culture 
for 16 h at 37 ºC with vigorous shaking (180 r.p.m.), the bacteria were centrifuged in a 
Sanyo MSE MicroCentaur at 13,000 r.p.m. and the DNA extracted from the bacterial pellet 
using the QIAprep miniprep kit according to the manufacturer’s instructions. 
 
 
2.2.3.6. Large Scale Plasmid Preparation from Transformed Bacteria 
 
A single colony from a freshly streaked selective agar plate was picked (Section 2.2.3.4) 
and used to inoculate a 5 ml starter culture of LB-Amp. Following 8 h incubation, the 
starter culture was diluted 1:500 into 200 ml of LB-Amp and cultured for 16 h at 37 ºC 
with vigorous shaking (180 r.p.m.). The bacteria were then harvested by centrifugation at 
3000 r.p.m. for 10 min at 4 ºC using a Sorval RC-5B Refrigerated Superspeed Centrifuge. 
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A large scale DNA preparation was then made from the bacteria using the Qiagen HiSpeed 
plasmid Maxi kit according to the manufacturer’s instructions.  
 
 
2.2.3.7. Isolation and Purification of DNA from Agarose Gels 
 
This method was employed to resolve DNA fragments produced by PCR (Section 
2.2.3.11) or restriction enzyme digestion (Section 2.2.3.2). To separate fragments slab gels 
containing 0.8 % agarose were prepared in 1 x TBE containing ethidium bromide (1 
µg/ml). DNA fragments were run alongside 1 Kbp or 100 bp ladders (NEB). DNA samples 
were mixed with 0.1 volumes of 10 x DNA loading dye before being loaded into the wells 
of the gel. Gels were typically run at 100 V in 0.5 x TBE buffer. To purify DNA, 
fragments were visualised with the aid of long wave UV light and then excised using a 
clean scalpel. Excised fragments were then purified using the QIAQuick gel extraction kit 
(Qiagen) according to the manufacturer’s instructions.  
 
 
2.2.3.8. Site-Directed Mutagenesis 
 
Mutagenesis reactions were performed using the QuickChange Site-Directed Mutagenesis 
kit (Stratagene). Forward and reverse primers for mutagenesis (Appendix 1) were designed 
to incorporate the desired mutation(s) in the middle of the primer sequence and were 
between 25 and 45 bases in length, according to the manufacturer’s instructions. PCR 
reactions were performed in a GeneAmp PCR machine (Applied Biosystems) as follows: 
 
Reaction components: 
Component Amount 
DNA template 50.0 ng 
Forward primer (10 μM) 1.25 μl 
Reverse primer (10 μM) 1.25 μl 
dNTP mix 1.0 μl 
10x reaction buffer 5.0 μl 
dH2O Up to 50.0 μl 
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Reaction cycle: 
Stage 1  
- Hold at 95 °C for 30 s  
Stage 2 (6 cycles) 
- Hold at 95 ° C for 30 s 
- Hold at 55 ° C for 1 min 
- Hold at 68 ° C for 6 min 
 
Following PCR, each reaction was chilled on ice for 2 min followed by the addition of 
DpnI (10 U) to digest the non-mutated dam-methylated parental DNA. Reactions were 
mixed by pipetting, then centrifuged in a Sanyo MSE MicroCentaur at 13,000 r.p.m. for 1 
min, followed by incubation at 37 ºC for 1 h. DpnI-treated DNA was transformed into 50 
μl XL1-Blue Supercompetent bacteria. Bacteria were thawed on ice after which 2 μl 
mutant DNA was added to the competent cells, which were incubated on ice for a further 
30 min. DNA-bacteria mixtures were then heat-pulsed at 42 ºC for 45 s and then incubated 
on ice for a further 2 min. 0.5 ml of YTB pre-heated to 42 ºC was added to each mixture, 
followed by incubation at 37 ºC for 1 h with shaking at 180 r.p.m. Total cultures were 
pelleted at 4000 r.p.m using a Sanyo MSE MicroCentaur. for 3 min, resuspended in 50 μl 
YTB and plated onto LB-agar + Amp and incubated at 37 ºC overnight. 
 
 
2.2.3.9. Introducing Core Mutations into pJFH1 
 
All core mutations were individually introduced into pGEM T-JFH11-2614 by site-directed 
mutagenesis (Section 2.2.3.8). Three colonies from each agar plate were picked and used 
to prepare plasmid mini-preps (Section 2.2.3.5). Plasmids were sequenced (Section 
2.2.3.12) between nucleotides 1-1369 using primers NA7, NA11, NA12, NA13, NA15 and 
NA18 (Appendix 1). Positive clones were then restriction digested with EcoRI and BsiWI 
(Section 2.2.3.9.1) to remove nucleotides 1-1369 of JFH1, which were subsequently 
ligated (Section 2.2.3.3) back into the parental pJFH1 vector backbone. The ligation 
mixture was then transformed into bacteria and used to prepare a plasmid maxi-prep 
(Section 2.2.3.6). To confirm the fragment had ligated correctly and contained the desired 
sequence, a diagnostic digest was performed on an aliquot of plasmid preparation using 
EcoRI and BsiWI (Section 2.2.3.9.1) in addition to nucleotide sequencing the insert region 
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using the same primers as before. Following these checks the plasmids were linearised 
(Section 2.2.3.13) and used to prepare in vitro transcribed viral RNA (Sections 2.2.4.1) 
 
2.2.3.9.1. EcoRI/BsiWI Digest Reaction Mix 
Component Volume (µl) 
Plasmid DNA 5.0 
Buffer 3 2.0  
BsiWI 1.0 
dH2O 12.0 
The above digest was incubated at 55 ºC/ 1 h. The reaction was then incubated on ice for 2 
min to reduce the temperature before adding 1 µl EcoRI and incubating at 37 ºC/ 1 h. 
 
 
2.2.3.10. Preparation of HCV cDNA for Sequencing 
 
Total RNA was extracted from infected Huh-7 cells using the RNeasy kit (Section 2.2.4.2). 
Total RNA (100 ng) was then subjected to a reverse transcription reaction (Section 2.2.6.1) 
using 2 pmol of the HCV specific primer NegRT (Appendix 1) to synthesise cDNA from 
negative-strand viral RNA. After digestion with 1 U RNase H for 20 min at 37 ºC, one 
quarter of the cDNA reaction was amplified by PCR using core specific primers (Section 
2.2.3.11). PCR products were gel purified (Section 2.2.3.7) and sequenced (Section 
2.2.3.12).  
 
 
2.2.3.11. Polymerase Chain Reaction (PCR) Amplification of DNA 
 
PCR was performed to amplify viral cDNA generated from infected cell total RNA. The 
product of this reaction was to be used for direct sequence analysis (Section 2.2.3.12) and 
thus it was crucial to obtain high yields of accurately amplified DNA. This was done using 
the Advantage cDNA polyermase kit (Clonetech), which uses two DNA polymerases 
simultaneously (KlenTaq-1 and proof-reading enzyme) along with the TaqStart® antibody 
to provide automatic “hot start” PCR. These components increase the range, accuracy and 
yield of the PCR reaction. The reaction was performed in a GeneAmp PCR machine 
(Applied Biosystems) as follows: 
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Reaction components: 
Component Volume (µl) 
dH2O 36.0 
10x cDNA PCR reaction buffer 5.0 
cDNA template 5.0 
Forward primer (NA11) (10 μM) 1.0 
Reverse primer (NA14) (10 μM) 1.0 
10 mM dNTP 1.0 
DNA polymerase 1.0 
Total volume 50.0 
 
 
 
Reaction Cycle: 
Stage 1 
-Hold at 95 °C for 1 min – Denaturation of taq antibody 
Stage 2 (35 cycles) 
-Hold at 94 °C for 30 s – Denaturation of template 
-Hold at 68 °C for 3 min – Primer annealing 
Stage 3 
-Hold at 68 °C for 3 min – Primer extension 
Stage 4 
-Hold at 15 °C  
 
The entire PCR reaction was then subjected to agarose gel electrophoresis and the band of 
interest purified by gel extraction (Section 2.2.3.7). 
 
 
2.2.3.12. Nucleotide Sequencing 
 
Nucleotide sequencing of plasmid and amplified cDNA was performed using the core 
specific primers NA11, NA12, NA13 and NA14 (Appendix 1) by GATC biotech, 
Germany. A minimum of 30 µl of DNA (100 ng/µl) and primers (10 µM) were required 
for each reaction. Completed sequences were analyzed using Chromas (Applied 
Biosystems) and NCBI alignment software. 
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2.2.3.13. Restriction Digestion of pJFH1 for In Vitro Transcription 
 
Plasmids were linearised by XbaI digestion in a 100 μl reaction in an 1.5 ml RNase-free 
tube (Ambion) followed by treatment with Mung Bean nuclease to digest the sticky ends 
(30 °C for 30 min). To clean the template of proteins Proteinase K (final concentration 100 
μg/ml) and SDS (final concentration 0.5 %) were added and incubated at 50 °C for 30 min. 
The template was then treated with 100 μl of neutral phenol-chloroform (25 parts saturated 
neutral phenol: 24 parts chloroform: 1 part isoamylalcohol), vortexed for 1 min and 
centrifuged at 13,000 r.p.m. for 2 min using a Sanyo MSE MicroCentaur. The aqueous 
layer was placed in a fresh RNase-free centrifuge tube and 0.1 volumes 5 M NH4OAc 
added along with 3 volumes 100 % ethanol. The sample was stored at -20 °C for 30 min 
before being centrifuged in a Sanyo MSE MicroCentaur at 13,000 r.p.m. for 15 min to 
pellet the precipitated DNA. The ethanol was carefully removed from the tube and the 
pellet dried at room temperature before being resuspended in 30 μl nuclease-free dH2O. 
The concentration of linear DNA template was then determined (Section 2.2.3.1). 
 
 
2.2.4. RNA Manipulation 
 
2.2.4.1. In Vitro Transcription  
 
In vitro transcription was carried out using a T7 Megascript kit (Ambion) following the 
manufacturer's instructions using 1 µg of linear DNA template. The RNA was then 
purified using the MEGAclear kit to remove nucleotides, short oligonucleotides, proteins, 
and salts from the RNA. The amount of RNA was obtained by diluting an aliquot of the 
RNA 1:50 in dH2O and reading the OD using a BioPhotometer (Eppendorf). Typically, 
this kit yielded RNA concentrations of 70-100 μg. 
 
 
2.2.4.2. Preparation of Total RNA 
 
RNA was extracted from cells grown on a 25 cm2 flask, a 6-well or a 24-well dish using 
the RNeasy Mini kit (Qiagen) according to the manufacturer’s instructions. This kit is 
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designed to purify up to 100 µg of total RNA from mammalian cells that is ready for use in 
downstream applications including RT-PCR (Section 2.2.3.11) and RT-qPCR (Section 
2.2.6). This technology relies on the selective binding properties of silica-based 
membranes within microspin columns that bind RNA longer than 200 bases under the high 
salt buffer conditions. DNase digestion is not required with RNeasy Kits since RNeasy 
silicamembrane technology efficiently removes DNA without DNase treatment. 
 
 
2.2.4.3. Preparation of Extracellular HCV RNA 
 
All RNA extractions were performed in RNase-free 1.5 ml tubes (Ambion). Aliquots of 
viral pellets resupsended in PBS(A) or sucrose gradient fractions were lysed in TRIzol LS 
reagent to a total volume of 400 µl. Chloroform (110 μl) was added and the sample shaken 
vigorously for 15 s before being incubated at room temperature for 15 min. Samples were 
then centrifuged in a Sanyo MSE MicroCentaur at 13,000 r.p.m. for 15 min and the 
aqueous (upper) phase added to 500 μl isopropanol. This was incubated at room 
temperature for 10 min before being centrifuged as before. After decanting, the pellet was 
washed in 75 % ethanol, mixed by vortexing, and centrifuged in a Sanyo MSE 
MicroCentaur at 13,000 r.p.m. for 10 min. The pellet was then dried at room temperature 
and resuspended in 20 μl of nuclease-free H2O (Ambion). RNA was stored at -70 °C or 
used for quantification by RT-qPCR (Section 2.2.6). 
 
 
2.2.5. Introduction of DNA/RNA into Eukaryotic Cells 
 
2.2.5.1. Transfection of DNA 
 
The calcium phosphate transfection method was used to introduce plasmid DNA into 
HEK-293T cells. This method is based upon the formation of a precipitate containing 
calcium phosphate and DNA. Two million cells were seeded into 90 mm tissue culture 
dishes in 20 ml complete DMEM 24 h before transfection. In a sterile 1.5 ml eppendorf 8 
μg DNA and molecular biology-grade water were added to a total volume of 400 μl 
followed by 100 μl of 2.5 M CaCl2. In a second 1.5 ml tube, 500 μl of 2x HEPES-Buffered 
Saline (HeBS), pH 7.05 was added. To prepare the precipitate, the HeBS solution 
containing sodium phosphate was slowly mixed with the CaCl2 solution containing the 
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DNA. To do this the HeBS was gently bubbled using an automatic pipette pump attached 
to a 1 ml sterile serological pipette during which time the CaCl2/DNA solution was added 
drop wise with a sterile pipette tip. The precipitate was then incubated for 20 min at room 
temperature. The precipitate was then distributed over the cells in the culture dish in a drop 
wise fashion using sterile pipette tip followed by gentle agitation for mixing. This DNA-
calcium phosphate co-precipitate adheres to the cell surface and is taken up by the cell, 
presumably by endocytosis. At 24 h post-incubation, the cells were washed once in 
PBS(A) and lysed for Western immunoblotting (Section 2.2.8.3).  
 
 
2.2.5.2. Electroporation of RNA 
 
Following trypsin treatment and counting, aliquots of 4 x 106 cells were centrifuged in 15 
ml centrifuge tubes at 1000 r.p.m. for 5 min at room temperature using a Thermoscientific 
Heraeus Megafuge 16R. Media was decanted and pelleted cells were washed by 
resuspension in 10 ml PBS(A), and centrifuged as before. PBS(A) was decanted and cell 
pellets were resuspended in a total volume of 400 μl PBS(A) and added to a 4 mm gap 
cuvette along with 10 μg of in vitro-transcribed viral RNA. Electroporation was performed 
using a BioRad GenePulser Xcell (250 V, 950 μF), following the manufacturer’s 
instructions. Cells were then diluted and resuspended in the indicated amount of complete 
DMEM and seeded into the appropriate tissue culture flask or plate.  
 
 
2.2.6. Reverse Transcription-Quantitative PCR (RT-qPCR) 
 
RT-qPCR was a two-step protocol involving the reverse transcription of RNA followed by 
a real-time PCR reaction using either relative or absolute quantification conditions.  
 
 
2.2.6.1. First-Strand cDNA Synthesis 
 
Reverse transcription of viral and cellular RNAs was performed using the TaqMan Reverse 
Transcription Reagents Kit. For each reaction 1 μl of RNA was reverse transcribed using 
the following reaction mix and temperature cycles:  
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cDNA Synthesis Reaction Mix (1x): 
Component Volume (µl) 
10x RT Buffer 2.0 
MgCL2 4.4 
dNTPs 4.0 
Random Hexamers 1.0 
RNase Inhibitor 0.4 
Multiscribe Reverse Transcriptase 0.5 
dH2O 6.7  
RNA 1.0 
 
Reaction Cycle: 
Stage 1 
- Hold at 25 °C for 10 min 
Stage 2 
- Hold at 37 °C for 60 min 
Stage 3 
- Hold at 95 °C for 5 min 
Stage 4 
-Hold at 4 °C 
 
 
2.2.6.2. REAL-TIME PCR 
 
2.2.6.2.1. Relative Quantification (RQ) 
 
The relative quantity of viral RNA from electroporated or infected cells was determined by 
an RQ reaction. The cDNA obtained from the reverse transcription of total intracellular 
RNA (Section 2.2.6.1) was amplified using both HCV-specific and GAPDH-specific 
primers (Applied Biosystems) in the presence of FAMTM (HCV-specific) and VIC® 
(GAPDH-specific) labelled probes. The JFH1 probe and primer sequences are located in 
the 5’ UTR of the viral genome (Appendix 1). Each sample was run in triplicate as a 
singleplex reaction. The reaction mixes are listed below along with the reaction cycle 
conditions performed on an Applied Biosystems 7500 Fast Real-Time PCR System using 
Fast Universal PCR conditions: 
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Real-Time PCR Reaction Mix for JFH1 RNA: 
Component Volume (µl) 
18 μm Forward Primer (Final 900 nm) 1.0 
18 μm Reverse Primer (Final 900 nm) 1.0 
5 μm FAM JFH1 Probe (250 nm) 1.0 
TaqMan Fast Universal Mix (2x) 10.0 
dH2O 5.0  
cDNA 2.0 
 
 
Real-Time PCR Reaction Mix for GAPDH RNA: 
Component Volume (µl) 
GAPDH Probe 1.0 
TaqMan Fast Universal Mix (2x) 10.0 
dH2O 7.0  
cDNA 2.0 
 
 
Thermal Cycler Protocol: 
Stage 1 
- Hold at 95 °C for 20 s 
Stage 2 (40 cycles)  
- Hold at 95 °C for 3 s 
- Hold at 60 °C for 30 s 
 
The HCV signals were normalised to the endogenous GAPDH control and data analysed 
using Applied Biosystems software (SDS version 1.3.1), according to the manufacturer’s 
instructions. 
 
 
2.2.6.2.2. Absolute Quantification (AQ) 
 
The absolute quantity of viral RNA obtained from purified virus was determined by an AQ 
reaction. The cDNA obtained from the reverse transcription (Section 2.2.6.1) of 
extracellular RNA was amplified using the HCV-specific primer/FAM probe combination 
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described for RQ (Section 2.2.6.2.1). In vitro-transcribed JFH1 genomic RNA of known 
concentration was used as a standard. Serially diluted standard cDNAs and undiluted 
sample cDNAs were analysed in triplicate and real-time reactions were amplified and 
analysed under the same Fast Universal PCR conditions as for RQ (Section 2.2.6.2.1). 
 
 
2.2.7. Generation of JFH1 Virus 
 
In vitro synthesized RNA (10 µg) was electroporated into Huh-7 cells (Section 2.2.5.2). 
The transfected cells were allowed to rest for 10 min before mixing with fresh medium and 
seeding into the indicated tissue culture dishes. Following incubation at 37 oC for the 
indicated time period, the medium containing the infectious virus progeny was filtered 
through a 0.45 µm pore-sized membrane before infectivity was determined (Section 
2.2.7.1). 
 
 
2.2.7.1 Measuring Virus Infectivity 
 
Limiting dilution assays were used to quantify the amount of virus infectivity using either 
the focus forming unit (FFU) assay, as described by Zhong et al. (2005) or the 50 % Tissue 
Culture Infectious Dose (TCID50) assay as described by Lindenbach et al. (2005). The 
TCID50 assay measures the dilution of virus that will infect 50 % of replicate cell cultures. 
To determine the virus titer by TCID50 assay Huh-7 target cells were seeded at a 
concentration of 1000 cells per well of a 96-well plate in a total volume of 100 μl complete 
DMEM. Twenty-four hours later, serial 5 or 10-fold dilutions of cell medium were added, 
with six wells per dilution. Forty-eight hours later, the medium was removed and the cells 
were fixed with ice-cold methanol and incubated at -20 °C for 24 h. The cells were then 
washed three times with PBS(A) and probed with anti-NS5A mAb 9E10 or sheep anti-
NS5A pAb at dilutions of 1:20,000 and 1:10,000 in PBST, respectively for 1 h at room 
temperature. Cells were washed again three times with PBS(A) and bound primary 
antibody detected by incubation with the appropriate FITC-conjugated secondary antibody 
at 1:500 dilutions in PBST for 1 h at room temperature. After three washes in PBS(A) the 
cells were overlaid with 100 μl of dH2O before visualization under a fluorescent 
microscope (Nikon Eclipse TS100) to determine the number of positive wells at each 
dilution. Wells with at least one NS5A-expressing cell were counted as positive, and the 
TCID50 was calculated according to the method of Reed and Muench. An excel 
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spreadsheet was used to calculate the TCID50, which is accessible at the following web 
link: http://www.med.yale.edu/micropath/pdf/Infectivity%20calculator.xls. 
 
Cell-associated virus was obtained using previously established methods (Gastaminza et 
al., 2006; Shavinskya et al., 2008). Cells were electroporated with viral RNA as before and 
reseeded into a 90 mm tissue culture dish. Forty-eight hours post-incubation, cells were 
washed once in PBS(A) before being removed from the culture dish using a cell scraper in 
the presence of 10 ml PBS(A). The cells were then transferred to a 15 ml centrifuge tube 
and resuspended by rigorous pipetting before being centrifuged at 1000 r.p.m. for 5 min 
using a Thermoscientific Heraeus Megafuge 16R. After the PBS(A) was decanted, the cell 
pellet was resuspended in 0.8 ml complete DMEM, and freeze-thawed rapidly three times 
using dry ice/ethanol and a water bath set to 37 ºC. The samples were centrifuged at 4000 
r.p.m. for 5 min using a Thermoscientific Heraeus Megafuge 16R to remove cell debris, 
and the supernatant assayed by TCID50 to determine virus infectivity. Titration of HCVcc 
by FFU is based on the previously described method for measuring HCV infectivity 
(Zhong et al., 2005). This assay uses an identical infection setup as for TCID50, except 
using only 3 wells per dilution. The immunostaining protocol for HCV positive cells is 
also the same as TCID50. The viral titer is calculated as FFU/ml by the average number of 
NS5A-positive foci detected at the highest dilution.  
 
 
2.2.7.2. Analysis of Virus Replication 
 
To measure virus replication at 120 h post-electroporation cells were transfected with the 
viral RNA, seeded into 10 cm culture dishes and split 1:2 at 48 h post-incubation. After 
further 72 h incubation, the cells were lysed in RLT buffer (RNeasy kit) to measure the 
intracellular HCV RNA levels by RT-qPCR assay (Section 2.2.6) and the cell culture 
medium was harvested for titration by TCID50 assay (Section 2.2.7.1). To determine virus 
replication kinetics over a 72 h period electroporated cells were seeded into 10 cm culture 
dishes in 15 ml DMEM and incubated at 37 ºC/5 % CO2 for 4 h. The cells were then 
washed in 20 ml PBS(A), trypsinized in 2 ml of TV and resuspended in 15 ml DMEM. 
Next, 14 ml of the cell suspension was pelletted in a Thermoscientific Heraeus Megafuge 
16R at 1000 r.p.m./5 min, while the remaining ~1 ml of cells were transferred to a 2 ml 
cyrotube, pelletted as before and lysed in RLT buffer for RT-qPCR assay. The pelletted 
cells were then resuspended in 10 ml of DMEM and split 1:3 into 3 T25 flasks in a total 
volume of 5 ml of medium per flask. Cell lysates and cell culture supernatants were 
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harvested at 24, 48 and 72 hours for RT-qPCR (Section 2.2.6) and TCID50 assay (Section 
2.2.7.1), respectively. To measure virus replication after infection, 53,000 naïve Huh-7 
cells were seeded into three 6-well culture dishes. For each virus cells were infected at the 
indicated multiplicity of infection (m.o.i.) in a total volume of 900 µl for 6 h before 
supplementing with 2 ml of fresh DMEM. At 24, 48, 72 and 96 h cell lysates and culture 
supernatants were harvested as before. Reseeding cells from 96 h post-infection into a T25 
flask with 5 ml of fresh DMEM achieved the 144 h time-point. To monitor virus infectivity 
during serial passaging, 2 x 106 naïve Huh-7 cells were electroporated with the in vitro-
transcribed viral RNA and seeded into a T80 flask in a total of 25 ml of DMEM. Cells 
were passaged at the time of subconfluency into a new flask containing 24 ml fresh 
DMEM. At each passage the cell culture supernatants were harvested and the released 
virus infectivity determined by TCID50 assay (Section 2.2.7.1) 
 
 
 
 
2.2.8. Detection of Cellular and Viral Proteins 
 
2.2.8.1. Sample Lysis for SDS-PAGE Analysis 
 
To detect intracellular antigens, cultured cells were washed once in PBS(A) and either 
lysed directly in SDS-PAGE sample loading buffer (reducing) or lysed in 500 µl of Masaki 
buffer. For lysis in sample loading buffer, the lysates were homogenized by passing 
through a 22-gaugle needle five times before use. Following lysis in Masaki buffer, the 
lysate was spun briefly (13,000 r.p.m. for 1 min using a Sanyo MSE MicroCentaur) to 
remove nuclei. After pre-clearing, the clarified lysates (10 or 20 µl aliquots each) were 
mixed 1:1 with 2x sample loading buffer. To detect extracellular core, 10 ml of each 
conditioned media were overlaid onto 1 ml of a 20 % (w/v) sucrose cushion made with 
PBS(A), centrifuged at 25,000 r.p.m. for 4 hours using a Sorvall Discovery 90SE 
ultracentrifuge, and the pellets were resuspended in 20 µl of Masaki buffer. Lysates were 
clarified and mixed with sample loading buffer as described. All samples were denatured 
by boiling at 100 ºC for 5 min before use. 
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2.2.8.2. Denaturing Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
Resolving gels were prepared using acrylamide solution at a final concentration of 10-14 
% in 1x resolving gel buffer. Addition of APS (to 0.1 %) and TEMED (to 0.08 %) initiated 
polymerisation and the solution was immediately poured into the gel assembly apparatus, 
leaving a gap of ~2 cm from the top. The solution was then overlaid with 1 ml of 100 % 
butanol. When polymerisation was complete, the butanol was discarded and the gel surface 
was washed thoroughly with dH2O. Stacking gels were prepared using acrylamide at a 
final concentration of 5 % in 1x stacking gel buffer. Again, polymerisation was initiated 
upon the addition of APS (to 0.1 %) and TEMED (to 0.08 %), before the solution was 
overlaid onto the resolving gel. A 10-tooth Teflon comb was typically used to form wells 
in the stacking gel. The gel was allowed to polymerise before removal of the comb. Gels 
were then loaded into a tank and submerged in running gel buffer. Denatured protein 
samples were then loaded into each well. Protein markers (Amersham) were also included 
for protein size determination and empty wells were filled with an equal volume of SDS-
PAGE sample loading buffer. Electrophoresis was performed at 100 V until the required 
separation of protein markers and samples was achieved. Gels were then removed from the 
apparatus for Western immunoblotting (Section 2.2.8.3). 
 
2.2.8.3. Western Immunoblotting  
 
Proteins separated on polyacrylamide gels were transferred to HybondTM-ECLTM 
nitrocellulose membranes using a BioRad transblot Semi-Dry blotting device. Transfer was 
carried out at 25 V for 15 min and membranes were incubated in PBST containing 5 % 
milk powder to block non-specific binding of antibody. Membranes were washed three 
times in PBST at room tempertaure and probed with the appropriate antibody (diluted in 
PBST) for 1 h at room temperature. The membrane was again washed three times with 
PBST and incubated with the appropriate secondary antibody (diluted in PBST) conjugated 
to HRP for 1 h at room temperature. Finally the membrane was washed three times in 
PBST and bound antibody was detected using Enhanced Chemiluminescence Reagents I 
and II (ECL I & II) (Amersham) in equal ratio. Bands were visualized by autoradiography 
using Kodak X-OMAT film and a Konica SRX-101-A film processor. 
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2.2.9. Immunoprecipitation (IP) of DDX3  
 
Approximately 5 x 106 Huh-7 cells were washed once with PBS(A) and lysed in 1 ml LB2 
and the lysate spun briefly to remove nuclei. Aliquots of 100 µl of the clarified cell lysates 
were incubated with rotation for 2 h with the anti-DDX3 antibodies described in the text 
followed by further 2 h incubation with 30 µl Protein G-sepharose beads (Sigma). The 
immune complexes were then precipitated by centrifugation at 2000 r.p.m. for 2 min using 
a Sanyo MSE MicroCentaur. Following three washes of the sepharose beads with 1 ml 
LB2, the immune complexes were analyzed by non-reducing SDS-10 % PAGE (Section 
2.2.8.2) followed by Western immunoblotting (Section 2.2.8.3) using biotinylated R648 
and anti-streptavidin-HRP conjugate.  
 
 
2.2.10. Co-immunoprecipitation (co-IP) of HCV Core Protein 
 
Huh-7 cells were electroporated with viral RNA (Section 2.2.5.2) and seeded into 100 mm 
tissue culture dishes. At 72 h post-incubation, the cells were washed once in PBS(A) and 
lysed in 0.5 ml of Masaki buffer. The lysates were spun briefly to remove nuclei. After 
pre-clearing, the clarified lysate was immunoprecipitated overnight with 30 μl of Protein 
G-sepharose beads that had been pre-incubated overnight with 6 μl of the anti-DDX3 
antiserum R648. The immune complex was precipitated with the beads by centrifugation 
using a Sanyo MSE MicroCentaur at 2000 r.p.m. for 2 min, washed 3 times with 1 ml 
Masaki buffer, and subjected to non-reducing SDS-14 % PAGE (Section 2.2.8.2) followed 
by Western immunoblotting (Section 2.2.8.3) using the anti-core mAb C7-50 (1:20,000 
dilution) and anti-mouse IgG-HRP conjugate. 
 
 
2.2.11. Sedimentation Equilibrium Gradient Analysis  
 
Gradients were formed in a 12 ml ultracentrifuge tube (Beckmann) by overlaying 1.3 ml of 
20 %, 25 %, 30 %, 35 %, 40 %, 45 %, 50 %, 55 % and 60 % (w/v) sucrose solutions in 
PBS(A) and incubating at 4 °C overnight. Virus particles obtained at 72 h post-
electroporation were purified through 20 % (w/v) sucrose cushions in PBS(A) at 25,000 
r.p.m. for 4 h using a Sorvall Discovery 90SE ultracentrifuge. Virus pellets were 
resuspended overnight in a total of 600 μl of PBS(A) before being added to the 20-60 % 
continuous gradient. Equilibrium was reached by ultracentrifugation for 24 h at 36,000 
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r.p.m. at 4 °C using a Sorvall Discovery 90SE ultracentrifuge. Either six 2 ml or twelve 1 
ml fractions were collected from the top after which their density was determined. Aliquots 
of 200 μl were used to determine the infectivity (Section 2.2.7.1) and RNA content 
(2.2.4.3) of each fraction. The remaining volume was then diluted in PBS(A) to a total 
volume of 11 ml and pelleted at 25,000 for 4 h using a Sorvall Discovery 90SE 
ultracentrifuge. The pellets were then lysed in 20 μl of Masaki buffer and subjected to 
reducing SDS-14 % PAGE (Section 2.2.8.2) following by Western immunoblotting 
(Section 2.2.8.3) using mAbs AO196 and C7-50. 
 
 
2.2.12. RNA Interference 
 
To assay virus replication from full-length JFH1 following infection of DDX3 knockdown 
cells, siRNAs were transfected into naïve Huh-7 cells using the lipofectamine RNAiMax 
reagent. Transfections were performed in 24-well plates. For each well, 100 µl Optimem-I 
was mixed with 1 µl lipofectamine and followed by the addition of the siRNAs. For the 
control transfections 1 µl of scrambled siRNA mix (50 µM) was added to the wells. For 
the test transfections 0.5 µl of each DDX3 siRNA mix (50 µM) was used. The transfection 
cocktail was gently mixed by pipetting and incubated for 20 min at room temperature. 
Wells were then seeded with 1 x 104 Huh-7 cells in 900 µl of DMEM, giving a total 
volume of 1 ml in each well with a final concentration of 50 nM of siRNAs. At 48 h post-
incubation, the control and knockdown cells were infected with JFH1WT and JFH1Y35A 
virus for 4 h and supplemented with 1 ml of fresh DMEM. At 48 h post-infection, the 
culture medium was harvested and titrated by TCID50 assay (Section 2.2.7.1) and the cells 
lysed in RLT buffer (Section 2.2.4.3) for RT-qPCR assay (Section 2.2.6). The efficiency of 
DDX3 knockdown at the time of virus infection was determined by lysing control and 
DDX3 knockdown cells in reducing SDS-PAGE sample loading buffer (Section 2.2.8.1) at 
48 h post-transfection and subjecting them to SDS-10% PAGE (Section 2.2.8.2) following 
by Western immunoblotting (Section 2.2.8.3) with mAb AO196. To measure virus 
replication of JFH1∆E1E2 following DDX3 knockdown, 2 x 106 naïve Huh-7 cells were 
electroporated with 10 µg of viral RNA along with siRNAs in a total volume of 0.4 ml 
PBS(A). In the control cells 10 µl of scrambled siRNA was added and for the test cells 5 µl 
of each DDX3 siRNA was used. After electroporation, cells were resuspended in 10 ml 
DMEM and seeded on to 100 mm dishes in a total volume of 15 ml DMEM and incubated 
at 37 ºC/ 5 % CO2 for 4 h. The cells were then washed in 20 ml PBS(A), trypsinized using 
2 ml of TV and resuspended in 10 ml DMEM. The cells were pelleted at 1000 r.p.m. /5 
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min using a Thermoscientific Heraeus Megafuge 16R, after which the pellet was 
resuspensed in 10 ml DMEM. Two 4 ml aliquots were then seeded onto 25 cm2 culture 
flasks with the remaining ~2 ml of cells being seeded onto coverslips on a 24-well dish. 
After 72 h post-incubation, the cells from one culture flasks were lysed in reducing SDS-
PAGE sample loading buffer (Section 2.2.8.1) and the remaining flask in RLT buffer 
(Section 2.2.4.3). The efficiency of DDX3 knockdown was determined by subjecting 
protein lysates to SDS-10% PAGE (Section 2.2.8.2) followed by Western immunoblotting 
(Section 2.2.9.3) with mAb AO196. The intracellular HCV RNA levels were determined 
by RT-qPCR (Section 2.2.6). The coverslips were fixed in methanol for 
Immunofluorescence analysis (Section 2.2.13). 
 
 
2.2.13. Indirect Immunofluorescence (IF) 
 
To examine the intracellular expression of HCV proteins, cells on coverslips were fixed in 
methanol, washed with PBS(A), blocked for 10 min with PBS(A) containing 2 % FCS and 
incubated at room temperature for 1 h with primary antibody in the blocking buffer. Cells 
were washed with PBS(A), stained with secondary antibody conjugated with either FITC, 
TRITC, or Cy5 in blocking buffer for 1 h, washed with PBS(A), and the coverslips 
mounted on a glass slide and examined with a Zeiss Laser Scanning LSM510 META 
inverted confocal microscope (Carl Zeiss Ltd., UK). The images were analyzed using 
LSM510 software. Three-dimensional (3D) reconstructions were performed from Z-stack 
images collected using optimum intervals. The 3D reconstructions were generated by 
deconvolving the image stacks by 3D-blind deconvolution using Autodeblur software 
(MediaCybernetics). 
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3. Results 
 
3.1. The Importance of the core-DDX3 Interaction in 
 HCV RNA replication and Infectious Particle 
 Production 
 
3.1.1. Introduction 
 
HCV core protein associates with LDs in many different cell lines (Section 1.11.2). Most 
importantly, recent studies using the HCVcc system have found this association to be 
crucial for the assembly of infectious virus particles in Huh-7 cells (Boulant et al., 2007; 
Miyanari et al., 2007). An interaction between core and the cellular DEAD-box RNA 
helicase DDX3 was first reported by 3 independent studies using yeast-two hybrid 
screening (Mamiya & Worman, 1999; Owsianka & Patel, 1999; You et al., 1999), and has 
been confirmed by co-IP assays (Ariumi et al., 2007; You et al., 1999). In line with this, 
proteomic analysis revealed DDX3 was present in the LD droplet fraction from core 
expressing Hep39 cells (Sato et al., 2006). Also, the colocalisation between core and 
DDX3 was confirmed in Huh-7 cells electroporated with JFH1 RNA or infected with the 
virus (Dalrymple, 2007). RNA silencing of DDX3 drastically reduces JFH1 replication, 
although it is uncertain if this effect is caused by a reduction in the core-DDX3 interaction 
or by another direct or indirect mechanism. Six residues (F24, G27, I30, G33, V34 and 
Y35) in core protein have been identified to disrupt the core-DDX3 interaction when 
changed to alanine (Dalrymple, 2007). Furthermore, the introduction of these mutations 
into the full-length JFH1 genome created mutants that replicated in Huh-7 cells but had 
reduced levels of core-DDX3 colocalisation by IF analysis. Importantly, all viruses 
released infectious particles except JFH1G33A. Upon serial passaging all mutants could be 
maintained in culture, including JFH1G33A which had acquired infectivity as well as a 
second mutation adjacent to the original alanine substitution (G32D). Together, these data 
suggest the interaction between core and DDX3 is not essential for the maintenance of 
replicating virus in cell culture. However, infection of naïve cells with each mutant virus 
(F24A, G27A, I30A, G32D/G33A V34A and Y35A) revealed substantially lower levels of 
intracellular RNA replication and viral protein expression compared to JFH1WT 
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(Dalrymple, 2007). These data would suggest the core-DDX3 interaction is dispensable for 
persistent infection of JFH1 but nevertheless may be required for enhancing some part of 
the virus life cycle involving early replication and translation events. 
 
In order to establish the true nature of this virus-host interaction in infected cells and its 
role in the HCV lifecycle, a co-IP assay was first developed to demonstrate the association 
of these two proteins in Huh-7 cells harbouring JFH1. Using a highly specific in-house 
generated anti-DDX3 antiserum and a commercial core mAb, the correct buffer conditions 
were established to allow efficient pull-down of core protein from cell lysates 
immunoprecipitated with anti-DDX3. A detailed time course analysis using high resolution 
confocal microscopy was conducted to understand the association of these two proteins 
with LDs during virus replication. This analysis was then extended to the six core mutants 
described above. The newly established core-DDX3 co-IP identified mutants with reduced 
levels of DDX3 binding. To study the effects of this interaction on virus replication, the 
levels of intracellular HCV RNA and infectious particle release was examined for 
particular mutants. One of these mutants was then used to determine the relationship 
between the core-DDX3 interaction and the inhibitory effects of DDX3 knockdown on 
HCV replication. This section also investigated if DDX3 is incorporated into extracellular 
virions through its interaction with core protein. 
 
 
3.1.2. Characterisation of DDX3 Antibodies  
 
To demonstrate a genuine interaction between two different proteins, it is critical to have 
highly specific antibodies to either protein, preferably in both mAb and pAb form. 
Numerous in-house generated mAb and pAb DDX3 antibodies were available for use in 
this project. Based on recommendations, the mouse mAb anti-DDX3 antibody AO196 and 
rabbit pAb anti-DDX3 antisera R648 were chosen. The epitope recognised by AO196 has 
been broadly mapped to the N-terminal end of the protein from residues 1-142 (Scott, 
2002). Both mAb AO196 and pAb R648 were previously shown to interact with DDX3 by 
ELISA, Western blotting and IF (Scott, 2002; Dalyrmple, 2007). By IF analysis, both 
antibodies recognised only the cytoplasmic form of DDX3 in Huh-7 cells, whereas both 
nuclear and cytoplasmic forms were identified by immunoblotting (Scott, 2002; 
Dalyrmple, 2007). To further confirm the specificities of AO196 and R648 for DDX3, 
their reactivity’s were determined by IP using the cytoplasmic extracts obtained from naïve 
Huh-7 cells. R648 but not the pre-immune control serum specifically immunoprecipitated 
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DDX3 from a cytoplasmic extract of Huh-7 cells, as did mAb AO196 (Fig. 3.1A). The 
specificity of both these antibodies was further demonstrated by immunoblotting the total 
cell extracts from HEK-293T cells transfected with and without green fluorescent protein 
(EGFP)-DDX3 fusion protein (Fig. 3.1B). 
 
 
3.1.3. Demonstrating an Interaction between Core and DDX3 in 
 Cells Replicating JFH1 
 
The core-DDX3 interaction was previously demonstrated in cells ectopically expressing 
HCV genotype 1a core, and in the absence of virus RNA replication and productive 
infection (Owsianka & Patel, 1999). Despite a recent publication describing an interaction 
between JFH1 core and DDX3, this was only shown by co-immunoprecipitating the 
lystates from HEK-293T cells over expressing core and HA-tagged DDX3. Moreover, this 
study failed to show an interaction between core and DDX3 in JFH1-infected cells (Ariumi 
et al., 2007). To confirm the core-DDX3 interaction in cells replicating JFH1, the ability of 
R648 to co-immunoprecipitate core protein was tested from the lysates of Huh-7 cells 
obtained 72 h post-electroporation with JFH1 in vitro-transcribed RNA. The IP buffer 
(Masaki buffer) recipe was obtained from a recent publication describing an interaction 
between core and NS5A from JFH1-electroporated cells (Masaki et al., 2008). It was 
reasoned that this buffer would be suitable for detecting the core-DDX3 binding by co-IP 
given this buffer was able to preserve an interaction between core and NS5A during co-IP. 
However, in the initial co-IP assay only very low quantities of core protein were detected 
using R648 (Fig. 3.2A). In an effort to increase the amount of precipitated core protein, the 
procedure was repeated in cells lysed with Masaki buffers containing lower concentrations 
of detergent (Triton-X-100). Reductions in detergent appeared to increase the amount of 
precipitated core protein, with buffer containing 0.1 % Triton-X-100 achieving the best 
pull-down (Fig. 3.2B). Using this concentration of Triton in the buffer, the specificity of 
this co-IP method was confirmed by showing only the immune R648 serum and not the 
R648 pre-immune serum could precipitate core protein from the cell lysates (Fig. 3.2C). 
The co-IP results presented in Figs 3.2A-C were obtained through precipitating lysates 
with 3 µl of R648. To test how the quantity of anti-DDX3 anti-serum affects the levels of 
core protein precipitated, three separate co-IP experiments were performed, each using 
different amounts of R648. The levels of core protein detected directly correlated with the 
amount of R648 added with 6 µl of antibody achieving the greatest pull-down (Fig. 3.2D). 
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Figure 3.1. Characterisation of two anti-DDX3 antibodies.  
 
(A) Huh-7 cell lysates were immunoprecipitated with the immune (I) and pre-immune (PI) 
antiserum R648, or mAb AO196 or an isotype control mAb. The immune complexes were then 
immunoblotted with biotinylated R648. (B) Lysates from HEK-293T cells transfected with a 
plasmid expressing EGFP alone or an EGFP-DDX3 fusion protein were harvested 24 h after 
transfection. Cell extracts were immunoblotted using anti-GFP mAb, AO196 and R648. 
DAPI Merge + DAPI
Core DDX3
DAPI Merge + DAPI
Core DDX3
DAPI Merge + DAPI
Core DDX3
A E
F G
1 2 3 4
1 2 3
1 2
1 2 3 4 5
B
C
D
1 2 3
Figure 3.2. Interaction of HCV core with cellular DDX3.  
 
(A) Co-immunoprecipitation of core by R648. Huh-7 cells electroporated with and without 10 µg 
of JFH1 RNA were lysed at 72 h post-incubation with IP buffer containing 1 % Triton-X-100. The 
test and control cell lysates were immunoprecipitated with 3 µl R648 and followed by 
immunoblotting using using anti-core mAb C7-50 (lanes 1 and 2, respectively). One twentieth of 
the control and test cell lysate used in the co-IP assay was immunoblotted for core as the input 
control (lanes 3 and 4, respectively). (B) Effect of detergent concentrations on co-IP of core 
protein. Co-IP was performed on JFH1-electroporated cell lysates as before but containing 0.1 % 
(lane 1), 0.2 % (lane 2) and 0.5 % (lane 3) of Triton-X-100. Upper and lower panels represent 
immunoblotting of core protein from precipitated lysates and input control (1/20th), respectively. 
(C) Specificity of the core-DDX3 co-IP assay. (Upper Panel) Co-IP with lysates from JFH1-
electroporated cells using 3 µl R648 (lane 1) as before and 3 µl of pre-immune serum (Lane 2). 
One twentieth of the lysate was loaded as the input control (lower panel). (D) Optimising the co-IP 
conditions. Lysates from 3 JFH1 electroporations were pooled together and divided into three 
separate co-IP assays using 1 µl (lane 1), 3 µl (lane 2), and 6 µl (lane 3) of R648. One sixtieth of 
the pooled lysate was loaded as the input control (lane 5) alongside mock electroporated cell 
lysates (lane 4). (E-G) Core protein redistributes cytoplasmic DDX3 in JFH1 replicating cells. 
Naïve (E), JFH1-electroporated (F) and JFH1-infected (G) cells were fixed at 72 h post-incubation 
and double stained for core (R308) and DDX3 (AO196). Scale bar, 10 µm.  
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Together, these experiments show a direct interaction occurs between core and DDX3 in 
cells replicating JFH1. Next, IF analysis was performed by probing naïve, JFH1-RNA 
electroporated and JFH1-infected Huh-7 cells with anti-DDX3 mAb AO196 and the anti-
core pAb R308. As expected, DDX3 had a diffuse cytoplasmic localisation in naïve cells 
but was redistributed and colocalised with core protein in both JFH1-transfected and -
infected cells (Fig. 3.2E-G). These IF results are in agreement with previous data obtained 
using these antibody combinations in Huh-7 cells harbouring JFH1 (Dalrymple, 2007). It 
should be noted that the core-bound DDX3 emitted a stronger fluorescent signal compared 
to the free DDX3 occupying the cell cytoplasm. Thus, adjustment of the core-bound DDX3 
signal to prevent overexposure resulted in the apparent loss of free DDX3 from the image. 
A representative image of core and DDX3 in virus-infected and surrounding non-infected 
cells taken at two different intensities is depicted in Fig 3.3. Interestingly, the staining of 
infected cells with R648 allowed the free DDX3 to be visualised without overexposure of 
the core-bound protein. This observation highlights the diverse staining patterns that can be 
obtained using different antibodies against the same protein.  
 
 
3.1.4. DDX3 Associates with HCV Core on LDs 
 
The association of HCV core with LDs is essential for infectious virus production (Boulant 
et al., 2007; Miyanari et al., 2007). Substitution of core residues P138 and P143 to alanine 
severely affects coating of LDs by core. Interestingly, both the JFH1WT core and the 
P138A/P143A (DP) mutant localize at a single site in close juxtaposition to LDs at an early 
time-point (24 h). However, at later time-points (48 to 72 h), unlike the WT core, the DP 
mutant fails to fully coat LDs which is coupled to the loss of infectious virus production 
(Boulant et al., 2007). To gain further insight into the distribution of the core-DDX3 
complex in the context of the HCVcc system the localisation of core, DDX3 and LDs was 
analysed in Huh-7 cells electroporated with JFH1WT RNA at 24, 48 and 72 h. At each time-
point post-electroporation core associated with ADRP and the localisation of DDX3 was 
precisely coincident with both proteins, indicating its redistribution to LDs (Fig. 3.4A-C). 
Together, these data show that there is a direct correlation between core and DDX3, since 
DDX3 follows core in coating LDs and it does not associate with LDs without core. To 
examine the subcellular position of DDX3 and core in relation to ADRP in greater detail, a 
series of Z-stacks was obtained and used after blind deconvolution to create a 3D model of 
LDs coated by core, ADRP and DDX3 (Fig. 3.4A-C, i-ii). As reported before, the coating 
of LDs by core protein occurred in a time-dependent manner. Also, DDX3 by virtue of its 
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Figure 3.3. Images of JFH1-infected Huh-7 cells probed with different antibodies.  
 
In the upper and middle panels, cells were probed with anti-DDX3 mAb AO196 and anti-core pAb 
R308. The core-bound DDX3 signal in the top panel was obtained under normal detector gain 
settings. Enhancement of this signal in the middle panel overexposed core-bound DDX3, but 
allowed visualization of non-sequestered DDX3. Lower panel, image of JFH1-infected cells probed 
with anti-DDX3 pAb R648 and anti-core mAb C7-50 taken under normal detector gain settings. 
Scale bar, 10 µm. 
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Figure. 3.4. Localisation of DDX3 and JFH1 core on LDs.  
 
Huh-7 cells electroporated with the JFH1 RNA were fixed at 24 (A), 48 (B) and 72 h (C) post-
electroporation and probed using antibodies to core (R308), DDX3 (AO196) and ADRP (ADRP 4). 
Z-stack analysis of all three proteins was performed in each image with the 3D reconstructions of 
the boxed areas shown (i). A selected area of the 3D image is shown in greater detail (ii) where 
ADRP is depicted in wire frame at 24 h and DDX3 is in wire frame at 48 and 72 h. Scale bar, 10 
µm for confocal images and 1 µm for 3D images. 
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interaction with core was associated with LDs at all time-points. In cells replicating 
JFH1DP mutant RNA, the intracellular distribution of DDX3 matched that of core at each 
time-point analyzed, indicating that the sequestration of DDX3 on LDs by core is 
independent of the full core-LDs association (Fig. 3.5A-C). Z-stack analyses of each image 
revealed the DP mutant core failed to fully coat LDs over 72 h, and neither did DDX3 
although it still co-localized with core (Fig. 3.5A-C, i-ii). In addition, the localisation of 
DDX3 was analyzed in cells replicating a JFH1 mutant (JFH1VLVL) harbouring four aa 
substitutions (A180V, S183L, C184V and T186L) at the C-terminal region of core that 
delays SPP cleavage. A time course analysis revealed the delayed maturation of core 
affects its ability to coat LD at early times following electroporation (Targett-Adams et al., 
2008b). In accordance with these data, at 48 h post-electroporation with JFH1VLVL RNA, 
there was a mixed population of core protein signals colocalising with ADRP (Fig. 3.6A). 
Z-stack analyses revealed that both core attached and unattached to LDs were bound by 
DDX3 (Fig. 3.6A, i-ii). To test if HCV alters the subcellular localisation of DDX3 in the 
absence of stable core protein expression, cells were electroporated with another JFH1 core 
mutant (JFH1F130E) containing the substitution F130E. This mutation results in the 
immediate degradation of core protein by the proteasome following its translation but does 
not effect the stability of the remaining viral proteins (Boulant et al., 2007). At 72 h post-
electroporation with JFH1F130E the cytoplasmic distribution of DDX3 was unaltered despite 
the presence of virus replication as indicated by NS5A expression (Fig. 3.6B). 
 
 
3.1.5. Core Residues Required for DDX3 Interaction.  
 
It was previously reported that aas 1-59 of core protein are involved in its interaction with 
DDX3 (Owsianka & Patel, 1999). More recently, Dalrymple (2007) identified six critical 
residues within this region that were required for the colocalisation of JFH1 core protein 
with DDX3. As these mutants form the basis of the results presented in the following 
section it is appropriate to begin by describing briefly how this region was identified. 
Firstly, a library of mutants was constructed by error prone PCR (EP-PCR). The N-
terminal 59 aas of core protein (containing single or multiple aa substitutions generated by 
EP-PCR) was cloned downstream of GFP in a bacterial expression vector (pKK223-3). 
ELISA was used to screen the core mutants. Briefly, a soluble GST-DDX3 fusion protein, 
previously used to delineate the domain of DDX3 interacting with core (Owsianka & Patel, 
1999) was immobilized on the ELISA plate and bound mutants were detected using a 
rabbit polyclonal anti-GFP antiserum. Of 130 clones tested by ELISA, only nine (mutants 
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Figure 3.5. Localisation of DDX3 and JFH1DP core on LDs.  
 
Huh-7 cells electroporated with the JFH1DP RNA were fixed at 24 (A), 48 (B) and 72 h (C) post-
incubation and probed using antibodies to core (R308), DDX3 (AO196) and ADRP (ADRP 4). Z-
stack analysis of all three proteins was performed in each image with the 3D reconstructions of the 
boxed areas shown (i). A selected area of the 3D image is shown in greater detail (ii) where ADRP 
is depicted in wire frame at each time point. Scale bar, 10 µm for confocal images and 1 µm for 3D 
images. 
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Figure 3.6. Localisation of DDX3 in cells replicating JFH1 core mutants.  
 
(A) Huh-7 cells electroporated with the JFH1VLVL RNA were fixed at 48 h post-incubation and 
probed using antibodies to core (R308), DDX3 (AO196) and ADRP (ADRP 4). 3D reconstructions 
of the boxed areas shown (i) and in greater detail (ii) where ADRP is depicted in wire frame. (B) 
Huh-7 cells electroporated with JFH1F130E RNA were fixed at 72 h post-incubation and probed 
using antibodies to DDX3 (AO196), NS5A (sheep) and core (R308). Scale bar, 10 µm for confocal 
images and 1 µm for 3D images. 
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25, 36, 90, 99, 110, 111, 115, 125 and 126) were found to be defective in binding to GST-
DDX3 (Dalrymple, 2007). In order to confirm these results, all 9 mutants were individually 
sub-cloned into a sequence encoding the HCV genotype 1a strain H77c core, E1 and E2 
(pCE1E2) in a mammalian expression vector pcDNA3.1/Zeo+ (Invitrogen), and their 
expression was analyzed by IF. The results were in accordance with the data from the 
initial ELISA screen in that all 9 mutated core proteins failed to redistribute DDX3 
(Dalrymple, 2007). Instead, DDX3 maintained its typical diffuse cytoplasmic localization 
in cells ectopically expressing each of these mutated core proteins, similar to that observed 
in non-transfected cells. Nucleotide sequence analysis showed that each of the mutants 
carried between one and four aa substitutions (Fig. 3.7). Of interest, mutant 90 had only 
one aa substitution (I30N), indicating that this residue must be required for the interaction 
of core with DDX3. All nine mutant proteins had at least one aa substitution in the region 
spanning residues 24-36, indicating that this region may harbour residues that are critical 
for the core-DDX3 interaction. To test this hypothesis, site-directed mutagenesis was 
carried out to revert any mutations outside of this 13 aa region back to the WT residue. 
These new mutant core 1-59 fragments were then sub-cloned into pCE1E2, and their 
expression analyzed following transient transfection into Huh-7 cells as above. Again, 
none of these new core mutants redistributed DDX3 (Dalrymple, 2007), indicating that the 
13 aa region between residues 24 and 36 of core is indeed involved in the interaction 
between core and DDX3. To determine which residues in this 13 aa region were essential, 
alanine-scanning mutagenesis across aas 24-36, individually substituting each aa in this 
region with alanine was carried out. As before, these alanine mutant sequences were 
subcloned into pCE1E2 and transiently transfected into Huh-7 cells. IF analysis revealed 
seven mutants (P25A, G26A, G28A, Q29A, V31A, G32A and L36A) that showed distinct 
colocalization between core and DDX3 (similar to that seen with WT HCV core), whilst 
the other mutants (F24A, G27A, I30A, G33A, V34A and Y35A) displayed no 
colocalization with DDX3 at all. Thus, these results indicate that core residues F24, G27, 
I30, G33, V34 and Y35 are critical for its interaction with DDX3. Sequence comparison of 
core protein from strains H77c (genotype 1a) and JFH1 (genotype 2a) revealed 96.6 % 
homology within the first 59 residues of core, with the key residues (F24, G27, I30, G33, 
V34 and Y35) for interaction with DDX3 being fully conserved (Dalrymple, 2007). Thus, 
recombinant JFH1 genomes each containing one of the six mutations were constructed. 
Initial analysis of these mutants revealed that they disrupted the colocalisation of core and 
DDX3 but could spread in cell culture following electroporation (Dalrymple, 2007).  
 
 
             1       10         20         30         40         50        59         
Core         MSTNPKPQPK TKRNTNRRPE DVKFPGGGQI VGGVYLLPRR GPRLGVRTTR KTSERSQPR 
Mutant 25    --------K- ---------- ---------- ---G------ ---------- ------R-- 
Mutant 36    ---------- ---------- ---------- ---D-----W ---------- -S-------
Mutant 90    ---------- ---------- ---------N ---------- ---------- ---------
Mutant 99    ---------- ---------- -D-------- ---D------ ---------- ---------
Mutant 110   ---------- ---------- ---------N ---------- --S------- ---------
Mutant 111   -----E---- ---------- ---------- ----N----- ---------- ---------
Mutant 115   ---------D -E-------- ---S------ ---------- ---------- ---------
Mutant 125   ---------- -----I---- --------R- ----N----- ---------- ------R--
Mutant 126   -------H-- ---------- -----D---N -----W---- ---------- ---------
Figure 3.7. Identification of core residues critical for its interaction with DDX3.  
 
Amino acid substitutions in residues 1-59 of core in nine mutants unable to interact with DDX3. 
Residues in the region 24-36 (shaded box) were targeted for alanine-scanning mutagenesis, which 
identified residues at positions 24, 27, 30, 33, 34 and 35 (underlined in the sequence at the top) that 
were critical for DDX3 interaction (Adapted from Dalyrmple, 2002).  
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3.1.6. Detailed Characterisation of JFH1 Core Mutants 
 
The knockdown of the core-DDX3 interaction in cells replicating the core mutant viruses 
was shown by IF analysis (Dalrymple, 2007). To verify that these core mutations disrupt 
the core-DDX3 interaction but not the core-LD association, Huh-7 cells electroporated 
with each viral RNA were stained for core, DDX3 and ADRP at 72 h post-incubation. As 
shown from the images in Fig. 3.8, each mutant core, like its WT counterpart, fully 
associated with LDs. Colocalisation between core and ADRP was found in all cells 
analysed. However, no core-DDX3 colocalisation was observed for mutants JFH1F24A, 
JFH1G27A, JFH1I30A and JFH1Y35A, whereas JFH1G33A and JFH1V34A showed colocalisation 
in 37 and 52 % of cells counted, respectively. Thus, it appears that the latter two core 
mutations are unable to completely abolish DDX3 binding. Nevertheless, it was unusual to 
observe differing levels of core-DDX3 colocalisation in cells replicating JFH1G33A and 
JFH1V34A. It is possible that the level of interaction in these cells is governed by the 
amount of core protein expression, as those cells displaying core-DDX3 colocalisation 
appear to have higher quantities of core than those lacking colocalisation (Fig. 3.8). These 
irregularities may also be cell cycle related, with the core-DDX3 interaction for these 
particular mutants being tightly coupled to a particular phase in cell growth. Importantly, 
the core-DDX3 colocalisation observations described for each mutant in Fig. 3.8 are 
consistent with those reported previously (Dalrymple, 2007). Next, the protein expression 
and virus release of each mutant was tested. To do this Huh-7 cells were electroporated 
with viral RNA and after 72 h the cell medium was titrated and the cells were lysed for 
immunoblotting. All mutants were replication active as seen by the expression of NS5A 
protein at 72 h post-electroporation (Fig. 3.9A). However, differing levels of core 
expression was observed when immunoblotting these lysates with mAb C7-50. This 
antibody bound minimally or not at all to JFH1I30A and JFH1G33A core, but had increased 
affinity for the JFH1V34A protein. To determine whether these differences were due to 
altered affinity of this mAb to these mutants, the reactivities of the lysates to the pAb R308 
were tested. This pAb recognized all core forms equally except JFH1G33A, suggesting the 
altered detection levels observed with mAb C7-50 is due to the mutations JFH1I30A, 
JFH1G33A and JFH1V34A affecting antibody binding (Fig. 3.9A). The smaller quantities of 
JFH1G33A core detected using R308 suggests this mutation reduces the binding efficiency 
of both core antibodies. Importantly, there was no detectable change in DDX3 protein 
levels in any of the electroporated cell cultures tested (Fig. 3.9A). All core mutants 
released similar quantities of infectious virus into the cell medium at 72 h post-
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Figure 3.8. Mutations in core do not disrupt its association with LDs. 
 
Huh-7 cells electroporated with the indicated viral RNAs were fixed at 72 h post-incubation and 
analysed by confocal microscopy for the intracellular distribution of core, DDX3 and ADRP using 
antibodies R308, AO196 and ADRP 4, respectively. The percentage of cells (n=200) displaying 
core-DDX3 colocalisation is stated above each image. Bar, 10 µm. 
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Figure 3.9. Analysis of JFH1 core mutant viruses.  
 
(A) Huh-7 cells electroporated with viral RNAs as shown were subjected to immunoblotting at 72 
h post-incubation using anti-NS5A mAb 9E10, anti-core antibodies mAb C7-50 and pAb R308, 
anti-DDX3 mAb AO196 and anti-tubulin mAb. The released virus titers from these samples were 
assayed by TCID50 assay. (B and C) The interaction of DDX3 with JFH1 core mutants. Huh-7 cells 
were electroporated with the indicated viral RNAs and HCV core co-immunoprecipitated at 72 h 
post-incubation using pAb R648 followed by immunoblotting with mAb C7-50. (D) Persistent 
infection of Huh-7 cells with the JFH1 core mutant viruses. Cells were infected at an m.o.i. of 
0.005 and passaged 1:10 at the time of subconfluency for 5 passages. At passage 5 the infectivity of 
the culture medium was assayed by TCID50 assay, the percentage of cells (n=200) displaying core-
DDX3 colocalisation was determined by IF and the viral core gene was sequenced from total cell 
RNA following RT-PCR.  
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electroporation, except JFH1G33A. However, this difference is unlikely to be caused by 
disruption of the core-DDX3 interaction, as the remaining mutants do not share this defect.  
 
The co-IP experiment described in section 3.1.3 is a more valid assay than IF to test for 
alterations to core-DDX3 binding. As core mAb C7-50 was used to establish the co-IP 
assay, mutants JFH1I30A, JFH1G33A and JFH1V34A were excluded from the experiment due 
to their altered affinity to this antibody. The remaining mutant cores were co-
immunoprecipitated by the anti-DDX3 pAb R648 in much lower amounts (JFH1F24A & 
JFH1G27A) than the WT protein or not at all (JFH1Y35A), confirming that these changes 
affect the core-DDX3 interaction (Fig. 3.9, B and C). Together, the results obtained for 
these mutants in Fig. 3.9A-C, especially JFH1Y35A suggest the core-DDX3 interaction is 
not required for viral protein expression and infectious virus release at 72 h post-
electroporation. Next, the importance of the core-DDX3 interaction in the establishment of 
persistent infection was tested. Infectious viruses from JFH1F24A, JFH1G27A and JFH1Y35A 
were used to inoculate naïve Huh-7 cells alongside JFH1WT at an equal m.o.i. At the time 
of subconfluency, these cells were split 1:10 for a total of 5 passages. At passage 5 the cell 
medium was assayed for infectious virus, the cells were tested for core-DDX3 
colocalisation, and the core gene from intracellular viral RNA was sequenced. As 
summarised in Fig. 3.9D each mutant had similar levels of virus release to the WT 
indicating that they can persistently infect cells during serial passages. Moreover, their 
ability to persist was not due a reversion phenotype as IF analysis found no core-DDX3 
colocalisation in passage 5 cells and no sequence alterations to the core gene. 
 
Next, the intracellular RNA replication levels of JFH1F24A, JFH1G27A and JFH1Y35A were 
quantified. Huh-7 cells electroporated with RNAs derived from constructs representing the 
JFH1WT, a replication-deficient JFH1GND, or the JFH1 core mutants described above were 
harvested 120 h after electroporation for RNA analysis, while the progeny virus released 
into the medium was titrated. As expected, JFH1GND did not replicate, whereas all core 
mutants, like the parental virus, were competent at replicating RNA and releasing virus 
(Fig. 3.10A and B). Although no effects in virus replication were observed at 120 h post-
electroporation, it was possible that differences occured during earlier time-points. To test 
this theory, the intracellular RNA replication and virus infectivity was measured from 
electroporated cells at 24, 48 and 72 h post-incubation. In addition, the HCV RNA levels 
were quantified at 4 h as a measure of transfection efficiency. As seen in Fig. 3.10C, only 
JFH1G27A displayed considerably lower levels of RNA replication than JFH1WT at 24 and 
48 h. However, at 72 h the levels were more comparable to WT. Decreased infectious virus 
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Figure 3.10. Further characterization of the JFH1 core mutants.  
 
(A and B) Huh-7 cells electroporated with JFH1WT and mutant virus RNAs were split at 48 h post-
incubation, re-seeded, and incubated for a further 72 h. (A) The relative quantity of intracellular 
viral RNAs and (B) released infectious virus were quantitated by RT-qPCR and TCID50, 
respectively. The RNA levels were normalized to the GND value. (C and D) At the indicated time 
points following electroporation the intracellular HCV RNA levels (C) and released virus titers (D) 
were quantified by RT-qPCR and TCID50, respectively. The RNA levels were normalized to the 
GND value at 72 h. Error bars indicate variability of the assays and dotted line indicates cut-off of 
the TCID50 assay. 
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Figure 3.11. Infection kinetics of JFH1 core mutants.  
 
(A and B) Determination of virus yield and intracellular RNA levels following infection. Naïve 
Huh-7 cells were infected with JFH1WT or the core mutant viruses (obtained from electroporated 
cells) at an m.o.i. of 0.02. The intracellular viral RNA levels (A) and infectious virus released into 
the medium (B) were measured over 144 h by RT-qPCR and TCID50, respectively. The RNA levels 
were normalised to JFH1F24A values at 72 h. Error bars indicate variability of the assays and dotted 
line indicates cut-off of the TCID50 assay. (C-F) The intracellular viral RNA levels and released 
viral titers were measured over 72 h as before following inoculation of naïve Huh-7 cells at an 
m.o.i. of 0.2 (C and D) and 0.02 (E and F). The RNA levels were normalised to JFH1Y35A values 
obtained at 24 h (C) and JFH1WT values at 48 h (E). Means and error ranges from two independent 
infections experiments are shown. 
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release was observed in each mutant at 24 and 48 h, although these levels achieved parity 
with JFH1WT by 72 h (Fig. 3.10D). Next, the infectivity and replication efficiency of the 
core mutant viruses released from electroporated cells was examined. To do this, naïve 
cells were inoculated at an equal m.o.i. and the released infectious virus progeny and the 
intracellular viral RNA were measured at various times post-infection. Both the virus 
yields and RNA replication levels of JFH1Y35A were very similar to JFH1WT. In contrast, 
the replication kinetics of G27A were slightly reduced. However, JFH1F24A displayed the 
greatest decrease in viral replication and dynamics during the 144 h culture period (Fig. 
3.11A and B). The results obtained for JFH1Y35A were the most important for this study as 
this mutant has the greatest reduction in DDX3 binding yet shows comparable replication 
levels to JFH1WT. To unequivocally show that this mutant possesses no significant 
alterations to virus replication, two independent infection experiments were performed at 
an m.o.i. of 0.2 and 0.02. The intracellular HCV RNA and virus release levels were 
measured over three days. Again, no major alterations to virus replication were observed at 
either m.o.i. during the infection period, confirming that the fitness of this mutant is 
unaltered (Fig. 3.11 C-F).  
 
 
3.1.7. Effect of DDX3 Knockdown on HCV Replication 
 
Recent reports have shown that the silencing of DDX3 from target cells by RNAi impairs 
HCVcc replication (Ariumi et al., 2007; Randall et al., 2007). To assess the influence of 
DDX3 abundance on virus infection in the absence of the core-DDX3 interaction, the 
replication of JFH1WT and JFH1Y35A following infection of cells that had undergone 
efficient siRNA knockdown of DDX3 was measured. Knockdown of DDX3 protein from 
Huh-7 cells was demonstrated by immunoblotting using mAbs AO196 and anti-tubulin in 
combination (Fig. 3.12A). These mAbs are suitable to use in combination as they were 
known not to cross react with other proteins (Appendix 2). As previously described, DDX3 
knockdown cells were substantially less permissive for virus replication than normal cells 
following infection with JFH1WT. Similar reductions in JFH1Y35A replication levels were 
also observed, indicating that this mutant also relies on endogenous DDX3 levels for 
replication following infection (Fig. 3.12B-F).  
 
To determine the effects of DDX3 silencing during productive viral RNA replication in the 
absence of virus assembly, Huh-7 cells were electroporated with JFH1WT and JFH1Y35A 
genomes lacking the envelope coding genes (JFH1ΔE1E2) along with the DDX3 siRNAs. 
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Figure 3.12. Requirement of DDX3 for HCV replication.  
 
(A) Huh-7 cells were lipofected with siRNA duplexes as indicated. Cells were harvested after 48 h 
and examined by immunoblotting using the anti-DDX3 mAb AO196. (B) Naïve and DDX3-
deficient Huh-7 cells were infected with JFH1WT or JFH1Y35A virus. At 48 h post-infection the 
levels of released virus and intracellular HCV RNA were measured by TCID50 assay and RT-
qPCR, respectively. Error bars indicate variability of the assays. The HCV RNA levels were 
normalised to the values obtained from cells harbouring the control siRNAs. (C-F) Cells were 
transfected with control (C and E) and DDX3 (D and F) siRNAs and infected with JFH1WT (C and 
D) and JFH1Y35A (E and F) as before. At 48 h post-infection cells were fixed and probed with 
antibodies to core (C7-50) and DDX3 (R648) for IF analysis. The confocal laser intensities settings 
were identical for each image. Scale bar, 50 µm. 
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Figure 3.13. Requirement of DDX3 for HCV genome synthesis and protein expression.  
 
(A) RNA replication of JFH1ΔE1E2(WT) and JFH1ΔE1E2(Y35A). Huh-7 cells were electroporated with the 
indicated viral RNAs. At 24, 48 and 72 h post-incubation, Intracellular HCV RNA was quantified 
by RT-qPCR. HCV RNA levels were normalised to the GND value at 72 h. (B and C) RNA 
replication of JFH1∆E1E2(WT) and JFH1∆E1E2(Y35A) in DDX3 silenced cells. (B) Lysates from cells 
treated with control and DDX3 siRNAs were immunoblotted with antibodies to DDX3 (AO196), 
tubulin and core (C7-50). The percentage of intracellular HCV RNA levels were quantified as 
before with the values expressed relative to the control cell readings. (C) At 72 h post-
electroporation, cells were fixed and probed with antibodies to core (C7-50) and DDX3 (R648). 
Scale bar, 50 µm. 
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The JFH1ΔE1E2 genome is replication-competent but non-infectious (Wakita et al., 2005). 
The JFH1ΔE1E2 genomes were used in order to exclude possible defects in virus assembly 
and spread that could result from the removal of DDX3 from the cells and thereby 
influence the intracellular HCV RNA levels. A JFH1ΔE1E2 genome harbouring the Y35A 
mutation JFH1 ΔE1E2(Y35A) was included in this experiment to assess the relationship of 
core-DDX3 binding on RNA replication during DDX3 silencing. As expected, the RNA 
replication of JFH1ΔE1E2 was proficient with and without the Y35A mutation in normal 
Huh-7 cells (Fig. 3.13A).  At 72 h following the electroporation of the viral RNAs and 
DDX3 siRNAs, cells were harvested for immunoblotting, RT-qPCR and IF analysis. As 
shown in Fig. 3.13B efficient knockdown of DDX3 expression was achieved in cells 
harbouring the DDX3 siRNAs compared to the control siRNAs. Interestingly, 
quantification of intracellular HCV RNA found a 45 % reduction for JFH1ΔE1E2(WT) 
compared to only a 4 % drop for JFH1ΔE1E2(Y35A) in DDX3 silenced cells. Strikingly, 
immunoblotting and IF analysis found no alterations to the core protein expression levels 
in these samples (Fig. 3.13B and C). 
 
 
3.1.8. DDX3 Sediments with Extracellular Core Protein 
 
As discussed in section 1.11, core protein is the viral nucleocapsid and is critical for the 
assembly of infectious particles through its association with LDs. Given the redistribution 
of DDX3 to LDs in infected cells through its interaction with core protein, it is possible 
this cellular protein may be incorporated into assembled virions. To test this hypothesis, an 
initial experiment was performed to determine if core protein could be detected from 
pelleted cell medium containing infectious virus. Huh-7 cells were electroporated with 
JFH1GND, JFH1ΔE1E2, and JFH1WT RNA and incubated for 72 h before harvesting cell 
lysates and titrating the cell medium. The TCID50 assay indicated the cell medium from the 
JFH1WT electroporations contained infectious virus titers of 4.1 x 104 TCID50/ml, whereas 
no infectivity was released from cells with JFH1GND and JFH1ΔE1E2, as expected. The cell 
medium from each electroporation was centrifuged through a sucrose cushion and the 
pellet was lysed in Masaki buffer. Along with aliquots of cell lysates, these extracellular 
extracts were immunoblotted with core mAb C7-50. As expected, core protein was 
detected in the cell lysates from the JFH1ΔE1E2 and JFH1WT but not the replication deficient 
JFH1GND lysates. Importantly, extracellular core protein was detectable in the JFH1WT 
samples only under short exposure conditions (Fig. 3.14A, upper panel). A longer exposure 
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revealed a very low level detection of extracellular core protein from the JFH1ΔE1E2 sample 
(Fig. 3.14A, lower panel). These results are in accordance with a previous report showing 
JFH1ΔE1E2 electroporated cells can secrete a low level of core protein molecules, although 
the exact composition of these is unknown (Wakita et al., 2005). Importantly, these results 
showed that extracellular core protein was detectable from cell medium containing 
moderate titers of JFH1 virus. Next, to determine if DDX3 associates with the virus, the 
cell medium from JFH1WT electroporated cells was concentrated, overlayed onto a 20-60 
% sucrose gradient and centrifuged to equilibrium. The quantity of infectious virus, HCV 
RNA and protein levels for core and DDX3 was then determined from the six fractions 
collected from the top of the gradient by TCID50, RT-qPCR and immunoblotting, 
respectively. As reported previously (Gastaminza et al., 2006), the infectivity of JFH1 
sedimented to a lower density than the HCV RNA levels that are mainly comprised of non-
infectious virus particles (Fig. 3.14B). The presence of core and DDX3 protein by 
immunoblotting was examined using mAbs AO196 and C7-50 in combination. These 
mAbs are suitable to use simultaneously as they were known not to cross react with other 
proteins (Appendix 2). Strikingly, core and DDX3 protein co-sedimented together and 
were most prevalent in fractions 3 and 4, which corresponded to the peak HCV RNA 
content between densities 1.09 and 1.12 g/ml (Fig. 3.14C). These data indicate DDX3 may 
be incorporated onto HCV RNA containing virus particles and possibly infectious virus 
particles.  
 
To elaborate on these findings, gradient analyses were performed on JFH1Y35A and JFH1WT 
extracellular particles. For a more accurate representation of particle sedimentation 
equilibrium, twelve fractions were collected from these gradients. The buoyant density of 
the infectious JFH1WT particles were distributed over fractions 3 to 6 (between 1.06 and 
1.10 g/ml) (Fig. 3.15A and C), whereas the RNA containing particles were more abundant 
in fractions 6 and 8 (between 1.10 and 1.12 g/ml) (Fig. 3.15B and D). In contrast, the 
infectivity of JFH1Y35A was largely present within fraction 4, resulting in a leftward shift in 
the mean density of the virus (Fig. 3.15A and C). A similar change in density profile was 
also observed in the JFH1Y35A RNA containing particles (Fig. 3.15B and D), suggesting a 
significant alteration to the biochemical composition of the mutant particles. To determine 
if the core-DDX3 interaction was responsible for the observed phenotypic changes in the 
JFH1Y35A virus, immunoblotting was carried out on each gradient fraction using mAbs 
AO196 and C7-50. For both JFH1WT and JFH1Y35A, the detected core protein sedimented at 
similar densities as the peak RNA levels (Fig. 3.15E). Longer exposure found that DDX3 
was present in the JFH1WT core containing fractions, whereas its levels were barely 
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Figure 3.14. Detection of DDX3 on virus particles.  
 
(A) The culture medium from Huh-7 cells electroporated with JFH1GND, JFH1ΔE1E2 and JFH1WT 
was collected and the cells lysed in Masaki buffer. The medium was then pelleted through a 20 % 
sucrose cushion and the pellet lysed in Masaki buffer. Extracellular lysates were immunblotted 
with cell lysates (1/20th of total) using core mAb C7-50. Short and long exposures are shown. (B) 
The infectivity and HCV RNA levels of gradient fractions were determined by FFU assay and RT-
qPCR, respectively. (C) Immunoblotting of gradient fractions using mAbs AO196 and C7-50, 
alongside mock- and JFH1-electroporated cells lysates. 
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Figure 3.15. Biochemical and biophysical properties of JFH1WT and JFH1Y35A virus particles.  
 
(A-D) Culture medium from Huh-7 cells electroporated with JFH1WT and JFH1Y35A were purified 
through a 20 % sucrose cushion. The pelleted virus was then subjected to 20-60 % sucrose gradient 
ultracentrifugation. The infectivity (A and C) and HCV RNA levels (B and D) of gradient fractions 
were determined by TCID50 assay and RT-qPCR, respectively. (E) Immunoblotting of gradient 
fractions using the anti-DDX3 and anti-core mAbs AO196 and C7-50, respectively. Short and long 
exposure times are shown.  
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detectable in the JFH1Y35A core fractions under the same exposure conditions (Fig 3.15E). 
Thus, these results provide evidence that disruption of the core-DDX3 interaction reduces 
the incorporation of DDX3 into virus particles. As a consequence the infectious and RNA 
containing particles assembled are less dense.   
 
As DDX3 is potentially a component of the virion, it was important to test whether anti-
DDX3 antibodies could neutralize infection. For this, inhibition assays were performed on 
JFH1WT virus obtained from electroporated cells using mAb AO196 and pAb R648. Virus 
was incubated with high concentrations of each antibody, alongside the control antibodies 
prior to infection of target cells. As expected, the broadly neutralizing anti-E2 mAb AP33 
(Owsianka et al., 2005) was capable of almost complete inhibition of infection at 
concentrations of 100 µg/ml. However, like the non-neutralising anti-E2 mAb ALP98, 
AO196 was unable to significantly inhibit JFH1 infection. Although, R648 could inhibit 
infection by ~50 %, a similar effect was observed with the control pre-immune serum. 
(Fig. 3.16A). Thus, these inhibitory effects are non-specific and likely caused by inhibitory 
IgGs present in the polyclonal serum. Also, pre-incubation of naïve cells with the DDX3 
antibodies prior to infection showed no inhibition in contrast to the >90 % reduction 
obtained using a well characterized neutralizing mAb to CD81 (Fig. 3.16B), a receptor 
essential for virus entry into target cells (Section 1.10.1).  
 
 
3.1.9. Discussion  
 
The data in this section provide novel insights into the redistribution of cellular DDX3 by 
core protein during productive viral replication. By designing a co-IP assay, the interaction 
between these two proteins was demonstrated in the HCVcc system. While the 
colocalisation of DDX3 and core protein in JFH1-infected cells has been previously 
documented (Dalrymple, 2007), here the exact nature of its redistribution to LDs was 
dissected. IF analysis found that the redistribution of DDX3 by core protein occurred at 
early times post-electroporation, suggesting that this interaction takes place immediately 
following the translation of core protein. Analysis of cells replicating a range of JFH1 
domain II and III core mutants demonstrated that the colocalisation of DDX3 with core is 
independent of the core-LD association. Also, in the absence of core protein the remaining 
viral proteins had no effect on the cytoplasmic localisation of DDX3. To gain a more 
detailed insight into the distribution pattern of core and DDX3 in relation to LDs, confocal 
laser-scanned images of JFH1-electroporated cells were analysed with software designed 
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Figure 3.16. JFH1WT virus is not neutralised by anti-DDX3 antibodies.  
 
(A) Approximately 100 FFU of JFH1WT was incubated with 100 µg/ml of mAb AP33, ALP98, 
AO196 or 1/25 dilution of pAb R648 pre-immune (PI) and immune (I) serum for 1 h prior to 
infecting Huh-7 cells. At 48 h post-infection, virus infectivity was determined by FFU assay. 
Percent infectivity was calculated by quantifying viral infectivity in the presence antibodies relative 
to standard infection. (B) Naïve Huh-7 cells were pre-incubated for 1 h with 40 µg/ml of anti-
CD81, 100 µg/ml AO196 and 1/25 dilution of R648 PI and I serum before infection. Cells were 
then infected with ~100 FFU for 48 h and the infectivity levels determined by FFU assay. Percent 
infectivity was calculated by quantifying viral infectivity in the presence of inhibitory antibodies 
relative to a standard infection. Means and error ranges from triplicate infections are shown. 
 92
to generate high-resolution 3D reconstructions. The raw z-stack confocal images of the 
appropriately labelled cells were subjected to deconvolution, a computational 3D-image 
restoration technique, which serves to remove the unavoidable blurring effect of the point 
spread function in stacks of optical confocal sections. Regions of interest from the 
deconvolved z-stacks revealed a tight antigen complex comprising similar ratios of DDX3 
and core surrounding ADRP. Thus, this approach provided a more in-depth analysis of the 
relationships between the DDX3, core and ADRP antigens than that offered by 2D 
confocal microscopy. However, caution is warranted when interpreting these results as this 
technique depends crucially on the settings of signal-to-noise and background. Therefore, 
over- and underestimation of these two parameters during image sampling can lead to 
artifactual alterations (Landmann & Marbet, 2004). Although, each of the z-stacked images 
from section 3.1.4 were captured using the appropriate confocal settings with the aim to 
reduce background and signal-to-noise, one cannot exclude the possibility of artefacts 
occurring from sub-standard image acquisition.  
 
Given the putative function of DDX3 in RNA metabolism, initial identification of the core-
DDX3 interaction led to proposals about its possible role in virus replication and assembly 
(Mamiya & Worman, 1999; Owsianka & Patel, 1999; You et al., 1999). Recent data using 
the JFH1 system suggest that HCV RNA replication and virus assembly occur in LD-
associated membranes (Boulant et al., 2007; Miyanari et al., 2007). Core protein, which 
associates with LDs, recruits the viral non-structural proteins, replication complexes and 
envelope glycoproteins to these sites, allowing virus assembly to proceed in this local 
environment (Miyanari et al., 2007). Therefore, given that core recruits DDX3 to LDs, it 
was envisaged that this event may have a function in HCV replication. In keeping with this 
were the two reports showing reductions in HCVcc replication when DDX3 was removed 
from the cell by RNAi (Ariumi et al., 2007; Randall et al., 2007). To determine whether 
this effect on virus replication was pertinent to a reduction in the core-DDX3 interaction, a 
panel of JFH1 domain I core mutants were characterised. By implementing the co-IP 
assay, the Y35A mutation was identified as causing the greatest abolition in DDX3 
binding. However, this mutant virus still maintained core-LD association and JFH1WT 
replication levels, suggesting that the core-DDX3 interaction plays no role in virus 
replication in cell culture.  
 
The data showing RNA silencing impairs JFH1WT infection is in accordance with the 
previous reports (Ariumi et al., 2007; Randall et al., 2007). In addition to reproducing the 
deleterious effects of DDX3 knockdown on the JFH1WT replication, a similar phenotype 
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was also observed for JFH1Y35A. These findings provide strong evidence that the 
requirement of DDX3 for HCV replication is unrelated to its interaction with the viral core 
protein. Therefore, these data make a clear and important distinction between the effects of 
siRNA knockdown of DDX3 from the cells and disruption of the core-DDX3 interaction 
on HCV replication. Intriguing results were also obtained from the simultaneous 
electroporation of DDX3 siRNAs with JFH1∆E1E2(WT) and JFH1∆E1E2(Y35A) viral RNAs into 
cells. While the immunoblotting and IF data provided convincing evidence that efficient 
DDX3 knockdown caused no deleterious effects to the viral core protein expression from 
either genome, the JFH1∆E1E2(WT) HCV RNA levels were reduced by 45 %. Although, these 
results are consistent with the data showing ~2 fold reductions in the RNA replication 
levels of SGRs upon DDX3 knockdown (Ariumi et al., 2007), the RNA levels are 
contradicted by the unaltered core protein expression levels. Furthermore, the HCV RNA 
levels of JFH1∆E1E2(Y35A) were unaltered by DDX3 silencing, suggesting the Y35A 
mutation can prevent these reductions in HCV RNA. Another important observation from 
this experiment is the differential effect of DDX3 silencing prior to virus infection and 
during viral RNA synthesis. Indeed, the massive reductions in core protein expression 
demonstrated by IF following infection of DDX3 knockdown cells compared to the 
unaltered protein expression levels seen in the experiments with JFH1∆E1E2 genomes, 
suggest DDX3 functions at an early step in the HCV lifecyle prior to the release of the 
infectious genome.  
 
Another compelling finding in this section was the co-sedimentation of DDX3 protein with 
extracellular core protein from JFH1WT electroporated cells. However, this result is 
puzzling for several reasons. If DDX3 is indeed incorporated into the virion by virtue of 
the core-DDX3 interaction, it is curious that the disjuncture of these two proteins causes no 
significant alterations to virus infectivity, as indicated from the phenotype of JFH1Y35A. 
This alludes to DDX3 having no function on the virion during infection and its presence 
simply being a consequence of its interaction with core protein during viral replication in 
the cell. On the other hand, it is possible that JFH1Y35A virions possess sufficient levels of 
DDX3 or a related protein on the particle to fulfil any potential role in virus entry. It is also 
worth noting that no inhibition of virus infection was found following the incubation of 
WT virus or target cells with the anti-DDX3 mAb AO196 or pAb R648. However, caution 
is warranted when interpreting this result as it may be explained by these antibodies being 
non-neutralising or DDX3 being inaccessible to antibodies rather than DDX3 having no 
role in infection. Further studies will be necessary to distinguish between these 
possibilities.  
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3.2.  Identification of Core Mutations that Determine 
 Infectious Virus Assembly and Productive Infection 
 
 
3.2.1. Introduction 
 
The previous chapter (Section 3.1.6) described 6 alanine mutations in JFH1 core protein 
that affected the core-DDX3 colocalisation in Huh-7 cells electroporated with each mutant 
viral RNA. Despite all mutants having reductions in core-DDX3 colocalisation, these 
viruses were proficient in RNA replication. However, further analysis revealed that the 
infectious phenotype of two mutants (JFH1F24A and JFH1G33A) displayed marked 
differences to JFH1WT. Although the F24A mutation did not affect infectious virus release 
following electoporation of the viral RNA into cells, it was shown to cause substantial 
defects to the infection kinetics of the virus particles. To learn more about the function of 
the F24 residue in virus infection, various aa substitutions were introduced into the JFH1 
genome at this position. The effects of these changes were then analysed by measuring the 
HCV RNA replication levels and infectious virus production of each mutant. 
 
Of all the mutants characterised in section 3.1.6, only JFH1G33A had a reduced capacity to 
produce infectious virus, as manifested by a 200-fold drop in titer. The virus release defect 
of JFH1G33A has been reported previously (Dalrymple, 2007). However, in that study 
infectious virus titers were not detected immediately following electroporation of the viral 
RNA but instead after five cell passages. The reasons for this discrepancy is possibly due 
to differences in electroporation efficiency as the titers obtained for JFH1WT from this 
previous study were substantially lower than those obtained in the present study. 
Nevertheless, this study revealed that a hallmark of JFH1G33A was its ability to escalate 
infectious virus release during cell passaging. Furthermore, sequencing of the core gene 
revealed the presence of a second core aa mutation near the G33A change at the time when 
infectivity increased (typically passage 5). This phenotype was shown to occur in four 
independent electroporations, with a different second core mutation being detected in each 
experiment. The four second-site core mutations reported were G32D, V34A, L36S and 
L37S (Dalrymple, 2007). However, that study failed to provide conclusive evidence that 
these were the compensatory mutations responsible for the reversion phenotype of 
JFH1G33A. To further delineate the properties of this mutant, similar passaging experiments 
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were performed on JFH1G33A electroporated Huh-7 cells. In accordance with the previous 
report, the infectivity of JFH1G33A-progressively increased during cell passaging. 
Interestingly, sequencing of these fully infectious JFH1G33A genomes revealed the same 
second-site changes in the core gene reported previously. To confirm that these second-site 
changes were responsible for the increased JFH1G33A infectivity, each mutation was 
introduced separately into the original G33A genome. These four double mutants were 
then characterised alongside JFH1G33A to determine their effects on HCV RNA replication 
and infectious particle production.  
 
 
3.2.2. The Role of Phenylalanine 24 in Virus Replication and   
  DDX3 Binding 
 
Although the F24A mutation did not affect the peak infectious virus release following 
electoporation of the viral RNA into cells, it was shown to cause substantial defects to the 
infection kinetics of the virus particles (Section 3.1.6). To further assess the dependence of 
F24 for efficient virus infection, a detailed substitution analysis was performed on this 
residue. All 6 mutants described in section 3.1.6 were generated by Dalrymple (2007) 
using alanine-scanning mutagenesis. Alanine was chosen as the replacement residue due to 
its relatively neutral properties. Alanine is non-polar and not particularly hydrophobic. It is 
the second smallest aa (behind glycine) containing only a single methyl group for its side 
chain that is very non-reactive. As a result of its simplicity alanine is present in just about 
all non-critical protein contexts (Betts & Russell, 2003). It is for these reasons that alanine 
is frequently chosen in mutagenesis studies aiming to understand the functional properties 
of particular residues within a protein sequence. While the F24A change potentially 
highlighted an important function for F24, to more precisely dissect its role in virus 
infection, substitutions to leucine, isoleucine, valine and tyrosine were introduced into the 
JFH1 genome. These changes were carefully selected according to the BLOSUM62 
mutation matrix as well as the structural and functional properties of each aa. Mutation 
matrices are sets of numbers that show the propensities of exchanging one aa for another 
and can be useful as rough guides for how favourable a particular change will be. One of 
the most common matrices used is BLOSUM (blocks substitution matrix), which is 
generated from local multiple sequence alignments of protein sequences from a related 
family (Henikoff & Henikoff, 1992). These matrices are based on the minimum percentage 
identity of the aligned protein sequences used in deriving them. For example, the standard 
 96
BLOSUM62 matrix (Fig. 3.17) corresponds to alignments displaying at least 62 % 
identity. The scores in a BLOSUM matrix are presented as log-odds scores that measure 
the logarithm of the probability of two aas occurring in an alignment intentionally and the 
probability of two aas appearing by chance. A positive score is given to the more 
favourable substitutions while a negative score is given to the less preferred substitutions. 
As mutation matrices are based purely on sequence alignments, they do not provide any 
qualitative information regarding the chemistry involved in particular substitutions. 
However, such information can be obtained using Taylor classification that explains 
mutation data through correlation with the physical, chemical and structural properties of 
aas (Taylor, 1986). The Taylor classification is normally represented in a Venn diagram 
(Fig. 3.18) where each residue is positioned by multidimensional scaling of Dayhoff’s 
mutation matrix, followed by their grouping to common physico-chemical properties. 
Thus, the Venn diagram represents a compromise between mutation data and chemistry. 
Further expert guidance was kindly provided by Dr Francois Penin (Institute de Biologie et 
Chimie des Protèins, Lyon, France). 
 
BLOSUM62 considers F24A a disfavoured substitution (log-odds score = -2) (Fig. 3.17), 
which is likely due to the major differences in size and hydrophobicity of phenylalanine 
and alanine (Fig. 3.18). The differing properties of leucine, isoleucine, valine and tyrosine 
were selected to allow the effects of aas that are considered disfavourable, neutral and 
favourable phenylalanine substitutions to be compared in terms of their effects on virus 
infection. Leucine is a larger and more hydrophobic residue than alanine due to its 
aliphatic side chains (Figs 3.18 and 3.19). As for alanine, its side chain is very non-reactive 
and rarely involved in protein function (Betts & Russell, 2003). Leucine is considered to be 
a neutral substitution for phenylalanine (log-odds score = 0) (Fig. 3.17). Isoleucine has 
very similar properties to leucine and is also regarded as a neutral substitution (Figs 3.17 
and 3.18). However, isoleucine was selected as, unlike leucine, it contains two hydrogen 
substituents attached to the β-carbon (Cβ-branched) (Fig. 3.19). This feature causes a lot 
more bulkiness near the protein backbone meaning that this residue is more restrictive to 
the conformation the main chain can adopt. Valine was selected as its size and 
hydrophobicity properties fall between those of isoleucine, leucine and alanine (Figs 3.18 
and 3.19). Furthermore, valine is Cβ-branched (Betts & Russell, 2003) and considered a 
less disfavoured substitution than alanine (log-odds score = -1) (Fig. 3.17). Tyrosine was 
selected as, like phenylalanine, it is an aromatic residue (Fig. 3.19) that is a particularly 
favoured change for phenylalanine (log-odds score = 3) (Fig. 3.17). Tyrosine is classed as 
a polar residue as a result of the reactive hydroxyl group on the aromatic ring that makes it 
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Figure 3.17. BLOSUM62 substitution matrix.  
 
The log-odds score for each of the 210 possible substitutions of the 20 standard aas indicate those 
changes that are favoured (>0), neutral (0) and disfavoured (<0). Adapted from Henikoff & 
Henikoff (1992).  
Small
Hydrophobic
Polar
Proline
Tiny
Aliphatic
Aromatic
Charged
Negative
Positive 
P
A
D
E
QS-H
W
YF
M
L
I V
H R
K
NS
C
GCS-S
Figure 3.18. Venn diagram relating a selection of physico-chemical properties from the 20 
standard aas.  
 
The aas are divided into sets. Two major sets include all aas containing a polar group (polar) and 
those which exhibit a hydrophobic effect (hydrophobic). A third major set is defined by size (small) 
and contains the 9 smallest amino acids (with large defined by implication). Within this is an inner 
set of smaller residues (tiny), which have at most two side chains atoms. Cysteine has an uncertain 
location as the reduced form (CS-H) has similar properties to serine, whereas the oxidised form (CS-
S) may be more comparable to Valine. Other sets include full-charge (charged), which contains the 
subset positive (negative is defined by implication) and aromatic and aliphatic. Proline was 
excluded from the main body of the diagram due to its unique backbone properties. Adapted from 
Taylor (1986). 
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Figure 3.19. Structures of the aas relevant to this study.  
 
Each residue is illustrated in dipolar form consisting of an amino group (–NH3+), a carboxyl group 
(– COOH-), a hydrogen atom (–H) and a distinctive side chain (shown in bold) bonded to the α-
carbon atom. Adapted from Stryer (1988). 
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less hydrophobic (Betts & Russell, 2003). Together, this set of mutations will allow the 
study of two disfavoured changes (alanine and valine), two neutral changes (leucine and 
isoleucine) and one favourable change (tyrosine) to F24 on JFH1 virus infection. These 
mutations were introduced into the JFH1 genome using site-directed mutagenesis as 
described in section 2.2.3.9. 
 
Consistent with the results in section 3.1.6, the RNA replication of JFH1F24A was unaltered 
post-electroporation, whereas the levels of released virus yield were delayed as seen by the 
lower titers at 24 and 48 h (Fig. 3.20A and B). No differences in RNA replication were 
observed for the other F24 mutants; however their virus release levels were slightly altered. 
The virus release kinetics and peak titers of JFH1F24L and JFH1F24Y were similar to WT, 
whereas JFH1F24I and JFH1F24V had slightly lower infectivity at each time-point (Fig. 
3.20B). Next, the replication kinetics of these phenylalanine mutants was examined 
following infection. Using virus obtained 72 h post-electroporation, naïve cells were 
inoculated at an m.o.i. of 0.2 and 0.02 TCID50 per cell. The infectious progeny virus 
release and intracellular viral RNA replication levels were then monitored from these cells 
over 72 h. The virus release pattern of JFH1F24L, JFH1F24V and JFH1F24Y closely mimicked 
that of JFH1WT (Fig. 3.21A and C). The lower infectivity of JFH1F24I indicates subtle 
decreases in virus spread. However, the greatest reduction was observed for JFH1F24A, 
which had the lowest infectivity and intracellular RNA replication values at each time-
point for each m.o.i. (Fig. 3.21A-D).  
 
Given that the F24A mutation was shown to abrograte core-DDX3 binding (Section 3.1.6), 
it was important to demonstrate how the other residue changes at this position affected the 
level of core-DDX3 interaction. As shown in the representative images in Fig. 3.22, IF 
analysis found varying levels of core-DDX3 colocalisation for each mutant at 72 h post-
electroporation. No core-DDX3 colocalisation was observed for JFH1F24A, JFH1F24I and 
JFH1F24V; whereas all cells replicating JFH1F24Y displayed complete colocalisation 
between the two proteins as for JFH1WT. Mixed populations of cells were found for 
JFH1F24L with colocalisation being observed in 9 % of cells counted. Next, the co-IP assay 
(Section 3.1.3) was performed on Huh-7 cell lysates electroporated with each mutant to 
test for alterations to the core-DDX3 interaction. Fortunately, all the phenylalanine mutants 
were recognised by the core mAb C7-50 as shown in Fig. 3.23A by the similar detection 
levels of core and NS5A in the lysates. The mutant cores were co-immunoprecipitated by 
the anti-DDX3 antiserum R648 in various amounts compared to JFH1WT (Fig. 3.23B and 
C). Consistent with our previous findings the F24A mutation reduced the level of core 
BA
Re
lat
ive
 In
tra
ce
llu
lar
 H
CV
 R
NA
24 48 72
Lo
g 1
0 
TC
ID
50
/m
l
4 24 48 72
1
10
100
1000
GND 
WT 
F24A 
F24L 
F24I 
F24V 
F24Y 
3
4
5
6
WT 
F24A 
F24L 
F24I 
F24V 
F24Y 
HoursHours
Figure 3.20. Replication of JFH1 phenylalanine core mutants following electroporation.  
 
(A) Intracellular HCV RNA replication and (B) infectious virus production at 24, 48 and 72 h post-
electroporation of JFH1 RNA with and without the indicated mutations, as determined by RT-
qPCR and TCID50, respectively. RNA levels were normalised to GND values at 72 h. Means and 
error ranges from two independent experiments are given. 
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Figure 3.21. Infection kinetics of the JFH1 phenylalanine core mutant viruses.  
 
Naïve Huh-7 cells were infected with JFH1WT or mutant viruses at an m.o.i. of 0.2 (A and B) and 
0.02 (C and D) as indicated. At 24, 48, and 72 h post-infection, the released virus yield (A and C) 
and the intracellular HCV RNA levels (B and D) were determined by TCID50 and RT-qPCR, 
respectively. The RNA levels were normalised to the values from (B) JFH1F24A at 24 h and (D) 
JFH1F24A at 48 h. Means and error ranges from two independent experiments are given. Dotted line 
indicates cut-off of the TCID50 assay. 
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being precipitated by anti-DDX3 (Section 3.1.6). Substitution of F24 with L, I and V also 
caused similar decreases to the core-DDX3 interaction. Remarkably, more F24Y core 
protein was co-precipitated than WT suggesting the engagement of core with DDX3 is 
enhanced by this particular mutation (Fig. 3.23B-D). The specificity of the co-IP was 
confirmed on the cell lysates from JFH1F24Y-electroporated cells by showing only the 
immune R648 serum and not the R648 pre-immune serum could precipitate core (Fig. 
3.23E). Importantly, no alteration to the DDX3 expression levels was found in the lysates 
derived from cells electroporated with each mutant (Fig. 3.23F). Next, the stability of these 
mutations during persistent infection was measured. Infectious virus from each mutant was 
used to inoculate naïve Huh-7 cells alongside JFH1WT at an equal m.o.i. At the time of 
subconfluency, these cells were split 1:10 for a total of 5 passages. At passage 5 the cell 
medium was assayed for infectious virus, the cells were tested for core-DDX3 
colocalisation, and the core gene from intracellular viral RNA was sequenced. As 
summarised in Fig. 3.23G, each mutant had similar levels of virus release to JFH1WT 
indicating that they can persistently infect cells during serial passages. Moreover, each 
mutation appears stable as no changes to the core gene sequence or core-DDX3 
colocalisation was observed in passage 5 cells. 
 
 
3.2.3. Effects of Core Mutation G33A on Infectious Virus   
 Assembly 
 
The images in Fig. 3.24 clearly exhibit the defect of JFH1G33A. At 72 h post-
electroporation, an equal number of NS5A expressing cells were present for JFH1WT and 
JFH1G33A. However, when naïve cells were inoculated with the culture medium from these 
electroporated cells, there was a marked reduction in the number of NS5A positive foci for 
JFH1G33A infected cells compared to JFH1WT (Fig. 3.24B). These data are in agreement 
with those presented in Fig. 3.9A where no changes in NS5A expression were observed in 
JFH1G33A-electroporated cells, yet the cell culture medium contained a 200-fold reduction 
in infectious particle numbers compared to JFH1WT. Together, these data indicate this 
mutation does not affect virus RNA replication but grossly impairs infectious virus 
assembly. To determine more precisely the impact of the G33A mutation on virus 
assembly, the intracellular and extracellular virus titers were assayed at 48 h post-
electroporation. As shown in Fig. 3.25A, the cell-free and cell-associated infectivity of 
JFH1G33A RNA-electroporated cells was severely compromised, suggesting that this core 
Core-DDX3 (%)
-
100
0
MOCK
WT
F24A
Core DDX3 Merge + DAPI 
F24L 9
0
0
100
F24I
F24V
F24Y
Figure 3.22. Localisation of DDX3 in cells replicating the phenylalanine core mutants.  
 
Huh-7 cells electroporated with the indicated viral RNAs were fixed at 72 h post-incubation and 
analysed by confocal microscopy for the intracellular distribution of core and DDX3 using R308 
and AO196 antibodies, respectively. The percentage of cells (n=200) displaying core-DDX3 
colocalisation is stated next to each image. Bar, 10 µm. 
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Figure 3.23. Analysis of the core-DDX3 interaction from the phenylalanine mutants.  
 
(A) Reactivity of mutant core proteins to mAb C7-50. Huh-7 cells were electroporated with the 
indicated viral RNAs and immunoblotted for core (mAb C7-50) and NS5A (mAb 9E10) at 72 h 
post-incubation. (B-D) Interaction between DDX3 and the core phenylalanine mutants. HCV core 
was co-immunoprecipitated from the lysates obtained at 72 h post-electroporation using pAb R648 
followed by immunoblotting with mAb C7-50. Upper and lower panels represent immunoblotting 
of core protein from precipitated lysates and input control (1/20th), respectively (E) Specificity of 
the core-DDX3 co-IP. Lysates from two JFH1F24Y electroporations were pooled together and 
divided into two co-IP assays. (F) DDX3 expression levels in cells electroporated with the core 
phenylalanine mutants. Huh-7 cells were electroporated with the indicated viral RNAs and 
immunoblotted for core (C7-50), DDX3 (AO196) and tubulin at 72 h post-incubation. (G) 
Persistent infection of Huh-7 cells with the core phenylalanine mutant viruses. Cells were infected 
at an m.o.i. of 0.005 and passaged 1:10 at the time of subconfluency for 5 passages. At passage 5 
the infectivity of the culture medium was assayed by TCID50 assay, the percentage of cells (n=200) 
displaying core-DDX3 colocalisation was determined by IF and the viral core gene was sequenced 
from total cell RNA following RT-PCR. 
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mutant has a defect acting prior to infectious particle assembly. To determine what effect 
this mutation had on the secretion of non-infectious particles, sucrose cushion purification 
was performed on the cell medium obtained from Huh-7 cells electroporated with the viral 
RNA from JFH1G33A, JFH1WT and JFH1GND. As shown in Fig. 3.25B, JFH1G33A secreted a 
similar number of RNA containing particles as JFH1WT. To test the sedimentation 
equilibrium of these particles, sucrose gradient ultracentrifugation analysis was performed. 
The JFH1G33A RNA containing particles displayed a similar sedimentation pattern to 
JFH1WT with the peak RNA quantities residing within fractions 6-8 (Fig. 3.25C and D). 
The low level infectivity detected for JFH1G33A was found in the lighter density fractions 
(fractions 3-6), suggesting the JFH1G33A infectious particles are of a similar buoyant 
density to JFH1WT. As expected, the serial passaging JFH1G33A-transfected cells resulted in 
a progressive increase in extracellular viral titers (Fig. 3.26A) and further passaging 
experiments performed on this mutant confirmed that this behaviour was reproducible (Fig. 
3.26B). Sequence analysis of the JFH1G33A core protein from passage 6 virus (Fig. 3.26C) 
revealed the presence of second-site core mutations. Importantly, no core mutations were 
detected in the genome of the passage 6 JFH1WT virus. Overall, a total of 4 different 
second-site mutations in core were identified, all of which were located in very close 
proximity to the original engineered substitution and coincided with the increase in 
infectious virus (Fig. 3.26D). Interestingly, these same four mutations were documented 
previously from JFH1G33A passaging experiments (Dalrymple, 2007). 
 
To determine if these additional core mutations were responsible for the enhanced 
infectivity of JFH1G33A seen during passaging, these second-site changes were engineered 
individually into the original JFH1G33A genome by site-directed mutagenesis as described 
in section 2.2.3.9. Unlike JFH1G33A, these double core mutants displayed comparable cell-
free infectivity’s to JFH1WT (Fig. 3.27A), indicating these second core mutations are 
compensatory mutations. No changes were observed in the intracellular RNA replication 
levels for JFH1G33A or the double mutants (Fig. 3.27B), implying that the G33A mutation 
only negates infectious virus assembly. Next, the replication kinetics of each double 
mutant was examined following infection. Virus obtained 72 h post-electroporation was 
used to inoculate naïve cells at an m.o.i. of 0.1 and 0.01 TCID50 per cell. The levels of 
infectious progeny virus release and intracellular viral RNA replication were then 
measured at 24, 48 and 72 h after infection. Surprisingly, apart from JFH1G33A/L37S the 
remaining double core mutants displayed lower replication levels than JFH1WT. The 
greatest reduction was observed for JFH1G33A/V34A, which had the lowest infectivity and 
intracellular RNA replication values at each time-point for each m.o.i. (Figs. 3.28A-D). 
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Figure 3.24. NS5A expression from JFH1G33A-electroporated and -infected cells.  
 
(A) Huh-7 cells were electroporated with 10 µg of JFH1WT and JFH1G33A viral RNA. At 72 h post-
incubation, the cells were fixed and probed with the anti-NS5A mAb 9E10. (B) Naïve Huh-7 cells 
were inoculated with the culture medium obtained at 72 h post-electroporation with JFH1WT and 
JFH1G33A. At 48 h post-incubation, the cells were fixed and probed with the anti-NS5A mAb 9E10. 
Scale bar, 100 µm.   
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Figure 3.25. Requirement of JFH1G33A for virus release.  
 
(A) Huh-7 cells were electroporated with the genomes specified and 48 h later the cell-released 
(black bars) and cell-associated (grey bars) infectivity were determined by TCID50 assay. Mean 
values and standard errors of from two independent experiments are shown. Dotted line indicates 
assay sensitivity. (B) Genomic RNA levels purified by sedimentation of culture supernatants 
through a sucrose cushion were measured by RT-qPCR at 120 h post-electroporation. Error bars 
indicate variability of the assay. (C and D) Culture medium from Huh-7 cells electroporated with 
(C) JFH1WT and (D) JFH1G33A were purified through a sucrose cushion. The pelleted virus then 
underwent 20-60 % sucrose gradient ultracentrifugation. The infectivity and genomic RNA levels 
of gradient fractions were determined by TCID50 assay and RT-qPCR, respectively.  
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Figure 3.26. Reversion properties of JFH1G33A. 
 
(A) Cells electroporated with JFH1G33A or JFH1WT genomes were passaged 6 times. At each 
passage the infectivity of the cell culture supernatant was determined by TCID50 assay. Error bars 
demonstrate variability of the TCID50 assay. (B) Repeat passaging experiments on JFH1G33A-
electroporated cells. (C) Methodology for sequencing the core gene from passage 6 virus. (D) 
Mutations identified in the JFH1G33A core protein sequence from each passaging experiment with 
the engineered G33A mutation shown in bold and the second-site mutation underlined in bold. 
Roman numerals represent different passaging experiments. 
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Given that these second-site mutations are located within or close to the DDX3 binding 
region of core, the level of core-DDX3 association was measured. First, colocalisation 
studies were done by staining cells for core and DDX3 at 72 h post-electroporation. As 
shown in the representative images in Fig. 3.29, varying levels of core-DDX3 
colocalisation were observed for each mutant. Core-DDX3 colocalisation was diminished 
by JFH1G33A/V34A, whereas JFH1G33A/L37S emulated the complete colocalisation observed 
for JFH1WT. Mixed populations of cells were found for JFH1G32D/G33A and JFH1G33A/L36S 
with colocalisation being observed in 35 and 21 % of cells counted, respectively (Fig. 
3.29.). To determine the level of core-DDX3 interaction in cells replicating these double 
mutants, the co-IP assay described in section 3.1.3 was implemented. However, prior to 
this, the reactivity of these mutated core proteins to mAb C7-50 was analysed by 
immunoblotting. Cell lysates obtained from Huh-7 cells electroporated with each viral 
RNA were immunoblotted using mAb C7-50 in combination with the anti-NS5A mAb 
9E10. These mAbs are suitable to use in combination as they were known not to cross 
react with other proteins (Appendix 2). The presence of NS5A but barely detectable levels 
of core protein from the double mutant lysates indicated none of these mutated core 
proteins bound C7-50 (Fig. 3.30A). Next, these lysates were immunoblotted using pAb 
R308 and biotinylated pAb BR526. As shown in Fig. 3.30B, R308 detected similar levels 
of core protein in each lysate confirming that the double mutations did not affect core 
stability. BR526 detected the core expressed by all mutants except JFH1G33A/L37S, 
indicating that these two mutations reduce the antibody binding affinity. Although, R308 
recognised each mutant core protein, it was not suitable for immunoblotting of precipitated 
lysates due to the potential cross reactivity caused by the R648 rabbit IgGs. This problem 
was not applicable to BR526 as it was biotin labelled and thus requires a stretavidin-HRP 
conjugate. Unfortunately, due to the reduced affinity of BR526 to JFH1G33A/L37S this 
mutant had to be excluded from the co-IP assay. As shown in Fig. 3.30C, JFH1G32D/G33A 
and JFH1G33A/L36S core protein was co-immunoprecipitated in much lower amounts than 
the WT protein. However, the JFH1G33A/V34A core was not co-immunoprecipitated at all, 
indicating the interaction was abrogated. It should be noted that BR526 had a poor affinity 
for core mutants JFH1I30A and JFH1G33A (Appendix 3) that were also shown not to be 
recognised by C7-50 (Fig. 3.9A) and therefore could not be used in the co-IP assay with 
this antibody. Next, the stability of these double mutations during persistent infection was 
measured. Virus from each double mutant was used to infect naïve Huh-7 cells alongside 
JFH1WT at an equally low m.o.i. At the time of subconfluency, these cells were split 1:10 
for a total of 5 passages. At passage 5 the cell medium was assayed for infectious virus, the 
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cells were tested for core-DDX3 colocalisation, and the core gene from intracellular viral 
RNA was sequenced. As summarised in Fig. 3.30D, each mutant had similar levels of virus 
release to the JFH1WT indicating that they can persistently infect cells during serial 
passages. Moreover, each mutation appears stable as no changes to the core gene sequence 
or core-DDX3 colocalisation was observed in passage 5 cells. 
 
 
3.2.4. JFH1F24A and JFH1G33A/V34A have Reduced Virus Spread  
 
The results from sections 3.2.2 and 3.2.3 indicate that core mutations F24A and 
G33A/V34A both impede JFH1 viral spread. To better understand the nature of these 
abnormalities, further experiments were performed on these mutants. IF analysis at 72 h 
post-infection showed that the foci produced by both JFH1G33A/V34A and JFH1F24A had 
fewer infected cells per focus compared to JFH1WT (Fig. 3.31A and B). In addition, the 
individual NS5A-positive cells within each focus were generally less bright for each core 
mutant (Fig. 3.31A). These observations further support the notion that these core mutants 
are less efficient at spreading in cell culture. Given that both viruses replicate efficiently 
following electroporation of the viral RNA into cells, the defect likely acts at an early stage 
during infection, possibly before the release of the infectious genome into the cytoplasm. 
Given that the viral envelope glycoproteins are unaltered this defect is unlikely to occur 
during virus binding and entry. However, to experimentally exclude the possibility of an 
entry problem, the ability of JFH1G33A/V34A and JFH1F24A to bind and infect cells during a 
standard infection was measured. In this experiment, the internalised and cell-surface 
attached viruses were distinguished by their sensitivity to trypsin digestion. Cells were 
infected with virus according to protocols I or II (Fig. 3.31C). Following virus attachment 
(1 h at 4 oC) or standard infection, cells were either washed in cold medium or treated with 
trypsin for 30 min at 4 oC. The latter treatment degrades the cell-bound virus but not the 
internalised particle, which is able to proceed with subsequent stages of entry and 
replication. After appropriate treatment, cells were cultivated for 48 h following which 
infectivity was determined (Fig. 3.31D). After 3 h at 37 oC, ~ 80 % of the cell-associated 
WT and core mutant viruses were resistant to trypsin digestion and therefore represent the 
fraction of internalized viruses. In contrast, after 1 h at 4 oC, more than 95 % of the WT 
and core mutant viruses were inactivated by trypsin proteolysis, indicating that this 
treatment is efficient at degrading the vast majority of cell-bound virus (Fig. 3.31D). 
Therefore, during the 3 h time frame the degree of internalization is similar for all viruses, 
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Figure 3.27. Second-site mutations compensate JFH1G33A virus assembly. 
 
(A) Infectious virus production and (B) intracellular HCV RNA replication at 24, 48 and 72 h post-
electroporation into Huh-7 cells of JFH1G33A RNA with and without the second-site mutations, as 
determined by TCID50 and RT-qPCR, respectively. The relative RNA levels were normalised to the 
GND value at 72 h. Means and error ranges from two independent experiments are given. 
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Figure 3.28. Infection kinetics of double core mutant viruses.  
 
Naïve Huh-7 cells were infected with JFH1WT or mutant viruses at an m.o.i. of 0.1 (A and B) and 
0.01 (C and D) as indicated. At 24, 48, or 72 h post-infection, the released virus yield (A and C) 
and the intracellular HCV RNA levels (B and D) were determined by TCID50 and RT-qPCR, 
respectively. The relative RNA levels were normalised to JFH1G33A/V34A at 24 h. Means and error 
ranges from two independent experiments are given. Dotted line indicates cut-off of the TCID50 
assay. 
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Figure 3.29. The localisation of DDX3 in cells replicating the double core mutants.  
 
Huh-7 cells were electroporated with the indicated viral RNAs were fixed at 72 h post-incubation 
and analysed by confocal microscopy for the intracellular distribution of core and DDX3 using 
antibodies R308 and AO196, respectively. The percentage of cells (n=200) displaying core-DDX3 
colocalisation is stated next to each image. Scale bar, 10 µm. 
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Figure 3.30. Analysis of JFH1 core double mutant viruses.  
 
(A and B) Huh-7 cells electroporated with viral RNAs as shown were subjected to immunoblotting 
at 72 h post-incubation using anti-NS5A mAb 9E10, anti-core antibodies mAb C7-50, biotinylated 
pAb BR526 and pAb R308. (C) Analysis of the interaction of DDX3 with core mutants. Huh-7 
cells were electroporated with the indicated viral RNAs and HCV core co-immunoprecipitated at 
72 h post-incubation using R648 followed by immunoblotting with BR526. (D) Persistent infection 
of Huh-7 cells with the JFH1 core mutant viruses. Cells were infected at an m.o.i. of 0.005 and 
passaged 1:10 at the time of subconfluency for 5 passages. At passage 5 the infectivity of the 
culture medium was assayed by TCID50 assay, the percentage of cells (n=200) displaying core-
DDX3 colocalisation was determined by IF and the viral core gene was sequenced from total cell 
RNA following RT-PCR. 
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indicating that the delayed spread of JFH1V34A and JFH1F24A is not attributed to virus 
binding and entry into the host cell. 
 
 
3.2.5. Discussion 
 
The results in section 3.1.6 confirmed that the core-DDX3 interaction was not required for 
virus replication as the viral fitness of the JFH1Y35A mutant that failed to bind DDX3 was 
unaltered. Nevertheless, there were other mutant viruses characterised in this section that 
were clearly attenuated. One of these was JFH1G33A, which was defective in the assembly 
of infectious virus particles but not intracellular viral RNA replication as observed by the 
presence of NS5A. Further characterisation of this mutant was not performed in this 
section due to the inability of JFH1G33A to bind to core mAb C7-50, which prevented its 
DDX3 binding properties from being ascertained. However, JFH1G33A was chosen for 
further analysis in order to gain better insight into the reasons for its deficiency in 
infectious virus release. The results showed that JFH1G33A has no effect on intracellular 
viral RNA replication or the secretion of non-infectious particles. Its major defect is a large 
reduction in infectious virion assembly, which strikingly can be rescued by closely 
positioned compensatory mutations within core. Unfortunately, the underlying reason for 
the intriguing phenotype of JFH1G33A can only be speculated upon at this time. There are 
many potential explanations giving the broad functional properties that this region of core 
has been assigned. Currently, these include RNA binding, homo-oligomerisation, and the 
interaction with numerous cellular factors. This domain also harbours the residues required 
for generation of the F protein (Section 1.11.4) and the nucleotides that comprise the two 
highly conserved stem-loop structures SL47 and SL87 (Section 1.11.5). Alterations to the 
F protein sequence are likely to be irrelevant as two independent studies found that the F 
protein was dispensable for HCV replication in vitro and in vivo (McMullan et al., 2007; 
Vassilaki et al., 2008). To date, only one study has performed a comprehensive aa 
mutagenesis on core protein to determine its effects on HCVcc replication (Murray et al., 
2007). However, this study avoided mutagenesis within the first 57 residues of domain I to 
avoid complications caused by the presence of SL47 and SL87, which are known to 
influence viral RNA replication (McMullan et al., 2007; Vassilaki et al., 2008). Indeed, the 
G33 codon is located within a base pairing region of SL87. To determine if the nucleotide 
change that created the G33A mutation caused any structural re-arrangements of SL47 and 
SL87, the sequence was entered into the mfold web server for nucleic acid folding and 
hybridization prediction (Zuker, 2003). As shown in Fig. 3.32A, this change created no 
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structural alterations to either stem-loop. This is supported by the proficiency of the 
JFH1G33A genome in RNA replication. Therefore, the defect in infectious particle assembly 
is more likely caused by alterations to the protein structure. Although, the BLOSUM62 
mutation matrix (Fig. 3.17) indicate glycine can tolerate substitutions with other small 
residues such as alanine (log-odds score = 0), the unique structure of glycine can mean that 
even neutral mutations can be forbidden in certain contexts. Glycine is the simplest aa due 
to its side chain containing only a single hydrogen (Fig. 3.19), as apposed to a carbon as is 
the case for all other aas. For this reason, glycine has more conformational flexibility 
allowing it to reside in regions of protein structures that are forbidden to all other aas, such 
as tight turns (Betts & Russell, 2003). Thus, in the case of a highly conserved glycine, such 
as G33 even neutral alanine substitutions can have a major impact. In addition, the NMR 
structure of WT core residues 2-45 (unpublished data, Protein Data bank I.D. 1CWX, 
http://hepatitis.ibcp.fr) has identified a helix-loop-helix motif between residues 17-37 (Dr 
Francois Penin, personnal communication). Interestingly, G33A and the four compensatory 
mutations all reside within the proposed helix 2 (Fig. 3.33). It is plausible that this helix is 
crucial for the infectious particle assembly process and the properties of glycine at position 
33 are required for its integrity. It is important to note that other than V34A, which is 
considered a neutral change, the remaining compensatory mutations are disfavoured 
substitutions with log-odds scores of -1 for G32D and -2 for both L36S and L37S (Fig. 
3.17). It is interesting to speculate that such drastic reversion mutations may be necessary 
to repair the structural damage caused by G33A. It is intriguing that despite the reversion 
mutations having similar effects on infectious virus production following electroporation, 
the particles produced have dissimilar infection kinetics. This is exemplified by the 
JFH1G33A/V34A virus that displayed the lowest levels of virus release and intracellular HCV 
RNA levels following infection.  Strikingly, the nucleotide changes that created the 
G33A/V34A substitutions are predicted to alter the complete stem-loop structure of SL87. 
In contrast, no alterations in SL47 or SL87 are predicted to arise by the nucleotide changes 
corresponding to the remaining double mutants (Fig. 3.33C). Therefore, these results 
suggest the structural integrity of SL87 is required for the efficient spread of JFH1 virus in 
cell culture.  
 
A marked reduction in infection kinetics was also observed for JFH1F24A during its initial 
characterisation (Section 3.1.6). To further investigate the impact of residue F24 in virus 
proliferation, aa substitutions to leucine, isoleucine, valine and tyrosine were engineered at 
this position. The virus replication levels of these four mutants was then characterised 
alongside the original F24A mutant virus. Despite some modulation in viral titers at 24 and 
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Figure 3.31. JFH1G33A/V34A and JFH1F24A have reduced virus spread.  
 
(A) Huh-7 cells were infected with the indicated virus.  At 72 h post-infection cells were fixed, 
probed with the anti-NS5A mAb 9E10 and analyzed by confocal microscopy. The laser intensity 
was kept constant for each image. Scale bar, 20 μm. (B) The average number of NS5A-positive 
cells from 24 individual foci was determined. Means and error ranges of three independent 
infections are shown. (C) Protocols used in the binding and internalization assay. Protocol I 
corresponds to a standard infection where the virus added to the cells was incubated for 3 h at 37 
oC after which the cells are washed and treated before being incubated further in fresh medium for 
48 h. Protocol II involves a cell binding step for 1 h at 4 oC, which allows synchronization of virus 
attachment to cells but not virus entry. Black arrows indicate virus inoculations. Grey arrows 
represent virus removal and the cells being washed and treated with trypsin (test cells) or medium 
(control cells) for 30 min at 4 oC. #, addition of fresh medium to control cells or resuspension of 
test cells in fresh medium. (D) The percentage infectivity values for each mutant and JFH1WT 
obtained from protocols I and II with trypsin treatment normalised to those obtained with the 
control treatment. Means and error ranges from two independent experiments are shown. 
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48 h post-electroporation, all mutants achieved titers comparable to that of JFH1WT at the 
72 h time-point. However, the infection experiments revealed that the replication levels of 
the JFH1F24A virus was consistently lower than the other mutants over a 72 h period. The 
phenotype of JFH1F24A was very similar to that of JFH1G33A/V34A where virus particles are 
efficiently assembled but are defective in spreading following infection. Indeed, further 
characterisation of both these mutants found that they each share a defect that acts at an 
early stage post-infection, following virus binding and internalisation. Importantly, the F24 
codon is situated in the upper stem of SL47. Given the predicted alterations to SL87 caused 
by the G33A/V34A changes (Fig. 3.32C), it was important to test what effects the 
nucleotide substitutions that created each F24 mutation had on SL47. Mfold analysis 
indicated that all but one of the phenylalanine mutations (JFH1F24L) could potentially 
rearrange the structure of SL47 (Fig. 3.32B). Interestingly, JFH1F24L was the most closely 
matched to JFH1WT with respect to RNA replication and virus release levels post-
electroporation and post-infection. Mfold analysis indicated that JFH1F24I, JFH1F24V, and 
JFH1F24Y likely cause minor changes that affect the number of nucleotides occupying the 
two loops of SL47, whereas JFH1F24A could re-order the entire structure, separating SL47 
into two smaller stem-loops. Thus, the similar anomalies in viral spread from both 
JFH1G33A/V34A and JFH1F24A suggest both SL47 and SL87 function in viral infection.  
 
From the evidence presented in section 3.2, it seems more likely that the F24 mutations, 
particulary F24A, effect virus infectivity by acting on the underlying RNA sequence as 
opposed to the protein. However, the properties of the aa substitutions introduced at this 
position can explain somewhat the effects observed on core-DDX3 binding. Substitutions 
with the smaller aliphatic residues L, I, and V reduced the core-DDX3 interaction to 
similar levels as the alanine change. These effects, together with the improved interaction 
generated by the favourable F24Y change, suggests an aromatic side chain at this position 
is crucial for maintaining a stable contact between the two proteins.  
 
 
 
 
 
 
 
 
 
GU
U U A A
G
A
C
G
A
C
A
C
G
C
G
A
C
G
C
G
C
G
C
G
C
G
C
G C
G
U
A
C
G
U
A
C G
U A
C
G
U
A
C
G
UA
C
G
G
G
G
U
G
U
G
U
G
U
C
G
U
CG
U
A
C
G
U
A
C
G
A
C
A
A
G
A
G
G
U
G
G
G
C
G
A
C
U
A
C
C
G
G
C
G
C
G
C
G
C
G
C
A
G
A
U
C
A
C U
G G
G
C
G
3’
C
C
G
U
C
G
C
C
C
A
G
A
A
G
A
C
G
U U A
A
G
U
U
C
C
C
G
G
G
C
G
G
C
G
G5’
G
U
C
G
U
A
G
U A
U
A
UA
C
G
G
G
U
G
U
G
U
G
U
C
G
U
CG
U
A
C
G
U
A
C
G
A
C
A
A
G
A
G
G
U
G
G
G
C
G
A
C
U
A
C
C
G
G
C
G
C
G
C
G
C
G
C
A
G
A
U
C
A
C U
G G
G
C
G
C AC CA C
WT
C
G27A
3’
C
C
G
U
C
G
C
C
C
A
G
A
A
G
A
C
G
U U A
A
G
U
U
C
C
C
G
G
G
C
G
C
G
G
5’
G
U
C
G
U
A
G
U A
U
A
UA
C
G
G
G
U
G
U
G
U
G
U
C
G
U
CG
U
A
C
G
U
A
C
G
A
C
A
A
G
A
G
G
U
G
G
G
C
G
A
C
U
A
C
C
G
G
C
G
C
G
C
G
C
G
C
A
G
A
U
C
A
C U
G G
G
C
G
C AC CA C
3’
C C
5’
A
3’
C
C
G
U
C
G
C
C
C
A
G
A
A
G
A
C
G
U U A
A
G
U
U
C
C
C
G
G
G
C
G
G
C
G
G
5’
G
C
G
U
G
U A
U
A
UA
C
G
G
G
U
G
U
G
U
G
U
C
G
U
CG
U
A
C
G
U
A
C
G
A
C
A
A
G
A
G
G
U
G
G
G
C
G
A
C
U
A
C
C
G
G
C
G
C
G
C
G
C
G
C
A
G
A
U
C
A
C U
G G
G
C
G
C AC CA C
I30A
G
C
3’
C
C
G
U
C
G
C
C
C
A
G
A
A
G
A
C
G
U U A
A
G
U
U
C
C
C
G
G
G
C
G
G
C
G
G
5’
G
U
C
G
U
A
G
U A
U
A
UA
C
G
G
G
U
G
U
G
U
G
U
C
U
CG
U
A
C
G
U
A
C
G
A
C
A
A
G
A
G
G
U
G
G
G
C
G
A
C
U
A
C
C
G
G
C
G
C
G
C
G
C
G
C
A
G
A
U
C
A
C U
G G
G
C
G
C AC CA C
G33A
C
3’
C
C
G
U
C
G
C
C
C
A
G
A
A
G
A
C
G
U U A
A
G
U
U
C
C
C
G
G
G
C
G
G
C
G
G
5’
G
U
C
G
U
A
G
U A
U
G
G
G
U
G
U
U
C
U
G
G
A
C
A
G
U
G
G
G
C
G
A
C
U
A
C
C
G
G
C
G
C
G
C
G
C
G
C
A
G
U
C
A
C U
G G
G
C
G
C AC CA C
V34A
G
U
G
U
U
A
C
A
G
A
C
A
C
C
G
C
A
G
A
A
G
3’
C
C
G
U
C
G
C
C
C
A
G
A
A
G
A
C
G
U U A
A
G
U
U
C
C
C
G
G
G
C
G
G
C
G
G
5’
G
U
C
G
U
A
G
U A
U
A
UA
C
G
G
G
U
G
G
C
G
CG
C
G
U
G
G
U
G
G
G
C
G
A
C
U
A
C
C
G
G
C
G
C
G
C
G
C
G
C
U
C
A
C U
G G
G
C
G
C AC CA C
Y35A
U
G
G
A
C
U
A
G
C G
C
G
U
U
A
A
A
A
A
nt 47 nt 87
F24A
G27A
I30A
G33A
V34A
Y35A
F24A
A
Figure 3.32. Effect of core mutations on the predicted structures of stem loops SL47 and 
SL87. 
 
The sequences incorporating SL47 and SL87 (nucleotides 388-507 with respect to the 5’ end of the 
JFH1 genome) with the indicated nucleotide substitutions that create the core mutants described in 
section (A) 3.1.6, (B) 3.2.2, (C) 3.2.3 were entered into the mfold web server for nucleic acid 
folding and hybridization prediction. The nucleotides substituted to create each mutant are marked 
with black arrows in the WT structure. Shaded boxes represent regions in the stem-loops altered by 
nucleotide substitution.  
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Figure 3.33. NMR model of core residues 2-45 proposed by Ladaviere et al. (Protein Data 
Bank I.D. 1CWX).  
 
For simplicity, the protein backbone (grey tube) is shown without atoms. Residues of interest are 
marked on the protein backbone in yellow. The helix-loop-helix motif present between residues 
R17 and L37 is indicated as well as the location of G33A within helix 2. The peptide N- and C- 
termini are indicated. 
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4  Conclusions 
 
4.1. Summary 
 
A number of revelations have emerged from this study regarding the role of DDX3 and its 
interaction with HCV core protein in virus morphogenesis. In addition, a novel function for 
domain I of core in virus assembly and spread was uncovered. The findings in this study 
are recapitulated below, followed by a discussion section exploring some possible theories 
relating to the major findings of this work.  
 
1. Core protein can be specifically co-immunoprecipitated from JFH1-electroporated cell 
lysates using an anti-DDX3 antibody, confirming this interaction occurs during authentic 
viral replication. 
 
2. The redistribution of DDX3 within cells replicating JFH1 was purely dependent on the 
stable expression of core protein. 
 
3. Mutations in JFH1 core that disrupted core-DDX3 colocalisation did not alter the core-
LD association.  
 
4. Co-IP assay identified a previously generated JFH1 core alanine mutant (JFH1Y35A) that 
thwarted the core-DDX3 interaction. 
 
5. Detailed characterisation studies found that the replication kinetics of JFH1Y35A 
resembled JFH1WT. 
 
6. DDX3 knockdown from Huh-7 cells severely impaired the replication of JFH1WT and 
JFH1Y35A following infection.  
 
7. Viral protein expression levels were unchanged when DDX3 was silenced in cells 
replicating JFH1∆E1E2(WT) and JFH1∆E1E2(Y35A).  
 
8. DDX3, like core, co-sedimented with the JFH1WT extracellular virus particles but was 
less prevalent on JFH1Y35A particles.  
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9. Core mutation G33A impaired the assembly of infectious virus particles but caused no 
alteration to intracellular RNA synthesis or the secretion of non-infectious RNA containing 
particles.  
 
10. Four separate compensatory mutations in core altered the assembly phenotype of 
JFH1G33A to emulate that of JFH1WT. These assembly competent double core mutants had 
diverse phenotypes in terms of their infection kinetics and capacity to bind DDX3.  
 
11. Mutagenesis of the phenylalanine residue at position 24 in core protein revealed that 
this aa is an important determinant for DDX3 binding. Certain mutations at this position 
also had negative affects on viral spread.  
 
12. Mutants JFH1G33A/V34A and JFH1F24A significantly reduced viral spread, which was 
likely caused by the respective nucleotide substitutions altering the confirmation of RNA 
stem loops SL87 and SL47, respectively.  
 
 
4.2. The Core-DDX3 Interaction and HCV Replication 
 
The HCV core-DDX3 interaction was first shown in cells transiently transfected with 
constructs expressing the genotype 1a core, but in the absence of virus replication and fully 
productive infection (Mamiya & Worman, 1999; Owsianka & Patel, 1999; You et al., 
1999). The HCVcc system made it possible here to analyse the effects of this interaction on 
the full viral life cycle. Given the importance of DDX3 in the life cycle of several viruses 
including HCV, it was surprising to find no alterations to HCVcc proliferation when the 
interaction was disrupted. Although, the replication data from JFH1Y35A appear conclusive, 
there are several counter arguments that must be considered when interpreting these 
results. One possibility that cannot be discounted is the lack of DDX3 interaction with core 
could be supplanted by recruiting another cellular factor(s) by HCV. In line with this, 
another DEAD-box protein, DDX1 is present on LDs alongside DDX3 in core expressing 
Hep39 cells (Sato et al., 2006). It is interesting to note that DDX1, like DDX3, has been 
implicated in the nuclear export of HIV-1 RNA, where the two proteins indeed may 
conceivably act in concert with each other in carrying out this function (Fang et al., 2004; 
Yedavalli et al., 2004). Furthermore, DDX5 has also been reported to interact with core 
and NS5B (Goh et al., 2004; Kang et al., 2005). Such related cellular proteins may be 
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functionally interchangeable with DDX3 during virus replication. Another major 
complicating factor in interpreting these results is the unique features of the HCVcc 
system. Given the peculiarities in the HCV strain and cell line used it is questionable 
whether HCVcc truly represents HCV replication in vivo. The permissive nature of Huh-7 
cells may be related to the marked differences in the host environment relative to other 
liver cell lines and primary human hepatocytes that are naturally infected by HCV. In the 
context of this study, several reports have described increased expression levels of DDX3 
in tumour cell lines and thus it is conceivable that Huh-7 hepatoma cells have an excess of 
DDX3 compared to normal hepatocytes. Therefore, if HCV sequesters DDX3 to 
concentrate this protein at the virus assembly and replication sites, it is possible the high 
expression levels of DDX3 in Huh-7 cells make the core-DDX3 interaction obsolete. Also, 
the JFH1 strain is atypical among all HCV isolates, because it is the only isolate that 
replicates without requiring replication-enhancing mutations. JFH1 may contain genetic 
alterations that provide advantages for viral replication but at the same time make 
functions exerted by the core-DDX3 interaction dispensable.  
 
 
4.3. Requirement of DDX3 for HCV Replication 
 
It is intriguing that DDX3 is essential for HCV replication, yet this effect appears to be 
independent of its interaction with core. This effect is not caused by cell death as reports 
described previously and this study found no changes to cell viability following DDX3 
silencing, at least up to 96 h (Ariumi et al., 2007; Randall et al., 2007). Another 
explanation is that knockdown of DDX3 has an indirect role on HCV replication. Despite 
the exact function(s) of DDX3 being unknown, the large number of cellular processes that 
it has been implicated in suggests that the protein is a very important component of the 
cell.  Thus, downregulating its functions may affect an alternate pathway utilised by HCV 
during replication, subsequently causing these negative effects on virus replication. The 
exact mechanism by which HCV uses this host factor is unclear, however the work from 
this study indicates that the effects are more relevant in the virus infection setting rather 
than during viral RNA synthesis. However, there are important differences between the 
data in this study and those of Ariumi et al. (2007) that need to be discussed. Ariumi et al. 
(2007) found a 50 % decrease in the RNA levels of the JFH1 SGR following DDX3 
knockdown, although this decrease in replication was not confirmed by protein expression 
or colony forming units. Similarly, a 45 % drop in HCV RNA levels was observed in the 
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present study for JFH1ΔE1E2(WT) in DDX3 knockdown cells. However, unlike the reduction 
in HCV RNA, the core protein expression levels were unaltered in the knockdown cells. 
This suggests that the viral genome translation is not altered by DDX3 silencing but either 
less RNA is being synthesised or more RNA is being subjected to degradation. The RT-
qPCR probe used in this study is designed to quantify the total positive-strand HCV RNA 
within cells and therefore cannot decipher what proportion of molecules are functioning 
within viral replication complexes. Indeed, studies have shown that positive-, negative- and 
double-stranded HCV RNA molecules are dispersed throughout the cytoplasm of infected 
cells and are not solely confined to the viral replication compartments (Miyanari et al., 
2007; Targett-Adams et al., 2008a). Thus, it is possible that DDX3 binds to rogue RNA 
molecules and delays their degradation. Indeed, DDX3 has been shown to interact with 3’ 
UTR of the HCV genome (Harris et al., 2006). However, the results with JFH1ΔE1E2(Y35A) 
contradict this theory as both the HCV RNA and core protein levels were unchanged in the 
knockdown cells replicating these genomes. While this result implicates the involvement 
of the core-DDX3 interaction in this event, it doesn’t explain the HCV RNA reductions 
obtained with the SGR that does not possess core (Ariumi et al., 2007). Clearly, further 
knockdown studies are required to resolve these discrepancies. In contrast, to the 
differences observed with JFH1ΔE1E2(WT) and JFH1ΔE1E2(Y35A), infection of DDX3 
knockdown cells with the JFH1WT and JFH1Y35A infectious virus gave identical results for 
intracellular HCV RNA levels, virus release and protein expression. This implies that the 
mechanism inhibiting infection is the same for both viruses. Clearly, the results with the 
full-length JFH1 virus and the JFH1ΔE1E2 genomes suggest that DDX3 functions at an early 
event in the virus lifecycle prior to the release of the genome into the cytoplasm. However, 
Ariumi et al. (2007) also showed DDX3 knockdown in cells harbouring a full-length 
genotype 1b replicon severely inhibited RNA replication (>90 %) and colony formation 
after cell selection. This result opposes the theory of DDX3 knockdown only affecting 
HCV in the infection setting. However, this effect could well be genotype-dependent as 
Ariumi et al. (2007) found that their genotype 1b core protein had a greatly increased 
binding capacity to DDX3 compared to JFH1 core, which was barely detectable in their 
co-IP assay. Thus, it is possible that the core-DDX3 interaction has an important function 
in the productive RNA replication of this particular genotype.  
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4.4. Is DDX3 a Component of the Virion? 
 
The co-sedimentation of DDX3 with JFH1WT extracellular core was an intriguing finding. 
However, this result doesn’t necessarily prove that DDX3 is a component of the virus 
particle. The first critique of this finding is the detection of core protein only within the 
lower density fractions corresponding to the peak HCV RNA content. To strengthen the 
possibility of DDX3 being present on HCV it must be shown to co-sediment with the core 
and envelope proteins of infectious virions. It is widely reported that the RNA containing 
particles sediment differently to the infectious virions and are present in greater numbers 
(Chang et al., 2007; Gastaminza et al., 2006; Grove et al., 2008; Lindenbach et al., 2005). 
As with the results in this study, these particles have been shown to co-sediment with core 
protein (Gastaminza et al., 2006). It is possible that DDX3 may only be present on these 
denser particles and not on the infectious virion. Indeed, it has been reported that DDX3 is 
a host component of HCMV non-infectious dense bodies but not of the infectious viral 
progeny (Varnum et al., 2004). Dense bodies constitute the majority of a virion preparation 
obtained from HCMV-infected fibroblasts, but as for the HCV RNA containing particles, 
their significance during infection is unknown. DDX3 was also recently shown to be 
encapsidated into HBV particles, although the exact mechanism and physiological 
relevance behind these findings remain to be determined (Wang et al., 2009).  
 
Another logical explanation for the co-sedimentation of DDX3 with core is the 
contamination of the virus preparation with cell debris. Ideally, the purity of the fractions 
should be assessed by EM following negative staining to check for no obvious 
contamination by cellular debris (Shaw et al., 2008). Also, to determine whether the 
cellular proteins are really an integral part of the virion or perhaps derived from a 
microvesicle or exosome that co-purified with the virus, an Optiprep gradient should be 
used. Unlike sucrose, Optiprep medium maintains iso-osmotic conditions at high densities 
and is therefore particularly good at separating membranous organelles such as enveloped 
viruses and microvesicles (Shaw et al., 2008). This would be a crucial assay to show 
whether DDX3 is really co-purifying with virus particles or just cellular organelles with 
similar densities. Another possibility is the adherence of DDX3 to the virion exterior due 
to contaminating levels of the protein in the virion preparation. This theory is plausible 
given the large amount of cell death and debris generated by the electroporation procedure. 
Unfortunately, the above possibilities could not be investigated in the present study due to 
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time constraints. However, the gradient results on the JFH1Y35A virus particles provide a 
strong argument against the above criticisms. The reduced core: DDX3 protein ratio 
observed by immunoblotting from fractions 6 and 7 imply the cells replicating this mutant 
secrete less DDX3 into the culture medium. Also, the leftward shift observed in the 
infectious and RNA particle buoyant density of JFH1Y35A could be due to a decrease in the 
DDX3 content of the particle. These two points allude to the possibility of DDX3 being a 
component of both types of particles through its intracellular interaction with core protein. 
However, further research is needed to ascertain whether or not these two events are 
coincidental.  
 
Knowledge of the protein composition of infectious viral particles is an important 
prerequisite for functional studies, as it focuses the analysis on specific proteins and their 
roles during assembly and/or infection. Enveloped viruses have considerable potential to 
incorporate both viral and host proteins into their membrane(s) as well as inside the 
envelope, and these can be present at low levels, making their detection difficult. Mass 
spectrometry (MS) approaches have been invaluable in the identification of the viral and 
cellular protein content of many different viruses. Examples of well characterised envelope 
viruses and the number of host proteins associated to these are listed in Table 5. 
 
Table 5. Numbers of host proteins found on enveloped viruses by MS 
Virus  Number of host proteins Reference 
HIV-1 253 Chertova et al. (2006)  
Influenza 36 Shaw et al. (2008) 
HSV-1 49 Loret et al. (2008) 
HCMV 71 Varnum et al. (2004) 
EBV 6 Johannsen et al. (2004) 
KSHV 21  Zhu et al. (2005) 
Vaccinia virus 23  Chung et al. (2006) 
 
Some cellular proteins may be specifically recruited and packaged into the virion, 
presumably via an interaction with either a viral protein or the viral genome. There is a 
high probability that such proteins are actively involved in the virus life cycle, either at late 
stages during virus assembly and egress from the producer cell or at early stages of entry 
into the new target cell. It seems unlikely that all of the 253 cellular proteins identified in 
HIV-1 virions (Table 5) are of functional significance, and some may be packaged 
accidentally due to their abundance and cellular localization (Chertova et al., 2006). 
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Detailed functional studies will be needed to determine which of the packaged cellular 
proteins actually contribute to HIV-1 infection. Perhaps one of the best characterised host 
proteins found on HIV-1 virions is cyclophilin A (CypA). This host protein is incorporated 
onto the virion through its association with virus capsid. Most importantly, it is the only 
incorporated cellular protein shown to be critical for viral infectivity. Its exact role in 
infectivity is debateable, with some authors arguing for a role in early events of the 
replication cycle, such as uncoating, and others for a role in late events, such as maturation 
(Scarlata & Carter, 2003). From the MS studies it has become apparent that there is some 
overlap in the nature of the host proteins incorporated into the different enveloped viruses. 
For example, actin is present in all the enveloped virions listed in Table 5 and all but EBV 
incorporate annexin A2 and CypA. The heat shock proteins HSC70 and HSC90 are also 
common host proteins with the former being present in all the virions from Table 5, except 
Influenza. It remains to be determined whether these cellular proteins play a conserved 
functional role in these virions or are simply passenger proteins that are accidentally 
packed due to their location. Importantly, a recent mass spectrometric analysis performed 
on purified J6/JFH1 virions identified the presence of HSC70. It was demonstrated that 
HCV particles from cell culture and patient sera could be immunogold labelled with an 
anti-HSC70 primary antibody. Also, HCVcc infection could be efficiently inhibited by 
anti-HSC70 antibodies implying that the virion requires this component for an early step in 
infection. However, RNAi studies also found HSC70 was important for infectious particle 
secretion. Although the mechanism by which HSC70 is incorporated into the particle was 
not demonstrated it was speculated to occur through the binding to an HSC70 substrate-
binding domain present on E2 (Parent et al., 2009). While this study was able to show 
potential functions of HSC70 on the virion, the present study was unable to show any 
possible function for DDX3 that would explains its presence on the virus. Nevertheless, the 
results provide a strong basis for future research into this subject. 
 
 
4.5. The Core-DDX3 Interaction and HCV-Associated   
 Pathogenesis 
 
With the data from this study indicating that the core-DDX3 interaction does not function 
in virus replication, the possibility of this interaction being pathogenesis related must be 
explored. Indeed, core protein has been widely implicated in modulating cellular functions, 
mainly due to its interaction with numerous host factors (Table 4). In particular, one could 
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anticipate an involvement of the core-DDX3 interaction in apoptosis and immune evasion 
given the recent evidence stating a role for DDX3 in each of these processes. As described 
in section 1.11.6, both pro- and anti-apoptotic effects of core protein have been described 
with the conflicting nature of these reports likely caused by the different core expression 
systems and cell lines used. It is widely reported in the literature that Huh-7 cells and 
derived subclones undergo considerable apoptotis during HCVcc infection (Deng et al., 
2008; Lan et al., 2008; Mateu et al., 2008; Sekine-Osajima et al., 2008). These effects 
could be inflicted directly or indirectly by the virus through a number of mechanisms given 
that virtually all HCV proteins have been shown to modulate the cell death process 
(Fischer et al., 2007). However, the core-DDX3 interaction could potentially contribute to 
such effects as both proteins have links to apoptosis. As DDX3 is a component of an anti-
apoptotic death receptor complex (Sun et al., 2008), its sequestration by core may release 
this inhibitory cap to allow for stronger apoptotic signalling upon death receptor 
stimulation initiated by the viral infection. Indeed, several viruses are known to induce 
apoptosis actively at later stages of infection, including HIV-1, human adenovirus, 
influenza and parvoviruses. This process may represent a mechanism by which the virus 
can disseminate progeny to neighbouring cells while also evading induction of host 
inflammatory and immune responses (Teodoro & Branton, 1997). Thus, HCV core may 
have been adapted to antagonize apoptosis before an antiviral defence is instituted by the 
host cell. Indeed, DDX3 has been shown to positively regulate IFN-induction through its 
interaction with kinases IKK-ε (Schroder et al., 2008), TBK1 (Soulat et al., 2008) and IPS-
1 (Oshiumi et al., 2010). Moreover, Schroder et al. (2008) found that a direct interaction 
between the vaccinia virus K7 protein and DDX3 could inhibit IFN-induction. Core 
protein may also be employing a similar strategy as K7 to limit the quantity of DDX3 
available in the cell to perform this innate immune function during virus infection. Thus, it 
is possible that the core-DDX3 interaction modulates both cellular processes, establishing a 
complex interplay between these two events during infection to function as an early 
evasion strategy from the host defence. However, if this theory is true then one would 
expect JFH1Y35A to be attenuated in virus replication as it is unable to counteract the cell 
defences via this particular mechanism. It is possible that Huh-7 cells lack efficient innate 
immune defences making the replication characteristics of JFH1WT and JFH1Y35A 
indistinguishable from one another. This would partly explain why Huh-7 cells are the only 
cell line capable of supporting high levels of HCV RNA replication. It is also important to 
note that the studies reporting the roles of DDX3 in apoptosis and innate immunity were 
conducted in cell lines other than Huh-7 cells. The possible contributions of this interaction 
to clinical manifestations of viral disease cannot be discounted. Indeed, differential 
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regulation of DDX3 has been reported in a number of tumours, including HCC (Botlagunta 
et al., 2008; Chang et al., 2006; Chao et al., 2006; Huang et al., 2004), suggesting it may 
be involved in HCV-associated pathogenesis. Although, no differences in DDX3 
expression levels were observed between HCVcc-infected cultured cells and uninfected 
cells, its relevance in vivo from a long-term disease perspective warrants further 
investigation.  
 
 
4.6. The Importance of Core Residue Glycine 33 
 
Of all the core mutants characterised in this project, JFH1G33A has by far the most 
compelling phenotype. Despite being unable to decipher its level of interaction with 
DDX3, the findings with the other mutants convincingly exclude changes to the core-
DDX3 interaction as an explanation for the JFH1G33A phenotype. This mutation is located 
within a highly conserved and multifunctional region of core protein and its coding gene 
and thus, a number of explanations could be proposed as to why this change significantly 
reduces infectious virus release. These are: 
 
1. Disrupting a core-cellular protein interaction that is important for virus assembly. As 
shown in Table 4, domain I of core protein interacts with a number of cellular proteins 
with binding sites that include residue G33.  
 
2. The inability of the mutant core to bind HCV RNA and thereby disallowing its proper 
encapsidation into infectious particles. The RNA binding region of core has been broadly 
mapped to residues 1-75 (Santolini et al., 1994). 
 
3. Impaired nucleocapsid assembly. Core multimerisation requires domain I, which may be 
compromised by G33A preventing the formation of the nucleocapsid during virion 
assembly. 
 
4. Dissociation between core and NS5A. A recent study found an interaction between core 
and NS5A that was required for infectious particle production (Masaki et al., 2008). This 
study mapped the interacting residues to domain III of NS5A, although the binding region 
in core was not identified. G33A may disjoin this interaction, which would explain the loss 
in infectivity. 
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Whatever the explanation for this defect, the G33A mutation is not completely lethal as the 
virus can generate reversion mutations in core to restore virion assembly. Since the 
development of HCVcc, there have been several reports of compensatory mutations that 
rescue the phenotype of assembly defective mutants and chimeric viruses (Gottwein et al., 
2009; Murray et al., 2007; Phan et al., 2009; Yi et al., 2007). This is likely caused by the 
high error-rate of nucleotide substitutions by the NS5B polymerase during viral genome 
synthesis allowing the selection of reversion variants. It would be interesting to 
characterise the phenotypes of the second core mutations in the absence of the G33A 
change. However, the V34A mutation was initially identified as an important residue for 
the core-DDX3 interaction and was tentatively characterised in section 3.1.6. From these 
data this mutant appeared to be competent for virus RNA replication and infectious particle 
release. Despite restoring infectious virus assembly, the second-site core mutations caused 
differential expansion kinetics to the virus at early time-points post-infection. This was 
most indicative for JFH1G33A/V34A virus particles, which displayed the lowest level of virus 
spread. A likely explanation for these findings is the V34A mutation being selected by 
JFH1G33A to restore the core protein conformation required for infectious virus assembly 
but as a negative consequence the nucleotide change alters an RNA structure important in 
viral spread. The gross alterations to SL87 appear to be caused by the combined nucleotide 
substitutions of G33A and V34A, as very little effect to this stem loop is observed by each 
individual mutation (Fig. 3.32A). JFH1G33A/V34A was still capable of persistently infecting 
cells in culture over serial passages without further changes to the core sequence. Thus, the 
defect of JFH1G33A/V34A may be short-lived and only apparent at early time-points post-
infection. Each double mutant also displayed lower levels of core-DDX3 interaction, 
supporting the notion that these second mutations do not fully reinstate the WT protein 
structure. The ability of this mutant virus to select compensatory mutations that are 
deleterious to DDX3 binding further highlights the core-DDX3 interaction playing no role 
in virus replication.  
 
 
4.7. The Importance of Core Residue Phenylalanine 24  
 
The phenylanine residue at position 24 was further investigated due to its profound effect 
on the productive infection of JFH1. This phenotype was confirmed by the more detailed 
characterisation of this mutant alongside JFH1F24L, JFH1F24I, JFH1F24V and JFH1F24Y, 
where JFH1F24A displayed the greatest decrease in infection kinetics. The phenotype of 
JFH1F24A was remarkably similar to that of JFH1G33A/V34A in that infectious virus particles 
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could be generated efficiently from electroporated cells but these were relatively inefficient 
at expanding in culture following infection. As with JFH1G33A/V34A, these effects did not 
compromise the ability of the virus to persist during long-term culture. It is intriguing to 
speculate that the similar defects in viral spread for JFH1G33A/V34A and JFH1F24A are caused 
by rearrangements to the functional RNA elements in which their codons are positioned. 
Indeed, the RNA folding predictions show that of all the mutants generated in this study, 
only JFH1F24A and JFH1G33A/V34A caused major alterations to SL47 and SL87, respectively 
(Fig. 3.32A-C). It is possible that the integrity of SL47 and SL87 may be necessary for 
efficient virus infection. Our results pinpoint the defect of both mutants to an early stage 
following virus entry and before the release of the infectious genome into the cell 
cytoplasm. One could speculate that these RNA secondary structures play a role in the 
translocation of the genome from the internalized, disassembling nucleocapsid to the 
translation initiation sites of the cell. The importance of SL47 and SL87 in HCVcc 
propagation has been analysed in a previous study by introducing silent mutations 
predicted to disrupt these stem-loops into the infectious genome (Vassilaki et al., 2008). 
However, the effects of these stem-loop disruptions on virus spread were not tested. 
Instead, this study monitored virus release and RNA replication following electroporation 
of JFH1 RNA into Huh-7.5 cells, where they found delayed kinetics in both processes. 
These defects were found to be caused by reduced translation levels of the viral genome at 
early time-points (Vassilaki et al., 2008). Mutant JFH1G27A was the only mutant 
characterised in the present study that possessed delayed replication kinetics post-
electroporation (Fig. 3.10). However, mfold analysis found the nucleotide substitutions that 
created the G27A did not change the conformation of SL47 (Fig. 3.32A), suggesting that 
the phenotype may be more relevant at the protein level. It is interesting that these delayed 
replication kinetics were not observed in either JFH1G33A/V34A or JFH1F24A following 
electroporation given how disruptive these mutations were to the structures of their 
respective stem loop. Nevertheless, these data provide important insights into a potentially 
novel function of these RNA structures in virus infection. Additionally, at the protein level 
these aa substitutions have provided further insights into the importance of this residue in 
the binding of core to DDX3. The differential binding of each phenylalanine mutant to 
DDX3 along with their replication properties again strengthen the previous findings that 
this interaction is not required for HCVcc replication. JFH1F24Y was an especially 
important finding as it demonstrates that this interaction can be increased without affecting 
viral proliferation. 
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4.8. Finishing Statement 
 
The aim of this project was to resolve the role of the core-DDX3 interaction in HCV 
replication. After characterising a panel of core mutant viruses, a lack of correlation 
between the level of core-DDX3 binding and virus replication was found to exist, strongly 
suggesting this virus-host interaction is dispensable for HCV propagation in cell culture. 
As well as fulfilling the major aim of this project, preliminary results were obtained 
regarding the importance of DDX3 in an early infection stage as well as its potential 
incorporation into the virus particle. Together, the above results suggest this 
multifunctional cellular protein may have several roles in the HCV lifecycle. Furthermore, 
two core mutants (JFH1G33A and JFH1F24A) were selected for further characterisation given 
their unique properties that appeared to be unrelated to the core-DDX3 interaction. 
Predictive structural modelling provided useful insights into the alterations caused by these 
mutations at the RNA level, which may be related to the peculiar phenotypes of these 
mutant viruses in cell culture. Undoubtedly, the data and reagents generated in this project 
will be of great utility for future studies investigating both the functions(s) of DDX3 in the 
HCV lifecycle and the importance of core domain I for virus assembly and spread.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendices 
 
Appendix 1: Primers used for core mutagenesis and sequencing  
 
Primer Name Sequence (5’-3’) Function 
JFH1 NegRT TTGCGAGTGCCCCGGGA Used to reverse transcribe 
negative-strand HCV JFH1 core 
sequence 
NA7 CAC TCC GCC ATG AAT CAC 
TC 
Used to sequence 5’ UTR and 
core gene 
NA11 GTCTCGTAGACCGTGC Used to amplify and sequence 
core gene 
NA12 GCCAGTGGAGCGCCGATCTTT
G 
Used to sequence core gene 
NA13 CAAAGATCGGCGCTCCACTGG
C 
Used to sequence core gene 
NA14 GTATTCTTCACCTGGGCAGC Used to amplify and sequence 
core gene 
NA15 CCTGTTGTCCTGCATCACCG Used to sequence E1 gene 
NA18 CGTGCAACAGCGCCTCCAAC Used to sequence E1 gene 
NA72 CGGCCAGATCGTTGACGCAGT
ATACTTGTTGC 
Forward primer for site-directed 
mutagenesis of G32D in G33A 
JFH1 plasmid 
NA73 GCAACAAGTATACTGCGTCAA
CGATCTGGCCG 
Reverse primer for site-directed 
mutagenesis of G32D in G33A 
JFH1 plasmid 
NA74 CGTTGGCGCAGCATACTTGTT
GCCGC 
Forward primer for site-directed 
mutagenesis of V34 A in G33A 
JFH1 plasmid 
NA75 GCGGCAACAAGTATGCTGCGC
CAACG 
Reverse primer for site-directed 
mutagenesis of V34 A in G33A 
JFH1 plasmid 
NA76 GTTGGCGCAGTATACTCGTTG
CCGCGCAGG 
Forward primer for site-directed 
mutagenesis of L36S in G33A 
JFH1 plasmid 
NA77 CCTGCGCGGCAACGAGTATAC
TGCGCCAAC 
Reverse primer for site-directed 
mutagenesis of L36S in G33A 
JFH1 plasmid 
NA78 GTTGGCGCAGTATACTTGTCG
CCGCGCAGG 
Forward primer for site-directed 
mutagenesis of L37S in G33A 
JFH1 plasmid 
NA 79 CCTGCGCGGCGACAAGTATAC
TGCGCCAAC 
Reverse primer for site-directed 
mutagenesis of L37S in G33A 
JFH1 plasmid 
NA82 CCAGAAGACGTTAAGTACCCG
GGCGGCGGCCAG 
Forward primer for site-directed 
mutagenesis of F24Y in pJFH1 
NA83 CTGGCCGCCGCCCGGGTACTT
AACGTCTTCTGG 
Reverse primer for site-directed 
mutagenesis of F24Y in pJFH1 
NA84 CCAGAAGACGTTAAGTTACCG Forward primer for site-directed 
GGCGGCGGCCAG mutagenesis of F24L in pJFH1 
NA85 CTGGCCGCCGCCCGGTAACTT
AACGTCTTCTGG 
Reverse primer for site-directed 
mutagenesis of F24L in pJFH1 
NA86 CCAGAAGACGTTAAGATCCCG
GGCGGCGGCCAG 
Forward primer for site-directed 
mutagenesis of F24I in pJFH1 
NA87 CTGGCCGCCGCCCGGGATCTT
AACGTCTTCTGG 
Reverse primer for site-directed 
mutagenesis of F24I in pJFH1 
NA88 CCAGAAGACGTTAAGGTCCCG
GGCGGCGGCCAG 
Forward primer for site-directed 
mutagenesis of F24V in pJFH1 
NA89 CTGGCCGCCGCCCGGGACCTT
AACGTCTTCTGG 
Reverse primer for site-directed 
mutagenesis of F24V in pJFH1 
RA16 TCTGCGGAACCGGTGAGTAC Used to amplify HCV JFH1 
5'NCR 
RA17 GCACTCGCAAGCGCCCTATC Used to amplify HCV JFH1 
5'NCR 
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Appendix 2: Binding of mAbs to JFH1-electroporated Huh-7 cell lysates when used alone or in 
combination with other mAbs 
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